<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002068" GROUP_ID="SYMPT" ID="577200021815235229" MERGED_FROM="" MODIFIED="2017-08-03 10:55:58 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="3" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2017-08-03 10:54:55 +0100" MODIFIED_BY="Anna Erskine">
<TITLE>Bisphosphonates for the relief of pain secondary to bone metastases</TITLE>
<CONTACT>
<PERSON ID="19756" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rebecca</FIRST_NAME>
<MIDDLE_INITIALS>KS</MIDDLE_INITIALS>
<LAST_NAME>Wong</LAST_NAME>
<SUFFIX/>
<POSITION>Radiation Oncologist</POSITION>
<EMAIL_1>rebecca.wong@rmp.uhn.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Radiation Oncology</DEPARTMENT>
<ORGANISATION>The Princess Margaret Hospital</ORGANISATION>
<ADDRESS_1>5th Floor, 610 University Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5G 2M9</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 946 2000</PHONE_1>
<PHONE_2>+1 416 946 2919</PHONE_2>
<FAX_1>+1 416 946 4586</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-08-03 10:54:36 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="19756" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rebecca</FIRST_NAME>
<MIDDLE_INITIALS>KS</MIDDLE_INITIALS>
<LAST_NAME>Wong</LAST_NAME>
<SUFFIX/>
<POSITION>Radiation Oncologist</POSITION>
<EMAIL_1>rebecca.wong@rmp.uhn.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Radiation Oncology</DEPARTMENT>
<ORGANISATION>The Princess Margaret Hospital</ORGANISATION>
<ADDRESS_1>5th Floor, 610 University Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5G 2M9</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 946 2000</PHONE_1>
<PHONE_2>+1 416 946 2919</PHONE_2>
<FAX_1>+1 416 946 4586</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="10441" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Philip</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Wiffen</LAST_NAME>
<SUFFIX/>
<POSITION>Editor</POSITION>
<EMAIL_1>phil.wiffen@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 01865225674</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-07-11 11:05:23 +0100" MODIFIED_BY="Jessica R Thomas">
<UP_TO_DATE>
<DATE DAY="10" MONTH="2" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="1" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-03 10:54:55 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-03 10:54:55 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="22" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-11-22 14:33:27 +0000" MODIFIED_BY="Jessica Thomas">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-11-22 14:33:27 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="12" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-12 17:11:38 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 12:29:12 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="11" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Princess Margaret Hospital, University Heath Network</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Marie Curie Cancer Care</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Toronto Sunnybrook Regional Cancer Center, Cancer Care Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-22 14:35:38 +0000" MODIFIED_BY="Jessica R Thomas">
<SUMMARY MODIFIED="2008-07-11 11:12:58 +0100" MODIFIED_BY="Jessica R Thomas">
<TITLE MODIFIED="2008-07-11 11:12:58 +0100" MODIFIED_BY="Jessica R Thomas">Bisphosphonates for the relief of pain secondary to bone metastases</TITLE>
<SUMMARY_BODY MODIFIED="2008-07-11 11:02:16 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Bisphosphonates give some relief from pain caused by cancer that has invaded bones. Patients with cancer that has spread to the bone frequently have pain. Pain control is an important part of cancer management. Bisphosphonates are medicines that affect the way bone develops, and are proving useful in treating patients with cancer that has invaded the bone (metastasis). This review looked at the effect of bisphosphonates on pain caused by bone metastases. Bisphosphonates do have some effect but are not as useful as either strong analgesics (such as morphine) or radiotherapy. However, where other methods of pain relief are inadequate, the addition of bisphosphonates can be beneficial. Bisphosphonates can cause nausea and vomiting.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-11 11:13:57 +0100" MODIFIED_BY="Jessica R Thomas">
<ABS_BACKGROUND>
<P>Bisphosphonates form part of standard therapy for hypercalcemia and the prevention of skeletal events in some cancers. However, the role of bisphosphonates in pain relief for bony metastases remains uncertain.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effectiveness of bisphosphonates for the relief of pain from bone metastases. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>MEDLINE (1966 to 1999), EMBASE (1980 to 1999), CancerLit (1966 to 1999), <I>T</I>
<I>he Cochrane </I>
<I>L</I>
<I>ibrary</I> (Issue 1, 2000) and the Oxford Pain Database were searched using the strategy devised by the Cochrane Pain, Palliative and Supportive Care Group with additional terms 'diphosphonate', 'bisphosphonate', 'multiple myeloma' and 'bone neoplasms'. (Last search: January 2000).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized trials of bisphosphonates compared with open, blinded, or different doses/types of bisphosphonates in cancer patients were included where pain and/or analgesic consumption were outcome measures. Studies where pain was reported only by observers were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-07-11 11:13:57 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Article eligibility, quality assessment and data extraction were undertaken by both review authors. The proportions of patients with pain relief at 4, 8 and 12 weeks were assessed. The proportion of patients with analgesic reduction, the mean pain score, mean analgesic consumption, adverse drug reactions, and quality of life data were compared as secondary outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Thirty randomized controlled studies (21 blinded, four open and five active control) with a total of 3682 subjects were included. For each outcome, there were few studies with available data. For the proportion of patients with pain relief (eight studies) pooled data showed benefits for the treatment group, with an NNT at 4 weeks of 11[95% CI 6-36] and at 12 weeks of 7 [95% CI 5-12]. In terms of adverse drug reactions, the NNH was 16 [95% CI 12-27] for discontinuation of therapy. Nausea and vomiting were reported in 24 studies with a non-significant trend for greater risk in the treatment group. One study showed a small improvement in quality of life for the treatment group at 4 weeks. The small number of studies in each subgroup with relevant data limited our ability to explore the most effective bisphosphonates and their relative effectiveness for different primary neoplasms. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is evidence to support the effectiveness of bisphosphonates in providing some pain relief for bone metastases. There is insufficient evidence to recommend bisphosphonates for immediate effect; as first line therapy; to define the most effective bisphosphonates or their relative effectiveness for different primary neoplasms. Bisphosphonates should be considered where analgesics and/or radiotherapy are inadequate for the management of painful bone metastases. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-11 12:07:06 +0100" MODIFIED_BY="Jessica R Thomas">
<BACKGROUND>
<P>Bisphosphonates are structural analogues of pyrophosphates, a naturally occurring component of bone crystal deposition. Different side chain modification of the basic pyrophosphate structure gives rise to the different generations of bisphosphonates, with different levels of activity. The mode of action of bisphosphonates are multiple. Predominantly, through strong affinity to bone, bisphosphonates provide physico-chemical protection by absorbing calcium phosphate, suppressing the normal functioning of mature osteoclasts, and prevent osteoclast precursors maturing.</P>
<P>Bisphosphonates have been shown to be effective in the management of patients with hypercalcemia (<LINK REF="REF-Body-1996" TYPE="REFERENCE">Body 1996</LINK>), securing their place as standard therapy for this condition. More recently, bisphosphonates have been shown to be effective in decreasing morbidity related to bony metastasis in patients with breast cancer (<LINK REF="REF-Lipton-1997" TYPE="REFERENCE">Lipton 1997</LINK>; <LINK REF="REF-CCOPGI-1999" TYPE="REFERENCE">CCOPGI 1999</LINK>) and multiple myeloma (<LINK REF="STD-Bloomfield-1998" TYPE="STUDY">Bloomfield 1998</LINK>). The available evidence has significantly changed the management of these patients in recent years, with the incorporation into standard clinical practice the use of bisphosphonates in breast cancer patients with early bone metastasis and newly diagnosed myeloma patients aimed to minimize the morbidity related to bony metastasis. In addition to the long-term effect of preventing tumor deposits into bone, bisphosphonates may also reduce pain arising from bone metastasis (<LINK REF="REF-Mannix-2000" TYPE="REFERENCE">Mannix 2000</LINK>; <LINK REF="REF-Johnson-2001" TYPE="REFERENCE">Johnson 2001</LINK>).</P>
<P>Pain is often a devastating symptom in the management of cancer patients. Analgesics have been indispensable in the management of cancer pain and are an integral part of cancer pain management. Despite the use of increasingly versatile and potent analgesics, co-analgesics, and other means such as radiotherapy, there remain situations where the achievement of adequate pain control is limited. In these situations the use of bisphosphonates in relieving pain from bone metastases is gaining popularity, although remains a subject of debate.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The primary objective of this review is to determine the effectiveness of bisphosphonates for pain relief in patients with painful bony metastases. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-11 12:03:35 +0100" MODIFIED_BY="Jessica R Thomas">
<SELECTION_CRITERIA MODIFIED="2008-07-11 11:06:44 +0100" MODIFIED_BY="Jessica R Thomas">
<CRIT_STUDIES>
<P>Only studies using a randomized design published in full were included. (Abstracts were excluded). It was our intention to include all studies where the effect of bisphosphonate on cancer pain was assessed. We therefore interpreted this criterion broadly and accepted studies with any pain or analgesic outcome measures. Whether pain was an eligibility criterion or not would have an impact on the proportion of patients eligible to experience pain relief. Pain expressed by observers only (e.g., physicians) has well-documented discordance with patient reported pain scores (<LINK REF="REF-Cleeland-1989" TYPE="REFERENCE">Cleeland 1989</LINK>; <LINK REF="REF-Sutherland-1988" TYPE="REFERENCE">Sutherland 1988</LINK>; <LINK REF="REF-Van-der-Does-1989" TYPE="REFERENCE">Van der Does 1989</LINK>). Only studies with subject (patient) reported pain were included. Studies where the source of the pain scores was not specified were included. </P>
<P>Sensitivity analyses were used to assess the impact of:<BR/>
</P>
<UL>
<LI>pain as an eligibility criterion in the primary studies</LI>
<LI>pain specified as being patient-reported</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Clinical trials including patients with bony metastases from any primary neoplasms were eligible for inclusion. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Reports describing the use of bisphosphonates (oral or intravenous) were eligible for inclusion. The control arm could comprise placebo or open controls. Studies where different doses of bisphosphonates were compared (i.e., active controls) were also included but were analyzed separately. The use of antineoplastic therapy (chemotherapy, radiotherapy) did not constitute exclusion from the review provided these treatments were available uniformly to study participants in both treatment arms.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-11 11:06:44 +0100" MODIFIED_BY="Jessica R Thomas">
<P>The types of outcome measures compared between the study and control groups were:</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-11 11:06:42 +0100" MODIFIED_BY="Jessica R Thomas">
<UL>
<LI>Proportion of patients with pain relief.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-07-11 11:06:44 +0100" MODIFIED_BY="Jessica R Thomas">
<UL>
<LI>Mean or median pain score.</LI>
<LI>Adverse drug reactions.</LI>
<LI>Quality of life.</LI>
<LI>Other pain and analgesic outcome measures reported in the trials.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-11 11:14:24 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Studies for inclusion in this review were identified from:</P>
<P>
<B>Electronic databases</B>
<BR/>
</P>
<UL>
<LI>MEDLINE (1966 to 1999)</LI>
<LI>EMBASE (1980 to 1999)</LI>
<LI>CancerLit (1966 to 1999)</LI>
<LI>
<I>The Cochrane Library</I> (CCTR) (2000)</LI>
<LI>the Oxford Pain Database (1950 to 1994)</LI>
</UL>
<P>
<BR/>The search strategy devised by the Cochrane Pain, Palliative and Supportive Care Group for identifying randomized trials was used, with the addition of the following terms:<BR/>
</P>
<UL>
<LI>diphosphonate*</LI>
<LI>bisphosphonate*</LI>
<LI>generic and trade names of bisphosphonates</LI>
<LI>multiple myeloma</LI>
<LI>bone neoplasms</LI>
</UL>
<P>
<BR/>The RCT filter developed by Dickersin et al (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) was applied.</P>
<P>
<B>Reference lists</B>
<BR/>Reference lists from published trial reports and reviews were searched for potential studies for inclusion in the review.</P>
<P>No language restriction was applied to the search strategy.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-11 12:03:35 +0100" MODIFIED_BY="Jessica R Thomas">
<SUBSECTION>
<HEADING LEVEL="3">Article selection</HEADING>
<P>Articles identified through the search strategy were assessed independently by both authors. Review authors were not blinded to the source or author of the document for article selection, data extraction or quality assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Classification of trials by type of control arm</HEADING>
<P>Studies with blinded placebo control arms produce less bias than over open controls (<LINK REF="REF-Schulz-1996" TYPE="REFERENCE">Schulz 1996</LINK>). Studies employing active controls were included in order to explore whether a dose response relationship existed. If a dose response relationship was found, this would provide additional evidence of treatment effectiveness. Studies employing active controls were analyzed separately to address the dose response relationship. The effect of blinded versus open controls on the analysis was explored through sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Special considerations for interpreting selected outcomes of interest</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Proportion of patients with pain relief</HEADING>
<P>This was chosen as the primary outcome for this review as it was most suited for quantitative systematic review analysis and allowed the calculation of odds ratios, the pooling of data, and was amenable to analyses based on the intention-to-treat principle. In adopting this dichotomous outcome approach, it should be noted that it is sensitive to how the pain response was defined.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Mean or median pain score between study arms post treatment and mean analgesic consumption</HEADING>
<P>This is a summary statistic that is commonly used in the reporting of pain trials but needs careful interpretation. In studies where the sample sizes are large, differences may be statistically significant without being clinically significant. The level of pain experienced by patients prior to the commencement of the intervention is rarely identical between study arms. This parameter is not amenable to an intention-to-treat analysis when the primary trialists did not use this approach in their reporting. Standard deviations are rarely reported, limiting the ability to use this as the summary statistic for quantitative analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Analgesic endpoints</HEADING>
<P>Analgesia is an unavoidable confounder in trials of this kind. As secondary outcomes, we chose to extract data regarding:<BR/>
</P>
<UL>
<LI>the proportion of patients with analgesic reduction, and</LI>
<LI>mean or median analgesic consumption.</LI>
</UL>
<P>The methodological considerations for the interpretation of these parameters are similar to those discussed above in relation to pain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Adverse drug reactions</HEADING>
<P>Reporting of adverse drug reactions was variable across the trials. Where available, similar descriptors were pooled. In general, the time frame in which adverse reactions were experienced was not specified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Quality of life</HEADING>
<P>Qualitative comparisons of available data were used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Other endpoints</HEADING>
<P>Clinical outcomes reported in addition to those selected as secondary outcomes for this review are tabulated and described in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time frame of interest</HEADING>
<P>To have significant clinical relevance, any pain relief intervention should have a measurable effect an immediate or intermediate time frame. We therefore selected our time frame of interest as within 12 weeks of the commencement of the intervention, and data were collected at 4 weeks, 8 weeks and 12 weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Data extraction sheets were designed a priori and completed independently by the two authors. Where discrepancies arose, these were discussed and a consensus reached. Details of the information sought are given in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pooling of data</HEADING>
<P>Homogeneity of outcome measures were assessed using Chi square statistics. Where results were considered homogeneous, data were pooled to provide a summary statistic. For dichotomous outcomes, odds ratios were used to compare pooled data. The number-needed-to-treat (NNT) for treatment effect was calculated where appropriate. For continuous data (e.g., standardized pain and analgesic scores) the weighted mean difference was used as the summary statistic.</P>
<P>In presenting the results in the MetaView tables, where more than two active arms are compared, the highest and lowest dose arms only are presented.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis/potential sources of heterogeneity</HEADING>
<P>Sensitivity analyses were planned to examine the robustness of the primary conclusions in relation to the following parameters:<BR/>1. Nature of control arm (blinded versus open controls)<BR/>2. Pain as a study entry criterion (yes versus no)<BR/>3. Pain specified as patient reported (specified versus not specified)<BR/>4. Blinded controls, pain as study entry criterion and pain specified as patient reported<BR/>5. Route/type of bisphosphonates (first versus second versus third generation, intravenous versus oral route)<BR/>6. Primary disease site (prostate versus breast versus others)<BR/>7. Quality of study (Oxford Quality Scale) (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>)</P>
<P>In order to conduct the sensitivity analyses, an outcome parameter that best represented the effectiveness of bisphosphonates in pain relief, and where the maximum number of studies were represented was desirable. We used, "the best response for the proportion of patients with pain relief within 12 weeks". This parameter was chosen retrospectively, due to the limited amount of data available at each time point of interest.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-11 12:07:06 +0100" MODIFIED_BY="Jessica R Thomas">
<STUDY_DESCRIPTION MODIFIED="2008-07-11 12:05:26 +0100" MODIFIED_BY="Jessica R Thomas">
<SUBSECTION>
<HEADING LEVEL="3">Search results</HEADING>
<P>Eighty-five publications (full papers and abstracts) were identified, reporting on 51 randomized studies of the use of bisphosphonates in cancer. Twenty-one studies were excluded; the reasons for exclusion are described in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. A total of 30 studies met the inclusion criteria for this review.</P>
<P>Twenty-one reports of placebo controlled double blind studies, four open control studies and five studies with active controls were eligible for inclusion (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). These described 3582 participants, with 2096 receiving active treatments and 1586 placebo. In addition to the five studies with active controls, three of the blinded studies (<LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>; <LINK REF="STD-O_x0027_Rourke-1995" TYPE="STUDY">O'Rourke 1995</LINK>; <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>), and one of the open control studies had more than one active arm (<LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>).</P>
<P>In summary, the results from 25 studies were available to address the primary objective of the review, and nine studies provided the basis to evaluate whether a dose response relationship existed. None of the active control studies compared different types of bisphosphonates.</P>
<P>Within the double-blind randomized studies, three were crossover studies (<LINK REF="STD-Siris-1983" TYPE="STUDY">Siris 1983</LINK>; <LINK REF="STD-Ernst-1992" TYPE="STUDY">Ernst 1992</LINK>; <LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>). Only results from the first randomization phase were included in our analyses since the washout periods were judged to be too short (two, two and zero weeks respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary disease sites</HEADING>
<P>The primary disease sites addressed were tabulated in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Nine studies addressed breast cancer, four prostate cancer, seven multiple myeloma, and ten studies included patients with any primary cancers. For studies which included patients with 'any primary site', the patients generally had more advanced disease.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain requirement as an entry criteria</HEADING>
<P>Fourteen of the 30 studies required pain at entry into the study (<LINK REF="STD-Siris-1983" TYPE="STUDY">Siris 1983</LINK>; <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>; <LINK REF="STD-Ernst-1992" TYPE="STUDY">Ernst 1992</LINK>; <LINK REF="STD-Lahtinen-1992" TYPE="STUDY">Lahtinen 1992</LINK>; <LINK REF="STD-Glover-1994" TYPE="STUDY">Glover 1994</LINK>; <LINK REF="STD-Robertson-1995" TYPE="STUDY">Robertson 1995</LINK>; <LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>; <LINK REF="STD-Strang-1997" TYPE="STUDY">Strang 1997</LINK>; <LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>; <LINK REF="STD-Cascinu-1998" TYPE="STUDY">Cascinu 1998</LINK>; <LINK REF="STD-Coleman-1998" TYPE="STUDY">Coleman 1998</LINK>; <LINK REF="STD-Moiseyenko-1998" TYPE="STUDY">Moiseyenko 1998</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain as the primary endpoint</HEADING>
<P>Of the 30 included studies, only five studies were designed with pain relief as a primary endpoint (<LINK REF="STD-Conte-1994" TYPE="STUDY">Conte 1994</LINK>; <LINK REF="STD-Glover-1994" TYPE="STUDY">Glover 1994</LINK>; <LINK REF="STD-Koeberle-1999" TYPE="STUDY">Koeberle 1999</LINK>; <LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>; <LINK REF="STD-Cascinu-1998" TYPE="STUDY">Cascinu 1998</LINK>). Of the remainder, seven studies were designed to describe differences in skeletal events, (<LINK REF="STD-Belch-1991" TYPE="STUDY">Belch 1991</LINK>; <LINK REF="STD-van-Holten-1993" TYPE="STUDY">van Holten 1993</LINK>; <LINK REF="STD-Berenson-1996" TYPE="STUDY">Berenson 1996</LINK>; <LINK REF="STD-Hortobagyi-1996a" TYPE="STUDY">Hortobagyi 1996a</LINK>; <LINK REF="STD-Hultborn-1996" TYPE="STUDY">Hultborn 1996</LINK>; <LINK REF="STD-Brinker-1998" TYPE="STUDY">Brinker 1998</LINK>; <LINK REF="STD-Theriault-1999" TYPE="STUDY">Theriault 1999</LINK>), two studies were designed to describe differences in radiological progression <LINK REF="STD-Lahtinen-1992" TYPE="STUDY">Lahtinen 1992</LINK>; <LINK REF="STD-Coleman-1998" TYPE="STUDY">Coleman 1998</LINK>), and one in urinary calcium excretion (<LINK REF="STD-O_x0027_Rourke-1995" TYPE="STUDY">O'Rourke 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of biphosphonates studied </HEADING>
<P>(<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>, <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>)<BR/>Etidronate was used in three studies (<LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>; <LINK REF="STD-Belch-1991" TYPE="STUDY">Belch 1991</LINK>; <LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>), pamidronate in 12 studies and clodronate in 15 studies.</P>
<P>Etidronate was administered orally in two studies (<LINK REF="STD-Belch-1991" TYPE="STUDY">Belch 1991</LINK>; <LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>) and an initial intravenous route followed by oral maintenance in a study by <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>. The dosing schedules used were as follows:</P>
<UL>
<LI>5 mg/kg/day for 28 days every other 28 days (<LINK REF="STD-Belch-1991" TYPE="STUDY">Belch 1991</LINK>)</LI>
<LI>10 mg/kg/day (<LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>),</LI>
<LI>Three dosing schedules were compared in one study:</LI>
</UL>
<P>- 7.5 mg/kg/day for 3 days, then 200 mg twice daily, orally, for one month;<BR/>- 7.5 mg/kg/day for 3 days then placebo;<BR/>- placebo for 3 days then 200 mg twice daily, orally, for one month;<BR/>versus placebo (<LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>).</P>
<P>Clodronate was used in 15 trials, administered<BR/>
</P>
<UL>
<LI>orally in nine studies,</LI>
<LI>intravenously in three studies, and</LI>
<LI>a mixture of intravenous, oral and intramuscular routes in three studies.</LI>
</UL>
<P>
<BR/>Pamidronate was used in 12 studies, administered:<BR/>
</P>
<UL>
<LI>orally in three studies,</LI>
<LI>intravenously in nine studies.</LI>
</UL>
<P>
<BR/>Additional details of the dose schedule are provided in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Co-intervention</HEADING>
<P>Co-interventions, either in the form of hormone therapy or chemotherapy, were administered in 22 of the 30 studies. Eight studies did not appear to use a co-intervention and, of these, seven recruited patients with any primary disease site, typically having failed systemic therapy (<LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>; <LINK REF="STD-Cascinu-1998" TYPE="STUDY">Cascinu 1998</LINK>; <LINK REF="STD-Ernst-1992" TYPE="STUDY">Ernst 1992</LINK>; <LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>; <LINK REF="STD-Koeberle-1999" TYPE="STUDY">Koeberle 1999</LINK>; <LINK REF="STD-Moiseyenko-1998" TYPE="STUDY">Moiseyenko 1998</LINK>; <LINK REF="STD-Piga-1998" TYPE="STUDY">Piga 1998</LINK>) and one recruited patients with prostate cancer (<LINK REF="STD-Strang-1997" TYPE="STUDY">Strang 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Life expectancy/performance status criteria</HEADING>
<P>The studies included patients at different stages of their illness, ranging from early to late stages of metastatic disease. Twenty studies provided criteria to define the general condition of patients invited into the trials.</P>
<UL>
<LI>'Life expectancy' was used in 17 studies (time criteria ranging from more than one month to more than one year).</LI>
<LI>performance status (WHO &lt;/ = 2, poor physical activity, Eastern Cooperative Oncology Group (ECOG) performance status &lt;/ = 2, ECOG &lt;/ = 3, &gt;/ = 50%, Karnofsky performance status (KPS) 50-80) in six studies.</LI>
<LI>Eleven studies did not provide any information.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain and analgesic measurement tools</HEADING>
<P>A wide variety of pain measurement tools were used. Similarly, the reporting of analgesic intake varied between studies.</P>
<UL>
<LI>One study integrated pain, analgesia and performance status to define treatment response (<LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>).</LI>
<LI>Six studies did not specify the pain measurement tools used (<LINK REF="STD-Siris-1983" TYPE="STUDY">Siris 1983</LINK>; <LINK REF="STD-Belch-1991" TYPE="STUDY">Belch 1991</LINK>; <LINK REF="STD-Elomaa-1992" TYPE="STUDY">Elomaa 1992</LINK>; <LINK REF="STD-van-Holten-1993" TYPE="STUDY">van Holten 1993</LINK>; <LINK REF="STD-Hortobagyi-1996a" TYPE="STUDY">Hortobagyi 1996a</LINK>; <LINK REF="STD-Harvey-1996" TYPE="STUDY">Harvey 1996</LINK>; <LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>).</LI>
<LI>The remaining 24 studies used the following:</LI>
</UL>
<P>
<BR/>1. Visual analogue scales (11 studies) (<LINK REF="STD-Ernst-1992" TYPE="STUDY">Ernst 1992</LINK>; <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>; <LINK REF="STD-Martoni-1991" TYPE="STUDY">Martoni 1991</LINK>; <LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>; <LINK REF="STD-O_x0027_Rourke-1995" TYPE="STUDY">O'Rourke 1995</LINK>; <LINK REF="STD-Robertson-1995" TYPE="STUDY">Robertson 1995</LINK>; <LINK REF="STD-Hultborn-1996" TYPE="STUDY">Hultborn 1996</LINK>; <LINK REF="STD-Strang-1997" TYPE="STUDY">Strang 1997</LINK>; <LINK REF="STD-Moiseyenko-1998" TYPE="STUDY">Moiseyenko 1998</LINK>; <LINK REF="STD-Piga-1998" TYPE="STUDY">Piga 1998</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>)</P>
<P>2. Ordinal scales with:<BR/>- 0-3 point scale (<LINK REF="STD-Heim-1995" TYPE="STUDY">Heim 1995</LINK>),<BR/>- 0-4 point scale (<LINK REF="STD-Lahtinen-1992" TYPE="STUDY">Lahtinen 1992</LINK>),<BR/>- 0-5 point scale (<LINK REF="STD-Brinker-1998" TYPE="STUDY">Brinker 1998</LINK>; <LINK REF="STD-Conte-1994" TYPE="STUDY">Conte 1994</LINK>; <LINK REF="STD-Coleman-1998" TYPE="STUDY">Coleman 1998</LINK>).</P>
<P>3. The Radiation Therapy Oncology Group (RTOG) pain scale (0-9 point scale based on the product of pain intensity (0-3) and severity (0-3)) was used in five studies (<LINK REF="STD-Delmas-1982a" TYPE="STUDY">Delmas 1982a</LINK>; <LINK REF="STD-Glover-1994" TYPE="STUDY">Glover 1994</LINK>; <LINK REF="STD-Berenson-1996" TYPE="STUDY">Berenson 1996</LINK>; <LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>; <LINK REF="STD-Theriault-1999" TYPE="STUDY">Theriault 1999</LINK>).</P>
<P>4. Combination of pain measurement tools<BR/>
<LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK> used both a visual analogue and a 0-4-point scale<BR/>
<LINK REF="STD-Koeberle-1999" TYPE="STUDY">Koeberle 1999</LINK> employed the visual analogue scale and present pain index.<BR/>
<LINK REF="STD-Cascinu-1998" TYPE="STUDY">Cascinu 1998</LINK> employed a quality of life questionnaire which focused on pain</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Physician versus patient reporting</HEADING>
<P>Subject/patient reported pain scores were specified in 18 studies. Of these 18 studies, physician reported scores were also collected in three studies (<LINK REF="STD-Delmas-1982a" TYPE="STUDY">Delmas 1982a</LINK>, <LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK>, <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>). A further thirteen studies did not specify whether pain was patient or physician reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain response criteria</HEADING>
<P>The definition of pain response is important when interpreting 'proportion of patients with pain reduction' as an outcome measure.</P>
<P>Eight of the blinded or open control studies presented data on the proportion of patients with pain reduction. The criteria used included:</P>
<P>- proportion with no pain (<LINK REF="STD-Siris-1983" TYPE="STUDY">Siris 1983</LINK>;<LINK REF="STD-Elomaa-1992" TYPE="STUDY">Elomaa 1992</LINK>; <LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK>)<BR/>- major pain reduction, not otherwise specified (<LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>)<BR/>- more than or equal to a 20% reduction in pain score (<LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>)<BR/>- no pain or no need for treatments (<LINK REF="STD-Heim-1995" TYPE="STUDY">Heim 1995</LINK>)<BR/>- more than or equal to two category reductions in pain score over at least two consecutive reports (<LINK REF="STD-Conte-1994" TYPE="STUDY">Conte 1994</LINK>)<BR/>- definition not specified (<LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>).</P>
<P>For studies with active controls, the criteria used included<BR/>- more than 10 mm decrease in pain (<LINK REF="STD-Moiseyenko-1998" TYPE="STUDY">Moiseyenko 1998</LINK>)<BR/>- major response, not otherwise specified (<LINK REF="STD-Coleman-1998" TYPE="STUDY">Coleman 1998</LINK>)<BR/>- did not provide a criterion although the pain scale used was an ordinal scale and it is reasonable to assume that any reduction of more than or equal to 1 point reduction was used (<LINK REF="STD-Cascinu-1998" TYPE="STUDY">Cascinu 1998</LINK>).<BR/>- definition not specified (<LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>)<BR/>- provided a definition but no data on proportion of patients responding (<LINK REF="STD-Koeberle-1999" TYPE="STUDY">Koeberle 1999</LINK>)</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The quality of the 30 included studies was assessed using the Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The Oxford Quality Scale scores achieved were not used to weight the results but used for sensitivity analyses to address the impact of quality on the primary conclusion. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-11 12:07:06 +0100" MODIFIED_BY="Jessica R Thomas">
<P>No clinical or statistical heterogeneity was observed across the outcomes of interest permitting pooling of the data to provide summary statistics.</P>
<SUBSECTION>
<HEADING LEVEL="3">Proportion of patients with pain relief</HEADING>
<P>(See Table of Comparisons: Comparison 01: 01-03)<BR/>Six placebo controlled trials (<LINK REF="STD-Siris-1983" TYPE="STUDY">Siris 1983</LINK>; <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>; <LINK REF="STD-Elomaa-1992" TYPE="STUDY">Elomaa 1992</LINK>; <LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK>; <LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>) and two open controlled studies (<LINK REF="STD-Conte-1994" TYPE="STUDY">Conte 1994</LINK>; <LINK REF="STD-Heim-1995" TYPE="STUDY">Heim 1995</LINK>) (i.e. eight of the 25 placebo or open control studies) provided data for this endpoint within the 12 -week time frame. Data were reported for different time points: five studies reported at four weeks, one study at eight weeks, and five studies at twelve weeks.</P>
<P>At week 4: OR 2.21 [95% CI 1.19 to 4.12], NNT 11 [95% CI 6 to 36]<BR/>At week 8: only one study provided these data so pooling for this time point was not meaningful<BR/>At week 12: OR 2.49 [95% CI 1.38 to 4.48], NNT 7 [95% CI 5 to 12]</P>
<P>Both week 4 and week 12 results showed a significant benefit for patients receiving bisphosphonates. Given the limited number of studies in which data were available, the results for 'best pain response within 12 weeks' were synthesized as follows:<BR/>OR 2.37 [95% CI 1.61 to 3.5] , NNT 6 [95% CI 5 to 11] in favor of the treatment group.<BR/>(This approach was adopted retrospectively, after the data extraction process revealed the limited data available).</P>
<P>Four of the remaining 17 studies with placebo or open controls (<LINK REF="STD-Martoni-1991" TYPE="STUDY">Martoni 1991</LINK>; <LINK REF="STD-O_x0027_Rourke-1995" TYPE="STUDY">O'Rourke 1995</LINK>; <LINK REF="STD-Strang-1997" TYPE="STUDY">Strang 1997</LINK>; <LINK REF="STD-Brinker-1998" TYPE="STUDY">Brinker 1998</LINK>) did not provide usable data, but reported on the lack of difference between the pain response for treatment and control groups. A total of 619 patients were involved in these four studies, compared with 771 patients in the eight double blind and open control studies in which data for the proportion of patients with response were available (<LINK REF="STD-Siris-1983" TYPE="STUDY">Siris 1983</LINK>; <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>; <LINK REF="STD-Elomaa-1992" TYPE="STUDY">Elomaa 1992</LINK>; <LINK REF="STD-Conte-1994" TYPE="STUDY">Conte 1994</LINK>; <LINK REF="STD-Heim-1995" TYPE="STUDY">Heim 1995</LINK>; <LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK>; <LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>). Fourteen of the 26 placebo or open control studies had no data on the proportion of patients with pain relief during the time frame of interest.</P>
<P>The analyses also provided some insight into the time to, and durability of, the response. The responses observed between 4 and 12 weeks appear to be similar. The response pattern at less than 4 weeks could not be assessed due to the lack of data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Mean/median pain score </HEADING>
<P>(See Table of Comparisons: Comparison 02: 01-03)<BR/>Data were available from seven of the 25 studies (<LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>; <LINK REF="STD-Robertson-1995" TYPE="STUDY">Robertson 1995</LINK>; <LINK REF="STD-Berenson-1996" TYPE="STUDY">Berenson 1996</LINK>; <LINK REF="STD-Hortobagyi-1996a" TYPE="STUDY">Hortobagyi 1996a</LINK>; <LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK>; <LINK REF="STD-Piga-1998" TYPE="STUDY">Piga 1998</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>). However, a quantitative analysis was not possible because:</P>
<UL>
<LI>in the majority of these studies there were differences in the baseline mean pain score,</LI>
<LI>with the exception of two studies (<LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>), the standard deviations were not provided and therefore results could not be pooled.</LI>
</UL>
<P>
<BR/>In addition, an 'intention-to-treat analysis' could not be undertaken because the trialist did not use this approach.</P>
<P>Of the seven studies, five employed visual analogue scales (VAS) to assess pain levels (<LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>; <LINK REF="STD-Robertson-1995" TYPE="STUDY">Robertson 1995</LINK>; <LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK>; <LINK REF="STD-Piga-1998" TYPE="STUDY">Piga 1998</LINK>; <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>) and two studies used a 0-9 point scale (<LINK REF="STD-Berenson-1996" TYPE="STUDY">Berenson 1996</LINK>; <LINK REF="STD-Hortobagyi-1996a" TYPE="STUDY">Hortobagyi 1996a</LINK>). Standardization of the pain scores was not attempted. The mean pain scores for the study and control arms reported in the original papers are presented in the meta-analysis. Whilst there was a general trend showing the mean pain score was lower for the treatment arm, the magnitude of difference between the treatment and control arms ranged from -0.53 to 2.1 at week 4, and -0.37 to 1 at week 12.</P>
<P>This review serves to highlight the limitation of using mean or median pain scores as an endpoint to evaluate pain relief, especially when trying to interpret the results within a quantitative systematic review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Proportion of patients with reduction in analgesics</HEADING>
<P>(See Table of Comparisons: Comparison 03: 01-02)<BR/>Data for the proportion of patients with reduction of analgesics were available in five of the 26 trials (<LINK REF="STD-Martoni-1991" TYPE="STUDY">Martoni 1991</LINK>; <LINK REF="STD-Elomaa-1992" TYPE="STUDY">Elomaa 1992</LINK>; <LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>; <LINK REF="STD-Kylmala-1997" TYPE="STUDY">Kylmala 1997</LINK>; <LINK REF="STD-Piga-1998" TYPE="STUDY">Piga 1998</LINK>). Data were reported at different time frames (three trials had results at week 4 and three trials had results at week 12). Only one study provided data at 8 weeks (<LINK REF="STD-Elomaa-1992" TYPE="STUDY">Elomaa 1992</LINK>).</P>
<P>Pooled results gave an OR in favor of the treatment groups as follows:<BR/>
</P>
<UL>
<LI>week 4: OR 2.81 [95% CI: 1.24 to 6.38]</LI>
<LI>week 12: OR 2.37 [95% CI: 1.1 to 5.12]</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Mean analgesic consumption</HEADING>
<P>Three of the 25 studies reported on mean analgesic consumption (<LINK REF="STD-Ernst-1992" TYPE="STUDY">Ernst 1992</LINK>; <LINK REF="STD-Robertson-1995" TYPE="STUDY">Robertson 1995</LINK>; <LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>). An additional three studies provided some description of the lack of difference in analgesic consumption (<LINK REF="STD-O_x0027_Rourke-1995" TYPE="STUDY">O'Rourke 1995</LINK>; <LINK REF="STD-Hultborn-1996" TYPE="STUDY">Hultborn 1996</LINK>; <LINK REF="STD-Brinker-1998" TYPE="STUDY">Brinker 1998</LINK>). There was insufficient information to allow a quantitative summary of the data.</P>
<P>Data from three studies that provided data were summarized here as reported from the original studies:<BR/>&#8226; <LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK> describes an average change in morphine equivalent (mg) of -6.4 (standard error: S.E. 2.9) for the treatment arm and +24.6 (S.E. 14.9) for the placebo arm (P = 0.03)<BR/>&#8226; A similar study (<LINK REF="STD-Ernst-1992" TYPE="STUDY">Ernst 1992</LINK>) reported an average change in morphine equivalent (mg) of + 10 (S.E. 8.1) for the treatment arm and + 62 (S.E. 29.6) for the placebo arm (P = 0.096)<BR/>&#8226; <LINK REF="STD-Robertson-1995" TYPE="STUDY">Robertson 1995</LINK> reported on the percentage increase in morphine equivalent (mg). At 4 weeks, this was 59% and 64% for treatment and control arm respectively.</P>
<P>These results should be interpreted in the context of the three studies that reported no difference in the analgesic use:</P>
<UL>
<LI>
<LINK REF="STD-Hultborn-1996" TYPE="STUDY">Hultborn 1996</LINK> reports that the use of analgesics was insignificantly lower in the pamidronate group during follow up.</LI>
<LI>
<LINK REF="STD-Brinker-1998" TYPE="STUDY">Brinker 1998</LINK> compares the amount of analgesics taken during the trial, and reports no difference between the treatment and control arms (p=0.26).</LI>
</UL>
<P>For both of these studies, the time frames for analgesic comparison were not stated but, based on the study duration, it is likely that a longer time period than that of interest in this review (within 3 months) was allowed.<BR/>
</P>
<UL>
<LI>
<LINK REF="STD-O_x0027_Rourke-1995" TYPE="STUDY">O'Rourke 1995</LINK> reports that after 4 weeks' treatment, the overall analgesic requirement remained the same.</LI>
</UL>
<P>
<BR/>The problems relating to the interpretation of this endpoint are similar to those discussed for mean change in pain score.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other analgesic endpoints reported</HEADING>
<P>Four studies used other analgesic endpoints. The small number of studies that employed other endpoints limited the power of inference.<BR/>
</P>
<UL>
<LI>
<LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK> reports on the number of patients taking codeine or morphine between the treatment arms</LI>
<LI>
<LINK REF="STD-Elomaa-1992" TYPE="STUDY">Elomaa 1992</LINK> and <LINK REF="STD-Heim-1995" TYPE="STUDY">Heim 1995</LINK> report on the proportion of patients with no analgesics</LI>
<LI>
<LINK REF="STD-Piga-1998" TYPE="STUDY">Piga 1998</LINK> reports on the proportion of patients with no increase in analgesics</LI>
</UL>
<P>
<BR/>No analgesic information is provided for 12 of the 25 blinded, placebo controlled trials and two open control studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Implications from studies with active controls</HEADING>
<P>(See Table of Comparisons: Comparison 04: 01)<BR/>Where more than two arms were available, the results for the highest and lowest dose arms only were presented in the MetaView tables. The results of these studies were best suited to address the effect of dose intensity. Within the context that the implications from the blinded placebo controlled trials support the effectiveness of the intervention, the presence of a dose response relationship would strengthen the primary conclusion that there was a treatment effect.</P>
<P>Of the nine studies with active controls, two studies cannot be used to assess dose response relationship. <LINK REF="STD-Moiseyenko-1998" TYPE="STUDY">Moiseyenko 1998</LINK> examines the same total dose given on day one versus over five days; and <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK> compares a regimen of 'loading and maintenance' with 'loading dose with placebo maintenance', and 'placebo loading with maintenance dose'.</P>
<P>Three studies present data on the proportion of patients with pain relief (<LINK REF="STD-Cascinu-1998" TYPE="STUDY">Cascinu 1998</LINK>; <LINK REF="STD-Coleman-1998" TYPE="STUDY">Coleman 1998</LINK>); <LINK REF="STD-Arican-1999" TYPE="STUDY">Arican 1999</LINK>). However, the results are not statistically significant and no conclusions on a dose response can be drawn.</P>
<P>Four of the seven studies use other outcome measures, not amenable to quantitative analysis, including:<BR/>
</P>
<UL>
<LI>the percentage reduction of pain score (<LINK REF="STD-Ernst-1997" TYPE="STUDY">Ernst 1997</LINK>; <LINK REF="STD-Koeberle-1999" TYPE="STUDY">Koeberle 1999</LINK>)</LI>
<LI>the median change in pain score (<LINK REF="STD-Glover-1994" TYPE="STUDY">Glover 1994</LINK>)</LI>
<LI>an insignificant p-value (<LINK REF="STD-O_x0027_Rourke-1995" TYPE="STUDY">O'Rourke 1995</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse drug reaction</HEADING>
<P>(See Table of Comparisons: Comparison 05: 01-02)<BR/>Fourteen of 20 blinded studies, four of four open control studies, and five of six active control studies present information on adverse drug reactions. Of these, three studies employ the WHO toxicity classification criteria (<LINK REF="REF-WHO-1979" TYPE="REFERENCE">WHO 1979</LINK>), and four studies report on the number of patients where adverse drug reaction led to discontinuation of therapy. Details are provided in the 'Characteristics of Included Studies' Table. Nausea and vomiting is reported in 24 studies: OR 1.11 [95% CI 0.79 to 1.58] and indicates a non-significant trend for increased nausea and vomiting.</P>
<P>Discontinuation of therapy due to adverse effects (reported in three studies) - an outcome reflecting their severity - gave an OR of 8.53 [95% CI 1.25 to 58], NNH 16 [95% CI 12 to 27].</P>
<P>Other types of reactions are described, including abdominal pain, allergic reactions, and hypocalcemia. Insufficient data are provided to permit any conclusions to be drawn.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Quality of life comparisons are presented in four of the 26 studies (<LINK REF="STD-Berenson-1996" TYPE="STUDY">Berenson 1996</LINK>; <LINK REF="STD-Harvey-1996" TYPE="STUDY">Harvey 1996</LINK>; <LINK REF="STD-Hortobagyi-1996a" TYPE="STUDY">Hortobagyi 1996a</LINK>; <LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>). Of these, three presented quality of life comparisons at a time point beyond our time frame of interest (three months). <LINK REF="STD-Berenson-1996" TYPE="STUDY">Berenson 1996</LINK> reports no difference in quality of life at baseline and nine months. <LINK REF="STD-Harvey-1996" TYPE="STUDY">Harvey 1996</LINK> reports that, at nine months, quality of life had decreased significantly less with bisphosphonates than with placebo. <LINK REF="STD-Hortobagyi-1996a" TYPE="STUDY">Hortobagyi 1996a</LINK> states that fewer patients in the pamidronate group than in the placebo group had a decrease in quality of life scores at last measurement (this study involved a treatment period of 12 months).</P>
<P>Only one study (<LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>) provided a quality of life comparison within the time frame of interest. This study described a small but non-significant improvement in quality of life compared with baseline in the pamidronate arm at four weeks; quality of life worsened in the placebo arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>In interpreting our sensitivity analyses, the small number of studies with usable quantitative data should be noted, which limits the strength of the conclusions that can be drawn. We used the parameter, "proportion of patients with pain relief using best response within 12 weeks", to conduct our sensitivity analyses because this measure has some clinical significance for the primary objective of this review, and permits the inclusion of data from the greatest number of studies.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Type/and route of bisphosphonates</HEADING>
<P>(See Table of Comparisons: Comparison 06: 01)<BR/>No formal sensitivity analysis was possible for etidronate since only one study addressed the outcome of interest (<LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>). Five studies provided data for oral clodronate and gave an OR of 3.26 [95% CI 1.8 to 5.89]. For intravenous pamidronate, two studies provided data (<LINK REF="STD-Conte-1994" TYPE="STUDY">Conte 1994</LINK>; <LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>), and gave an OR of 2.35 [0.77 to 7.15].</P>
<P>The small numbers of studies meant conclusions could not be made regarding the relative effectiveness of bisphosphonates on patients with different dose preparations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Primary disease site</HEADING>
<P>(See Table of Comparisons: Comparison 06: 02)<BR/>Studies were grouped according to primary disease site using best response for proportion of patients with pain relief within 12 weeks. The results were as follows:<BR/>
</P>
<UL>
<LI>breast cancer, OR 1.83 [95% CI 1.11 to 3.04]</LI>
<LI>prostate cancer, OR 1.81 [95% CI 0.82 to 4.02]</LI>
<LI>any primary cancer site, 8.47 [95% CI 2.69 to 27]</LI>
<LI>one study included multiple myeloma patients with an OR of 3.51 [95% CI 1.08 to 11.4].</LI>
</UL>
<P>
<BR/>The small numbers of studies meant conclusions could not be made regarding the relative effectiveness of bisphosphonates on patients with different primary disease sites.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Nature of control: Blinded versus open</HEADING>
<P>(See Table of Comparisons: Comparison 06: 03)<BR/>The exclusion of studies with open controls increased the homogeneity of the results from P = 0.28 for blinded and open studies to P = 0.62 for blinded studies only. The corresponding pooled estimates were 2.56 [95% CI: 1.57 to 4.18] and 1.92 [95% CI: 1.26 to 2.92] respectively, indicating that, while the pooled results remained statistically significant in favor of the use of bisphosphonates, the magnitude of the effect was smaller. The NNT was 6 for all studies and 8 for blinded studies only.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Pain as a study entry criteria</HEADING>
<P>(See Table of Comparisons: Comparison 06: 04)<BR/>Exclusion of studies where pain was not an entry criterion gave an OR of 3.8 [95% CI 1.42 to 10.17] suggesting a stronger pain relief effect in studies where the presence of pain was an eligibility requirement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Pain specified as patient reported</HEADING>
<P>(See Table of Comparisons: Comparison 06: 05)<BR/>Five studies specified that pain outcomes were patient reported, and gave an OR of 2 [95% CI 1.31 to 3.06]. This supports the primary conclusion (proportion of patients with pain relief) although the magnitude was slightly smaller than when all studies are included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Blinded studies; pain as eligibility requirement; and pain reported by patients</HEADING>
<P>(See Table of Comparisons: Comparison 06: 06)<BR/>As discussed in the 'Types of studies' section, the most robust data upon which to evaluate our primary outcome would come from the inclusion of studies that fulfil all three criteria. However, only two studies meet these criteria (<LINK REF="STD-Vinholes-1997a" TYPE="STUDY">Vinholes 1997a</LINK>; <LINK REF="STD-Smith-1989" TYPE="STUDY">Smith 1989</LINK>). In addition to the small number of studies eligible, the results were clinically heterogeneous making pooling of data illogical. The results are presented in the Table of Comparisons: Comparison 06: 04 for completeness only.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Quality of the studies</HEADING>
<P>(See Table of Comparisons: Comparison 06: 07)<BR/>The quality of the studies is reported in the 'Characteristics of Included Studies' Table. The Oxford Quality Scale scores ranged from 1 to 5 with a median of 3. Sensitivity analysis based on the quality of studies using, 'the proportion of patients with best response at 12 weeks', given the limitation of the small number of studies in each group, showed no quality effect.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-11 11:41:49 +0100" MODIFIED_BY="Jessica R Thomas">
<P>It is unfortunate that, despite the identification of over 50 randomized studies in this topic area, with 21 of these being blinded placebo controlled trials, the data available to facilitate a meta-analysis of the effectiveness of bisphosphonate in providing pain relief are so limited that no robust conclusions can be reached. The multiple methods used by trialists, and lack of consensus on which pain endpoints should be included in the reporting of pain response, represent the major limiting factors. These are problems, not only within bisphosphonate trials, that are observed in other areas where pain measurement is a key outcome. Clinicians and researchers planning analgesic trials should seek advice at the planning stage from experts in pain trials.</P>
<P>The most important and clinically relevant endpoint for inclusion in quantitative reviews is the proportion of patients with pain relief, described for each arm of the trial. Even when no significant differences are observed, the relevant data must be reported to allow appraisal. Mean pain scores are not helpful in calculating effectiveness. Other endpoints, such as adverse effects (based on standardized toxicity classification criteria) and quality of life assessment would provide useful data and should be integrated into future trials.</P>
<P>The following conclusions regarding the effectiveness of bisphosphonates for pain relief should be interpreted with consideration for the small number of eligible studies.</P>
<UL>
<LI>There is some evidence to suggest a significant benefit in favor of the use of bisphosphonates, OR 2.37 [95% CI: 1.61 to 3.5], NNT of 6 [95% CI 5 to 11] for the outcome, 'best response within 12 weeks';</LI>
<LI>When the three most stringent criteria are applied (blinded control, pain as an eligibility criteria, and patient reported pain), only two studies can be included, precluding meaningful pooling of the results, and the amount of pain relief achieved from bisphosphonates appears to be small;</LI>
<LI>In terms of the pattern of response over time, the magnitude of benefit from bisphosphonates at 4 weeks is similar to that observed at 12 weeks.</LI>
</UL>
<P>
<BR/>Despite the methodological limitations, the evidence suggests that bisphosphonates provide modest pain relief for patients with painful bony metastases.</P>
<UL>
<LI>Adverse drug reactions were generally mild. We calculated a number needed to harm (NNH) of 16 [95% CI 12 to 27] for adverse drug reactions requiring discontinuation of therapy. There is a trend towards increased incidence of nausea and vomiting although this does not reach statistical significance.</LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>There were insufficient data to evaluate the impact of drug type; route of administration; and variation of response between different primary disease sites.</LI>
</UL>
<P>
<BR/>Analgesics have and will continue to be an important part of the management of painful bony metastases. In addition, where clinically appropriate, radiotherapy has been shown to be an important modality. In a review conducted by <LINK REF="REF-McQuay-1997" TYPE="REFERENCE">McQuay 1997</LINK>, the NNT for the effectiveness of radiotherapy in pain relief was 3.6 [95% CI 3.2 to 3.9] for at least 50% pain relief, with a median duration of pain relief of 12 weeks.</P>
<P>For patients with diffuse, painful metastases, especially where analgesics, with or without radiotherapy, do not provide adequate pain relief, or are accompanied by unacceptable adverse drug reactions, the use of bisphosphonates for pain reduction is justifiable. Our review focused on answering the question whether patients in need of therapy for pain relief in the shorter term would benefit from bisphosphonate therapy, as in the example of patients with more advanced disease and limited life expectancies. The use of bisphosphonates with other longer term objectives such as reduction in skeletal event rates was not an objective of this review.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-07-11 11:42:06 +0100" MODIFIED_BY="Jessica R Thomas">
<IMPLICATIONS_PRACTICE MODIFIED="2008-07-11 11:42:06 +0100" MODIFIED_BY="Jessica R Thomas">
<P>This review provides an estimate of one patient benefiting with "some pain relief" for each six patients being treated. There are insufficient data to recommend its use to provide immediate effect, and the maximum response is likely to be observed by four weeks. Adverse drug reactions were severe enough to cause discontinuation of therapy in one out of every eleven patients treated.</P>
<P>Given these conclusions, there is insufficient evidence to recommend bisphosphonates for the management of painful bony metastases as first line therapy. Bisphosphonates should be considered in addition to analgesics and/or radiotherapy when these modalities alone are inadequate for the management of painful bony metastases. There is insufficient evidence to allow a recommendation to be made on the most effective bisphosphonates for this purpose. There is also insufficient evidence to recommend the selection of patients for this treatment strategy based on primary histologies.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This review shows that a significant body of research (30 studies) has failed to produce a clear answer, mainly because proven methods for assessing pain, and best practice in trial design, were not incorporated. This represents a terrible waste of research resources.</P>
<P>Future investigators should agree common criteria for the reporting of pain response in order to provide usable data in trials where pain as an outcome. The authors recommend the use of the proportion of patients with pain relief with predefined definitions for response. Ideally, this may involve an integrated pain and analgesic response criterion in order to take into account the potential confounding effect of other analgesics. The use of mean pain and/or analgesic scores as secondary endpoints is not recommended. If it is necessary to use this as an outcome, the inclusion of the standard deviation in the reporting of results is mandatory. </P>
<P>Studies focusing on subgroups who are most likely to benefit from bisphosphonates for pain relief, such as those with pain refractory to conventional analgesics, would be useful in order to better define the role of bisphosphonates for pain relief in patients with painful bony metastases.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-07-11 11:13:47 +0100" MODIFIED_BY="Jessica R Thomas">
<P>The review authors would like to thank Dr Svetlana Rutter for her assistance in translating a Russian trial report.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-07-11 11:42:27 +0100" MODIFIED_BY="Jessica R Thomas">
<P>None known<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-07-11 11:42:39 +0100" MODIFIED_BY="Jessica R Thomas">
<P>The protocol and review were written jointly by both authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2013-11-22 14:35:38 +0000" MODIFIED_BY="Anna Hobson">
<P>This review is out of date, and the original authors are no longer available to update it. The contents of this review should be accepted for historical interest only as they may be misleading for current practice.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-03 10:55:58 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2008-07-11 12:01:12 +0100" MODIFIED_BY="Jessica R Thomas">
<INCLUDED_STUDIES MODIFIED="2008-07-11 11:53:06 +0100" MODIFIED_BY="Jessica R Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Arican-1999" NAME="Arican 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Arican A, Icli F, Akbulut H et al. The effect of two different doses of oral clodronate on pain in patients with bone metastases. MED-ONCOL Medical-Oncology. 1999; 16(3):204-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arican A, Icli F, Akbulut H et al</AU>
<TI>The effect of two different doses of oral clodronate on pain in patients with bone metastases</TI>
<SO>Medical Oncology</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>3</NO>
<PG>204-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011966"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011965"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belch-1991" NAME="Belch 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Belch AR, Bergsagel DE, Wilson K et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9(8):1397-402.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belch AR, Bergsagel DE, Wilson K et al</AU>
<TI>Effect of daily etidronate on the osteolysis of multiple myeloma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1397-402</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011968"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011967"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenson-1996" NAME="Berenson 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Berenson JR LAPLDMBRGSLAKABOKMBHBRSJRDHMSJKR. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine. 1996; 334:488-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR ,Lichtenstein A, Porter L, Dimopolous M et al</AU>
<TI>Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<PG>488-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011970"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011969"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brinker-1998" NAME="Brinker 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Brincker-H, Westin-J, Abildgaard-N et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br-J-Haematol 1998; 101:280-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brincker H, Westin J, Abildgaard N et al</AU>
<TI>Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>280-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011972"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011971"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cascinu-1998" NAME="Cascinu 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cascinu S, Graziano F, Alessandroni P, Ligi M, Del Ferro E et al</AU>
<TI>Different doses of pamidronate in patients with painful osteolytic bone metastases</TI>
<SO>Support Care Cancer</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>139-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011974"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011973"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coleman-1998" NAME="Coleman 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Coleman RE, Houston S, Purohit OP, Rubens RD, Kandra A, Ford J. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. Eur J Cancer 1998; 34(6):820-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coleman RE, Houston S, Purohit OP, Rubens RD, Kandra A, Ford J</AU>
<TI>A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>6</NO>
<PG>820-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011976"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011975"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conte-1994" NAME="Conte 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Conte PF, Giannessi PG, Latreille J et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 1994; 5 Suppl 7:S41-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conte PF, Giannessi PG, Latreille J et al</AU>
<TI>Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial</TI>
<SO>Annals of Oncology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>Suppl 7</NO>
<PG>S41-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011978"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011977"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daragon-1993" NAME="Daragon 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Daragon-A, Humez-C, Michot-C et al. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myelome (GERM). Eur-J-Med 1993; 2:449-52.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daragon A, Humez C, Michot C et al</AU>
<TI>Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myelome (GERM)</TI>
<SO>European Journal of Medicine</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>449-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011980"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011979"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmas-1982a" NAME="Delmas 1982a" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, Meunier PJ</AU>
<TI>Long term effects of dichloromethylene diphosphonate on skeletal lesions in multiple myeloma</TI>
<SO>Metab Bone Dis &amp; Rel Res</SO>
<YR>1982</YR>
<VL>4</VL>
<PG>163-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011982"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011981"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elomaa-1992" NAME="Elomaa 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Elomaa I, Kylmala T, Tammela T et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. INT-UROL-NEPHROL International-Urology-and-Nephrology. 1992; 24(2):159-66.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elomaa I, Kylmala T, Tammela T et al</AU>
<TI>Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer</TI>
<SO>International Urology and Nephrology</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>2</NO>
<PG>159-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011984"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011983"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ernst-1992" NAME="Ernst 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992; 7(1):4-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E</AU>
<TI>A double-blind, crossover trial of intravenous clodronate in metastatic bone pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>1</NO>
<PG>4-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011986"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011985"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ernst-1997" NAME="Ernst 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997; 13(6):319-26.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E</AU>
<TI>A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1997</YR>
<VL>13</VL>
<NO>6</NO>
<PG>319-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011988"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011987"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glover-1994" NAME="Glover 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Glover D, Lipton A, Keller A et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994; 74(11):2949-55.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glover D, Lipton A, Keller A et al</AU>
<TI>Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>11</NO>
<PG>2949-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011990"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011989"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heim-1995" NAME="Heim 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Heim ME CMQWPMBCHMFAHZLREL. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie. 1995; 18:439-48.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heim M, Clemens MR, Queisser W, Pechersorfer M, Boewer Ch et al</AU>
<TI>Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie</TI>
<SO>Onkologie</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>439-48</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011992"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011991"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hortobagyi-1996a" NAME="Hortobagyi 1996a" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group [see comments]. N Engl J Med 1996; 335(24):1785-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hortobagyi GN, Theriault RL, Porter L et al</AU>
<TI>Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<NO>24</NO>
<PG>1785-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011994"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011993"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hultborn-1996" NAME="Hultborn 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Hultborn R, Gundersen S, Ryden S et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study. Acta Oncol 1996; 35 Suppl 5:73-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hultborn R, Gundersen S, Ryden S et al</AU>
<TI>Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study</TI>
<SO>Acta Oncol</SO>
<YR>1996</YR>
<VL>35</VL>
<NO>Suppl 5</NO>
<PG>73-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011996"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011995"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koeberle-1999" NAME="Koeberle 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Koeberle D, Bacchus L, Thuerlimann B, Senn HJ. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial [see comments]. Support Care Cancer 1999; 7(1):21-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koeberle D, Bacchus L, Thuerlimann B, Senn HJ</AU>
<TI>Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial</TI>
<SO>Support Care Cancer</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3011998"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011997"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kylmala-1997" NAME="Kylmala 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kylmala T, Taube T, Tammela TLJ, Risteli L, Risteli J, Elomaa I</AU>
<TI>Concomitant i.v. and oral clodronate in the relief of bone pain - a double blind placebo-controlled study in patients with prostate cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>7</NO>
<PG>939-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012000"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3011999"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lahtinen-1992" NAME="Lahtinen 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Published erratum appears in Lancet 1992 Dec 5;340(8832)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I</AU>
<TI>Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>1049-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012002"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012001"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martoni-1991" NAME="Martoni 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, Pannuti F</AU>
<TI>Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton</TI>
<SO>Oncology</SO>
<YR>1991</YR>
<VL>48</VL>
<PG>97-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012004"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012003"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moiseyenko-1998" NAME="Moiseyenko 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moiseyenko YM, Blinov NN, Semiglasov VU, Konsta MM</AU>
<TI>Randomized trial of two intravenous schedules of bonephos (clodronate) in patients with painful bone metastases</TI>
<SO>Voprosy Onkologii (Matters of Oncology)</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>6</NO>
<PG>725-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012006"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012005"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Rourke-1995" NAME="O'Rourke 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995; 13(4):929-34.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA</AU>
<TI>Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>4</NO>
<PG>929-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012008"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012007"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piga-1998" NAME="Piga 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Piga A, Bracci R, Ferretti B et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998; 17(2):213-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piga A, Bracci R, Ferretti B et al</AU>
<TI>A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy</TI>
<SO>J Exp Clin Cancer Res</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>2</NO>
<PG>213-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012010"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012009"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robertson-1995" NAME="Robertson 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13(9):2427-30.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robertson AG, Reed NS, Ralston SH</AU>
<TI>Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>9</NO>
<PG>2427-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012012"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012011"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1983" NAME="Siris 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris E, Hymann G, Canfield R</AU>
<TI>Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton</TI>
<SO>American Journal of Medicine</SO>
<YR>1983</YR>
<VL>74</VL>
<PG>401-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012013"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1989" NAME="Smith 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141(1):85-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith JA Jr</AU>
<TI>Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study</TI>
<SO>Journal of Urology</SO>
<YR>1989</YR>
<VL>141</VL>
<NO>1</NO>
<PG>85-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012016"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012015"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strang-1997" MODIFIED="2008-07-11 11:53:06 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Strang 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-07-11 11:53:06 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strang P, Nilsson S, Brandstedt S, Sehlin J, et al</AU>
<TI>The analgesic efficacy of clodronate compared with placebo in patients with painful bony metastases from prostatic cancer</TI>
<SO>Anticancer Research</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>4717-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012018"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012017"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theriault-1999" NAME="Theriault 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17(3):846-54.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theriault RL, Lipton A, Hortobagyi GN et al</AU>
<TI>Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>3</NO>
<PG>846-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012020"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012019"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Holten-1993" NAME="van Holten 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;van Holten Verzantvoort AT, Kroon HM, Bijvoet OL et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11(3):491-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL et al</AU>
<TI>Palliative pamidronate treatment in patients with bone metastases from breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>3</NO>
<PG>491-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012022"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012021"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinholes-1997a" NAME="Vinholes 1997a" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8(12):1243-50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE</AU>
<TI>Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease</TI>
<SO>Annals of Oncology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>12</NO>
<PG>1243-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012024"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012023"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-07-11 12:01:12 +0100" MODIFIED_BY="Jessica R Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Abildgaard-1998" NAME="Abildgaard 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brinckler H et al</AU>
<TI>Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma</TI>
<SO>European Journal of Haematology</SO>
<YR>1998</YR>
<VL>61</VL>
<NO>2</NO>
<PG>128-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012026"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012025"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmedzai-1997" NAME="Ahmedzai 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Ahmedzai S. Pain control in patients with cancer. EUR-J-CANCER-PART-A European-Journal-of-Cancer-Part-A. 1997; 33(SUPPL. 4):S55-S62.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmedzai S</AU>
<TI>Pain control in patients with cancer</TI>
<SO>European Journal Cancer</SO>
<YR>1997</YR>
<VL>33</VL>
<NO>Suppl 4</NO>
<PG>S55-S62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012028"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012027"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenson-1994" NAME="Berenson 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Berenson J, Lichtenstein A, Porter L, Bordoni R, George S, Lipton A</AU>
<TI>Pamidronate disodium reduced the occurence of skeletal-related events (SRE) in advanced multiple myeloma (MM) (Abstract)</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012030"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012029"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenson-1997" NAME="Berenson 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Berenson JR. Bisphosphonates in multiple myeloma. CANCER Cancer. 1997; 80(8 SUPPL.):1661-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR</AU>
<TI>Bisphosphonates in multiple myeloma.</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>8 Suppl</NO>
<PG>1661-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012032"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012031"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenson-1998a" NAME="Berenson 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR, Lichtenstein A, Porter L Dimopoulos M, Bardoni R et al</AU>
<TI>Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>2</NO>
<PG>593-602</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012034"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012033"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenson-1998b" NAME="Berenson 1998b" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Berenson JR. The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. Reviews in Contemporary Pharmacotherapy 1998; 9:195-203.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR</AU>
<TI>The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma</TI>
<SO>Reviews in Contemporary Pharmacotherapy</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>195-203</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012036"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012035"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blomqvist-1996" NAME="Blomqvist 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Blomqvist C, Elomaa I. Bisphosphonate therapy in metastatic breast cancer. Acta Oncol 1996; 35 Suppl 5:81-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blomqvist C, Elomaa I</AU>
<TI>Bisphosphonate therapy in metastatic breast cancer</TI>
<SO>Acta Oncol</SO>
<YR>1996</YR>
<VL>35 Suppl 5</VL>
<PG>81-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012038"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012037"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bloomfield-1998" NAME="Bloomfield 1998" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bloomfield DJ</AU>
<TI>Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers. An evidence based review</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>3</NO>
<PG>1218-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012040"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012039"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Body-1993" NAME="Body 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Body JJ. Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research. Support Care Cancer 1993; 1(1):26-33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Body JJ</AU>
<TI>Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research</TI>
<SO>Support Care Cancer</SO>
<YR>1993</YR>
<VL>1</VL>
<NO>1</NO>
<PG>26-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012042"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012041"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Body-1996b" NAME="Body 1996b" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. CANCER-TREAT-REV Cancer-Treatment-Reviews. 1996; 22(4):265-87.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Body JJ, Coleman RE, Piccart M</AU>
<TI>Use of bisphosphonates in cancer patients</TI>
<SO>Cancer Treat Rev</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>4</NO>
<PG>265-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012044"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012043"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Body-1998" NAME="Body 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Body JJ, Bartl R, Burckhardt P et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998; 16(12):3890-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Body JJ, Bartl R, Burckhardt P et al</AU>
<TI>Current use of bisphosphonates in oncology. International Bone and Cancer Study Group</TI>
<SO>J Clin Oncol</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>12</NO>
<PG>3890-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012046"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012045"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chantraine-1984" NAME="Chantraine 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;RCT, no pain endpoints&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chantraine A, Jung A, van Ouwenaller C, Donath A</AU>
<TI>Dichloromethylene diphosphonate in the treatment of lytic bone metastases</TI>
<SO>Presse Medicale</SO>
<YR>1984</YR>
<VL>13</VL>
<PG>479-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012048"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012047"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chapuy-1980" MODIFIED="2008-07-11 11:53:59 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Chapuy 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-07-11 11:53:59 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;RCT, no pain endpoints&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 11:53:59 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chapuy MC, Meunier PJ, Alexandre CM, Vignon EP</AU>
<TI>Effects of disodium dichoromethylene diphosphonate on hypercalcemia produced by bone metastases</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1980</YR>
<VL>65</VL>
<PG>1243-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012050"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012049"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clemens-1993" NAME="Clemens 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;RCT, interim analysis, reporting of the results from a subset treated at one of the participating institution. Final results reported in Heim 1995.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clemens-MR, Fessele-K, Heim-ME</AU>
<TI>Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications</TI>
<SO>Ann-Hematol</SO>
<YR>1993</YR>
<VL>66</VL>
<PG>141-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012052"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012051"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coleman-1994" NAME="Coleman 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT, Same study as COLEMAN 1998 cited in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coleman RE, Purohit OP, Vinholes J</AU>
<TI>Pamidronate for the treatment of metastatic bone disease (Meeting abstract)</TI>
<SO>Cancer Conference 12th Asia Pacific</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012054"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012053"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coleman-1996" NAME="Coleman 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;RCT, same study as Vinholes 1997 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Coleman RE, Vinholes J, Abbey ME, Purohit OP</AU>
<TI>Double-blind randomized trial of pamidronate (AREDIA) for the palliative treatment of metastatic, bone disease (Meeting abstract)</TI>
<SO>Proc Annu Meet Soc Clin Oncol</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>A1706</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012056"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012055"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coleman-1997b" NAME="Coleman 1997b" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Same study as Vinholes 1997b which is included in the review&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coleman RE, Purohit O, Vinholes JJ, Zekri J</AU>
<TI>High dose pamidronate - clinical and biochemical effects in metastatic bone disease</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>80</VL>
<PG>1686-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012058"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012057"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colleoni-1993" NAME="Colleoni 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Colleoni M, Bochicchio AM, Nole F, Bajetta E. Disodium pamidronate in the treatment of bone metastases from breast cancer. Tumori 1993; 79(5):340-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colleoni M, Bochicchio AM, Nole F, Bajetta E</AU>
<TI>Disodium pamidronate in the treatment of bone metastases from breast cancer</TI>
<SO>Tumori</SO>
<YR>1993</YR>
<VL>79</VL>
<NO>5</NO>
<PG>340-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012060"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012059"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conte-1996" MODIFIED="2008-07-11 11:54:31 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Conte 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-07-11 11:54:31 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;RCT, same study as Conte 1994 in included studies&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 11:54:31 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conte PF, Latreille J, Mauriac L, et al</AU>
<TI>Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>9</NO>
<PG>2552-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012062"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012061"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-1993" NAME="Costa 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Costa L, Moreira C, da Costa EB. [Disodium pamidronate (APD) in the treatment of bone metastases]. Acta Med Port 1993; 6(2):71-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa L, Moreira C, da Costa EB</AU>
<TI>Disodium pamidronate (APD) in the treatment of bone metastases</TI>
<TO>Pamidronato dissodico (APD) no tratamento das metastases osseas</TO>
<SO>Acta Med Port</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>2</NO>
<PG>71-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012064"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012063"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coukell-1998" NAME="Coukell 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. DRUGS-AGING Drugs-and-Aging. 1998; 12(2):149-68.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coukell AJ, Markham A</AU>
<TI>Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone</TI>
<SO>Drugs Aging</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>2</NO>
<PG>149-68</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012066"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012065"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cresswell-1995" MODIFIED="2008-07-11 11:54:47 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Cresswell 1995" YEAR="">
<REFERENCE MODIFIED="2008-07-11 11:54:47 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995; 76(3):360-5.&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 11:54:47 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM</AU>
<TI>Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer</TI>
<SO>British Journal of Urology</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>3</NO>
<PG>360-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012068"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012067"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crosby-1998" NAME="Crosby 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Crosby V, Wilcock A, Corcoran R. Re: A randomized controlled trial of intravenous clodronate [5]. J-PAIN-SYMPTOM-MANAGE Journal-of-Pain-and-Symptom-Management. 1998; 15(5):266-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crosby V, Wilcock A, Corcoran R</AU>
<TI>A randomized controlled trial of intravenous clodronate</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>5</NO>
<PG>266-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012070"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012069"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmas-1982b" NAME="Delmas 1982b" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;RCT, no pain endpoints&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmas PD, Chapuy MC, Vignon E, Briancon D, Charhon S,Meunier PJ</AU>
<TI>Dichloromethylene diphosphonate (CL2MDP) treatment of hypercalcemia produced from bone metastases (Authors' translation)</TI>
<SO>Nouvelle Presse Medicale</SO>
<YR>1982</YR>
<VL>11</VL>
<PG>1471-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012072"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012071"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmas-1991" NAME="Delmas 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Delmas PD. The use of clodronate in multiple myeloma. Bone 1991; 12 Suppl 1:S31-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmas PD</AU>
<TI>The use of clodronate in multiple myeloma</TI>
<SO>Bone</SO>
<YR>1991</YR>
<VL>12 Suppl 1</VL>
<PG>S31-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012074"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012073"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmas-1996" NAME="Delmas 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Delmas PD. Bisphosphonates in the treatment of bone diseases. NEW-ENGL-J-MED New-England-Journal-of-Medicine. 1996; 335(24):1836-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmas PD</AU>
<TI>Bisphosphonates in the treatment of bone diseases</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<NO>24</NO>
<PG>1836-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012076"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012075"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derrane-1998" NAME="Derrane 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Derrane M. Bisphosphonates: lingering questions about their use. Journal of the National Cancer Institute 1998; 90(18):1329-31.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derrane M</AU>
<TI>Bisphosphonates: lingering questions about their use</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1998</YR>
<VL>90</VL>
<NO>18</NO>
<PG>1329-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012078"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012077"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diel-1997" NAME="Diel 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;RCT, same study as Diel 1998 in excluded studies, no pain endpoints&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Diel IJ, Solomayer EF, Goerner R, Gollan C, Wallwiener D, Bastea G</AU>
<TI>Adjuvant treatment of breast cancer patients with bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases (meeting abstract)</TI>
<SO>Proc Annu Meet Am Soc Clin Oncol</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>A461</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012080"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012079"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diel-1998" NAME="Diel 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;RCT, no pain endpoints, same study as Diel 1997 in excluded studies.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diel IJ, Solomayer EF, costa SD, Gollan C, Goerner R, Wallwiener D</AU>
<TI>Reduction in new metastases in breast cancer with adjuvant clodronate treatment</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>357-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012082"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012081"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diener-1996" NAME="Diener 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Diener KM. Bisphosphonates for controlling pain from metastatic bone disease [see comments]. Am J Health Syst Pharm 1996; 53(16):1917-27.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diener KM</AU>
<TI>Bisphosphonates for controlling pain from metastatic bone disease</TI>
<SO>Am J Health Syst Pharm</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>16</NO>
<PG>1917-27</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012084"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012083"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dodwell-1990" NAME="Dodwell 1990" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Dodwell DJ, Howell A, Ford J. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. BR-J-CANCER British-Journal-of-Cancer. 1990; 61(1):123-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dodwell DJ, Howell A, Ford J</AU>
<TI>Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate</TI>
<SO>British Journal of Cancer</SO>
<YR>1990</YR>
<VL>61</VL>
<NO>1</NO>
<PG>123-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012086"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012085"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dooley--1999" NAME="Dooley  1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dooley M. Balfour JA</AU>
<TI>Ibandronate</TI>
<SO>Drugs</SO>
<YR>1999</YR>
<VL>57</VL>
<PG>101-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012088"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012087"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dranitsaris-1999" NAME="Dranitsaris 1999" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Dranitsaris G. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? Int J Technol Assess Health Care 1999; 15(1):108-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dranitsaris G</AU>
<TI>Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?</TI>
<SO>Int J Technol Assess Health Care</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>1</NO>
<PG>108-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012090"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012089"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dranitsaris-1999b" NAME="Dranitsaris 1999b" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999; 7(4):271-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dranitsaris G, Hsu T</AU>
<TI>Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer</TI>
<SO>Support Care Cancer</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>4</NO>
<PG>271-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012092"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012091"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elomaa-1983" NAME="Elomaa 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elomaa I, Blomqvist C, Grohn P</AU>
<TI>Long term controlled trial with diphosphonate in patients with osteolytic bone metastases.</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>8317</NO>
<PG>146-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012094"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012093"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elomaa-1987" NAME="Elomaa 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Elomaa I, Blomqvist C, Porkka L, Lamberg Allardt C, Borgstrom GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987; 8 Suppl 1:S53-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elomaa I, Blomqvist C, Porkka L, Lamberg Allardt C, Borgstrom GH</AU>
<TI>Treatment of skeletal disease in breast cancer: a controlled clodronate trial</TI>
<SO>Bone</SO>
<YR>1987</YR>
<VL>8 Suppl 1</VL>
<PG>S53-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012096"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012095"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elomaa-1988" NAME="Elomaa 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Elomaa-I, Blomqvist-C, Porkka-L et al. Clodronate for osteolytic metastases due to breast cancer. Biomed-Pharmacother 1988; 42:111-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elomaa I, Blomqvist C, Porkka L et al</AU>
<TI>Clodronate for osteolytic metastases due to breast cancer</TI>
<SO>Biomed Pharmacother</SO>
<YR>1988</YR>
<VL>42</VL>
<PG>111-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012098"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012097"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engler-1998" NAME="Engler 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Engler H, Koeberle D, Thuerlimann B, Senn HJ, Riesen WF. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med 1998; 36(11):879-85.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engler H, Koeberle D, Thuerlimann B, Senn HJ, Riesen WF</AU>
<TI>Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease</TI>
<SO>Clin Chem Lab Med</SO>
<YR>1998</YR>
<VL>36</VL>
<NO>11</NO>
<PG>879-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012100"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012099"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ernst-1993" NAME="Ernst 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;RCT , same study as Ernst 1997 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ernst DS, Brasher P, Hagen N, Paterson A, MacDonald RN, Bruera E</AU>
<TI>Randomized, controlled trial of IV clodronate in patients with painful bone metastases (Meeting abstract)</TI>
<SO>Pro Annu Meetg Am Soc Clin Oncol</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>A1563</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012102"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012101"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ernst-1994" NAME="Ernst 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT, same study as Ernst 1997 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ernst DS, Brasher P, Hagen N, Paterson A, MacDonald RN, Bruera E</AU>
<TI>Controlled trial of intravenous clodronate in patients with metastastic bone disease and pain (Meeting abstract)</TI>
<SO>Proc Annu Meet Am Soc Clin Oncol</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>A1478</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012104"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012103"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitton-1991" NAME="Fitton 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. DRUGS Drugs. 1991; 41(2):289-318.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitton A, McTavish D</AU>
<TI>Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease</TI>
<SO>Drugs</SO>
<YR>1991</YR>
<VL>41</VL>
<NO>2</NO>
<PG>289-318</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012106"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012105"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fontana-1998" NAME="Fontana 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fontana A, Herrmann Z, Menssen HD, Sakalova A, Boewer C, Facon T et al</AU>
<TI>Effects if intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma</TI>
<SO>Blood</SO>
<YR>1998</YR>
<VL>92 (Suppl)</VL>
<NO>106a</NO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012108"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012107"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francis-1995" NAME="Francis 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Francis RM. Oral bisphosphonates in the treatment of osteoporosis: A review. CURR-THER-RES-CLIN-EXP Current-Therapeutic-Research-Clinical-and-Experimental. 1995; 56(9):831-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francis RM</AU>
<TI>Oral bisphosphonates in the treatment of osteoporosis: A review</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>9</NO>
<PG>831-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012110"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012109"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fulfaro-1998" NAME="Fulfaro 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78:157-169&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C</AU>
<TI>The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>78</VL>
<PG>157-69</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012112"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012111"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gucalp-1994" MODIFIED="2008-07-11 11:56:09 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Gucalp 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-07-11 11:56:09 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;Gucalp R TRGIMSCRNRAFZKHMKR. Treatment of cancer-associated hypercalcemia: Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ARCH INTERN MED 1994; 154:1935-44.&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 11:56:09 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gucalp R</AU>
<TI>Treatment of cancer-associated hypercalcemia: Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>1935-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012114"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012113"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gurney-1993" NAME="Gurney 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. LANCET Lancet. 1993; 341(8861):1611-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gurney H, Grill V, Martin TJ</AU>
<TI>Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8861</NO>
<PG>1611-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012116"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012115"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-1996" NAME="Harvey 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Harvey HA, Lipton A. The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. Support Care Cancer 1996; 4(3):213-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey HA, Lipton A</AU>
<TI>The role of bisphosphonates in the treatment of bone metastases--the U.S. experience</TI>
<SO>Support Care Cancer</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>3</NO>
<PG>213-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012118"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012117"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hortobagyi-1996b" NAME="Hortobagyi 1996b" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;RCT, same study as Hortobagyi 1996 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hortobagyi GN, Porter L, Blayney D, Theriault RL, Lipton A, Gluck S</AU>
<TI>Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT) by monthly pamidronate sodium (PAM) (AREDIA) infusion (Meeting abstract)</TI>
<SO>Pro Annu Meet Am Soc Clin Oncol</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>A99</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012120"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012119"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hortobagyi-1997" NAME="Hortobagyi 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;RCT, same study as Hortobagyi 1996 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hortobagyi GN, Porter L, Blayney D, Theriault RL, Lipton A, Gluck S</AU>
<TI>Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (AREDIA) infusion (meeting abstract)</TI>
<SO>Pro Annu Meet Am Soc Clin Oncol</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>A530</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012122"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012121"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hortobagyi-1998" MODIFIED="2008-07-11 11:56:36 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Hortobagyi 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-07-11 11:56:36 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;RCT ,provide longer follow up , same study as Hortobagyi 1996 in included studies&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 11:56:36 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hortobagyi GN, Theriault RL, Lipton A, et al</AU>
<TI>Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>6</NO>
<PG>2038-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012124"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012123"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulin-1994" NAME="Hulin 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT: abstract only, no pain outcome, same study as Tubiana-Hulin 1995 in excluded studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hulin MT, Beuzeboc P, Mauriac L, Clavel M, Barbet N, Frenay M</AU>
<TI>Double blind placebo controlled trial of oral clodronate in patients with bone metastases from breast cancer. Effect on induced hyperosteolysis - preliminary results (Meeting abstract)</TI>
<SO>Annals of Oncology</SO>
<YR>1994</YR>
<VL>5</VL>
<PG>8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012126"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012125"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iddon-1998" NAME="Iddon 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Iddon J, Bundred N, Howell T. Pamidronate disodium in the treatment of osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer. REV-CONTEMP-PHARMACOTHER Reviews-in-Contemporary-Pharmacotherapy. 1998; 9(3):183-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iddon J, Bundred N, Howell T</AU>
<TI>Pamidronate disodium in the treatment of osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer</TI>
<SO>Reviews in Contemporary Pharmacotherapy</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>3</NO>
<PG>183-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012128"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012127"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iveson-1994" NAME="Iveson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain endpoint, same study as Kanis 1996 in excluded studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Iveson TJ, Powle TJ, Tidy A, Ashley S, Kanis J, Paterson A</AU>
<TI>Clodronate decreases the incidence of bone metastases in patients with advanced or metastastic breast cancer but no clinical evidence of bone metastases (Meeting abstract)</TI>
<SO>British Journal of Cancer</SO>
<YR>1994</YR>
<VL>71</VL>
<PG>24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012130"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012129"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-1983" NAME="Jung 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain assessment&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung AJ, Chantrane A, Donath A, van Ouwenaller, Turnhill D, Mermillod B, Kittler ME</AU>
<TI>Use of dichloromethylene diphosphate in metastatic bone disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>308</VL>
<NO>25</NO>
<PG>1499-1501</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012132"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012131"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanis-1991" NAME="Kanis 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Kanis JA, McCloskey EV. Clodronate. CANCER Cancer. 1997; 80(8 SUPPL.):1691-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanis JA, McCloskey EV</AU>
<TI>Clodronate</TI>
<SO>Cancer</SO>
<YR>1991</YR>
<VL>80</VL>
<NO>8 Suppl</NO>
<PG>1691-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012134"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012133"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanis-1996" NAME="Kanis 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain assessment, same study as Iveson 1994 in excluded studies&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S</AU>
<TI>Clodronate decreases the frequency of skeletal metastases in women with breast cancer</TI>
<SO>Bone</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>6</NO>
<PG>663-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012136"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012135"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koberle-1997" NAME="Koberle 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;RCT: same study as Koberle 1999 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Koberle D, Thurlimann B, Engler H, Bacchus L, Senn HJ, Riesen W</AU>
<TI>Double blind intravenous pamidronate (APD) 60mg versus 90mg in patients with malignant osteolytic bone disease and pain (Meeting abstract)</TI>
<SO>Proc Annu Meet Am Soc Clin Oncol</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>A182</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012138"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012137"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristensen-1999" MODIFIED="2008-07-11 11:57:00 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Kristensen 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-07-11 11:57:00 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;RCT: no patient reported pain&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 11:57:00 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT</AU>
<TI>Oral clodronate in breast cancer patients with bone metastases: a randomized study</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1999</YR>
<VL>246</VL>
<NO>1</NO>
<PG>67-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012140"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012139"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kylmala-1993" NAME="Kylmala 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;RCT: same study as Elomaa 1992. (included)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I</AU>
<TI>Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group</TI>
<SO>European Journal of Cancer</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>6</NO>
<PG>821-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012142"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012141"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laakso-1994" NAME="Laakso 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laakso M, Lahtinen R, Virkkunen P, Elomaa I, for the Finnish Leukaemia Group</AU>
<TI>Subgroup and cost-benefit analysis of the Finnish Multicenter trial of clodronate in multiple myeloma</TI>
<SO>British Journal of Haematology</SO>
<YR>1994</YR>
<VL>87</VL>
<PG>725-729</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012144"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012143"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LaCivita-1996" NAME="LaCivita 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaCivita CL</AU>
<TI>Pain management for bone metastases</TI>
<SO>Am J Health Syst Pharm</SO>
<YR>1996</YR>
<VL>53</VL>
<PG>1907</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012146"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012145"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipton-1994a" NAME="Lipton 1994a" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT: Interims results with no pain data, same design as Glover 1994 in included studies although unclear whether it is the same study or not since this abstract describes breast and prostate patients where as Glover 1994 include breast patients only. Same design as Lipton 1994b, which described two separate studies one for breast and one for prostate.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lipton A, Glover D, Harvey H, Grabelsky S, Givant E, Lipton N</AU>
<TI>Disodium pamidronate (APD) - a dose seeking study in patients with breast and prostate cancer: preliminary report (Meeting abstract)</TI>
<SO>Osteoclast inhibition in the management of malignant related bone disorders</SO>
<YR>1994</YR>
<VL>Bijvoet OL 7</VL>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012148"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012147"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipton-1994b" NAME="Lipton 1994b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata R, Seaman J</AU>
<TI>Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer</TI>
<SO>Annals of Oncology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>Suppl 7</NO>
<PG>S31-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012150"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012149"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipton-1997b" NAME="Lipton 1997b" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;RCT: abstract, same study as Theriault 1999 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lipton A, Theriault R, Leff R, Gluck S, Stewart J, Costello S</AU>
<TI>Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90mg pamidronate (Aredia) infusions (Meeting abstract)</TI>
<SO>Proc Annu Meet Am Soc Clin Oncol</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>A531</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012152"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012151"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipton-1998a" NAME="Lipton 1998a" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Lipton A. Aredia : the once monthly infusion for the treatment of bone metastases. Current Opinion in Oncology 1998; 10:Suppl 1: S1-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipton A</AU>
<TI>Aredia: the once monthly infusion for the treatment of bone metastases</TI>
<SO>Current Opinion in Oncology</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>S1-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012154"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012153"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipton-1998b" NAME="Lipton 1998b" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain outcome.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G</AU>
<TI>Markers of bone resorption in patients treated with pamidronate</TI>
<SO>European Journal of Cancer</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>13</NO>
<PG>2021-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012156"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012155"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipton-2000" NAME="Lipton 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;RCT: describe two RCTs, excluded as it represent updates with no addition data pertinent to the current review on Hortobagyi 1996 in included studies, and Theriault 1999 in included studies.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K et al</AU>
<TI>Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>88</VL>
<PG>1082-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012158"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012157"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lortholary-1999" NAME="Lortholary 1999" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Lortholary A, Jadaud E, Berthaud P. Bisphosphonates and bone metastases. BULL-CANCER. 1999; 86(9):732-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lortholary A, Jadaud E, Berthaud P</AU>
<TI>Bisphosphonates and bone metastases</TI>
<TO>Bisphosphonates et metastases osseuses</TO>
<SO>Bulletin Cancer</SO>
<YR>1999</YR>
<VL>86</VL>
<NO>9</NO>
<PG>732-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012160"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012159"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maolin-1998" NAME="Maolin 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Maolin J, Boqin Y, Lanying L. Treatment of metastatic bone pain with Aredia(pamidronate). CHIN-J-ONCOL Chinese-Journal-of-Oncology. 1998; 20(4):310-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maolin J, Boqin Y, Lanying L</AU>
<TI>Treatment of metastatic bone pain with Aredia (pamidronate)</TI>
<TO>[Chinese]</TO>
<SO>Chinese Journal of Oncology</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>4</NO>
<PG>310-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012162"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012161"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maxon-1991" NAME="Maxon 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;RCT: Excluded as study desigend to compare Radioactive isotope Rhenium therapy compared with using Technitium lablled bisphosphonate as a control arm.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maxon HR 3rd, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R et al</AU>
<TI>Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo</TI>
<SO>Journal of Nuclear Medicine</SO>
<YR>1991</YR>
<VL>32</VL>
<NO>10</NO>
<PG>1877-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012164"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012163"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCloskey-1998" NAME="McCloskey 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Physician reported pain response only&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA</AU>
<TI>A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>100</VL>
<NO>2</NO>
<PG>317-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012166"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012165"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercadante-1997" NAME="Mercadante 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain. 1997; 69(1-2):1-18.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercadante S</AU>
<TI>Malignant bone pain: Pathophysiology and treatment</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>1-2</NO>
<PG>1-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012168"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012167"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merlini-1990" MODIFIED="2008-07-11 11:57:42 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Merlini 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-07-11 11:57:42 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, et al</AU>
<TI>Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy</TI>
<SO>Hematological Oncology</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012170"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012169"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mundy-1999" NAME="Mundy 1999" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Mundy GR. Bisphosphonates as cancer drugs. Hospital Practice (Office Edition) 1999; 35(5):81-4,88-9,93-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mundy GR</AU>
<TI>Bisphosphonates as cancer drugs</TI>
<SO>Hospital Practice (Office Edition)</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>5</NO>
<PG>81-4, 88-9, 93-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012172"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012171"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musto-1998" NAME="Musto 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Musto P. The role of bisphosphonates for the treatment of bone disease in multiple myeloma. Leuk Lymphoma 1998; 31(5-6):453-62.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musto P</AU>
<TI>The role of bisphosphonates for the treatment of bone disease in multiple myeloma</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>5-6</NO>
<PG>453-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012174"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012173"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Namer-1991" NAME="Namer 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Namer M</AU>
<TI>Clinical consequences of osteolytic bone metastases</TI>
<SO>Bone</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>Suppl 1</NO>
<PG>S7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012176"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012175"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paterson-1991b" NAME="Paterson 1991b" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain assessment , same study as Paterson 1993a,b,Paterson 1994 in excluded studies&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paterson AHG, Ernst DS, Powles TJ, Ashley S, McCloskey EV, Kanis JA</AU>
<TI>Treatment of skeletal disease in breast cancer with clodronate</TI>
<SO>Bone</SO>
<YR>1991</YR>
<VL>Suppl 1</VL>
<PG>S25-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012178"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012177"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paterson-1993a" MODIFIED="2008-07-11 11:58:01 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Paterson 1993a" YEAR="1993">
<REFERENCE MODIFIED="2008-07-11 11:58:01 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;RCT: no pain assessment same study as Paterson 1991, Paterson 1993b, Paterson 1994 in excluded studies&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 11:58:01 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S</AU>
<TI>Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012180"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012179"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paterson-1993b" NAME="Paterson 1993b" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain assessment, same study as Paterson 1991, 1993a, 1994 in excluded studies&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S</AU>
<TI>Double blind trial of oral clodronate in breast cancer patients with bone metastases</TI>
<TO>Essai en double aveugle du clodronate per os chez des patientes atteintes d'un cancer du sein avec metastases osseuses</TO>
<SO>Bulletin du Cancer</SO>
<YR>1993</YR>
<VL>80</VL>
<NO>10 Suppl 6</NO>
<PG>50-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012182"/><IDENTIFIER TYPE="MEDLINE" VALUE="94362304"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012181"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paterson-1994" NAME="Paterson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain assessment, same study as Paterson 1993 a,b, in excluded studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Paterson AG, Goss G, Murphy K, Brennan JM</AU>
<TI>Quality of life measurement using the FLI-C in breast cancer patients receiving single agent mitoxantrone (Meeting Abstract)</TI>
<SO>International Association for Breast Cancer Research</SO>
<YR>1994</YR>
<VL>April</VL>
<PG>25-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012184"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012183"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paterson-1997" NAME="Paterson 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Paterson AH. Should bisphosphonates be standard therapy for bone pain? Support Care Cancer 1997; 5(3):200-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paterson AH</AU>
<TI>Should bisphosphonates be standard therapy for bone pain?</TI>
<SO>Support Care Cancer</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>3</NO>
<PG>200-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012186"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012185"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paterson-1999" NAME="Paterson 1999" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Paterson AHG. The emerging role of bisphosphonates in the prevention of bone metastases. TRENDS-ENDOCRINOL-METAB Trends-in-Endocrinology-and-Metabolism. 1999; 10(1):24-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paterson AHG</AU>
<TI>The emerging role of bisphosphonates in the prevention of bone metastases</TI>
<SO>Trends in Endocrinology and Metabolism</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>1</NO>
<PG>24-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012188"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012187"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peest-1996" NAME="Peest 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peest D, Deicher H, Fett W, Harms P, Braun HJ, Planker M et al</AU>
<TI>Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use of monitoring of intravenous clodronate therapy - a pilot study of the German Myeloma Treatment Group (GMTG)</TI>
<SO>European Journal of Cancer</SO>
<YR>1996</YR>
<VL>32A</VL>
<NO>12</NO>
<PG>2053-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012190"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012189"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelger-1998" NAME="Pelger 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Pelger RC, Hamdy NA, Zwinderman AH, Lycklama a Nijeholt AA, Papapoulos SE. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998; 22(4):403-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelger RC, Hamdy NA, Zwinderman AH, Lycklama a Nijeholt AA, Papapoulos SE</AU>
<TI>Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton</TI>
<SO>Bone</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>4</NO>
<PG>403-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012192"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012191"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plosker-1994" NAME="Plosker 1994" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47(6):945-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plosker GL, Goa KL</AU>
<TI>Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease</TI>
<SO>Drugs</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>6</NO>
<PG>945-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012194"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012193"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powles-1991" NAME="Powles 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Powles T</AU>
<TI>Clodronate: the potential for the future</TI>
<SO>Bone</SO>
<YR>1991</YR>
<VL>12</VL>
<PG>S43-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012196"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012195"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powles-1998" NAME="Powles 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Powles TJ, McCloskey E, Paterson AH et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. Journal of the National Cancer Institute 1998; 90(9):704-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Powles TJ, McCloskey E, Paterson AH et al</AU>
<TI>Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1998</YR>
<VL>90</VL>
<NO>9</NO>
<PG>704-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012198"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012197"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purohit-1994" NAME="Purohit 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT: Same study as Vinholes 1997. although the number of patients in the studies differ.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE</AU>
<TI>High-dose intravenous pamidronate for metastatic bone pain</TI>
<SO>British Journal of Cancer</SO>
<YR>1994</YR>
<VL>70</VL>
<NO>3</NO>
<PG>554-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012200"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012199"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radziwill-1993" NAME="Radziwill 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Radziwill AJ, Thurlimann B, Jungi WF. Improvement of palliation in patients with osteolytic bone disease and unsatisfactory pain control after pretreatment with disodium pamidronate: An intra-patient dose escalation study. ONKOLOGIE Onkologie. 1993; 16(3):174-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radziwill AJ, Thurlimann B, Jungi WF</AU>
<TI>Improvement of palliation in patients with osteolytic bone disease and unsatisfactory pain control after pretreatment with disodium pamidronate: An intra-patient dose escalation study</TI>
<SO>Onkologie</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>3</NO>
<PG>174-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012202"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012201"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravn-1996" NAME="Ravn 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain assessment&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravn P, Clemmesen B, Riis BJ, Christiansen C</AU>
<TI>The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study</TI>
<SO>Bone</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>5</NO>
<PG>527-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012204"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012203"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riccardi-1994" NAME="Riccardi 1994" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Riccardi A, Ucci G, Brugnatelli S et al. Prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. INT-J-ONCOL International-Journal-of-Oncology. 1994; 5(4):833-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riccardi A, Ucci G, Brugnatelli S et al</AU>
<TI>Prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma</TI>
<SO>International Journal of Oncology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>4</NO>
<PG>833-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012206"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012205"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ripamonti-1998" NAME="Ripamonti 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Ripamonti C, Fulfaro F, Ticozzi C, Casuccio A, De Conno F. Role of pamidronate disodium in the treatment of metastatic bone disease. Tumori 1998; 84(4):442-55.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ripamonti C, Fulfaro F, Ticozzi C, Casuccio A, De Conno F</AU>
<TI>Role of pamidronate disodium in the treatment of metastatic bone disease</TI>
<SO>Tumori</SO>
<YR>1998</YR>
<VL>84</VL>
<NO>4</NO>
<PG>442-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012208"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012207"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-1992" NAME="Rose 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain endpoint&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rose C, Ford J, Becher R, Possinger K, Coleman R, Rubens RD</AU>
<TI>Pamidronate disodium (Aredia) dose effect and tolerability evaluation in breast cancer patients with bone metastases (Meeting abstract)</TI>
<SO>Annals of Oncology</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012210"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012209"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rotstein-1992" NAME="Rotstein 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain endpoints&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rotstein S, Glas U, Eriksson M, Pfeiffer P, Hansen J, Soderqvist J</AU>
<TI>Intravenous clodronate for the treatment of hypercalcemia in breast cancer patients with bone metastases: a prospective randomized placebo- controlled multicenter study</TI>
<SO>European Journal of Cancer</SO>
<YR>1992</YR>
<VL>28A</VL>
<PG>890-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012212"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012211"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryzen-1985" NAME="Ryzen 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain endpoints&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Ryzen E, Rude RK, Elbaum N, Singer FR</AU>
<TI>Use of intravenous etidronate disodium in the treatment of hypercalcemia</TI>
<SO>Bone resorption, metastasis and diphosphonates. Monographs of athe Mario Negri Institute for Pharmacological Research</SO>
<YR>1985</YR>
<PG>99-108</PG>
<ED>Garattini S</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012214"/><IDENTIFIER TYPE="OTHER" VALUE="86626524"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012213"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shucai-1999" NAME="Shucai 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Shucai Z, Guimei L, Fanbin H. A clinical trial of Bonin in bone metastases of lung cancer. CHIN-J-CLIN-ONCOL Chinese-Journal-of-Clinical-Oncology. 1999; 26(6):445-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shucai Z, Guimei L, Fanbin H</AU>
<TI>A clinical trial of Bonin in bone metastases of lung cancer</TI>
<TO>Chinese</TO>
<SO>Chinese Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>6</NO>
<PG>445-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012216"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012215"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1983b" NAME="Siris 1983b" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain endpoints&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF, Canfield RE</AU>
<TI>Effect of dicholoromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1980</YR>
<VL>302</VL>
<PG>310-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012217"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strang-1996" NAME="Strang 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Strang P. Analgesic effect of bisphosphonates on bone pain in breast cancer patients. A review article. ACTA-ONCOL-SUPPL Acta-Oncologica,-Supplement. 1996; 35(5):50-4.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Strang P</AU>
<TI>Analgesic effect of bisphosphonates on bone pain in breast cancer patients. A review article</TI>
<SO>Acta Oncologica</SO>
<YR>1996</YR>
<VL>35</VL>
<NO>5</NO>
<PG>50-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012220"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012219"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taube-1994" NAME="Taube 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;RCT: No pain assessment&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taube T, Kylmala T, Lamberg Allardt C, Tammela TLJ, Elomaa I</AU>
<TI>The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study</TI>
<SO>European Journal of Cancer</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>6</NO>
<PG>751-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012222"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012221"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theriault-1996a" NAME="Theriault 1996a" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Theriault R. Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients. Br J Clin Pract Suppl 1996; 87:8-12; discussion 13-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theriault R</AU>
<TI>Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients</TI>
<SO>Br J Clin Pract Suppl</SO>
<YR>1996</YR>
<VL>87</VL>
<PG>8-12 (discussion 13-4)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012224"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012223"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theriault-1996b" NAME="Theriault 1996b" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;RCT: same study as Theriault 1999 in included studies&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Theriault R, Lipton A, Leff R, Gluck S, Stewart J, Costello S</AU>
<TI>Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (Aredia) infusion (Meeting abstract)</TI>
<SO>Proc Annu Meet Am Soc Clin Oncol</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>A152</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012226"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012225"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thurlimann-1994a" NAME="Thurlimann 1994a" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Thurlimann B. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? Ann Oncol 1994; 5 Suppl 7:S45-7.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Thurlimann B</AU>
<TI>Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?</TI>
<SO>Ann Oncol</SO>
<YR>1994</YR>
<VL>5 Suppl 7</VL>
<PG>S45-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012228"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012227"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thurlimann-1994b" NAME="Thurlimann 1994b" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Thurlimann B, Morant R, Jungi WF, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2(1):61-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thurlimann B, Morant R, Jungi WF, Radziwill A</AU>
<TI>Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study</TI>
<SO>Support Care Cancer</SO>
<YR>1994</YR>
<VL>2</VL>
<NO>1</NO>
<PG>61-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012230"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012229"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tubiana_x002d_Hulin-1995" NAME="Tubiana-Hulin 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;RCT: Abstract only, state pain reduction was significantly different but no data, P value only&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A</AU>
<TI>Double blind placebo controlled trial of oral clodronate in patients with bone metastases from breast cancer: effects on induced hyperosteolysis (Meeting abstract)</TI>
<SO>Proc Annu Meet Am Soc Clin Oncol</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>A1718</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012232"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012231"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyrrell-1994" NAME="Tyrrell 1994" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Tyrrell CJ, Bruning PF, May Levin F et al. Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial. ANN-ONCOL Annals-of-Oncology. 1994; 5(SUPPL. 7):37-40.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyrrell CJ, Bruning PF, May Levin F et al</AU>
<TI>Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial</TI>
<SO>Annals of Oncology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>Suppl 7</NO>
<PG>37-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012234"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012233"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyrrell-1995" NAME="Tyrrell 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Tyrrell CT, Bruning PF, May Levin F et al. Pamidronate infusions as single-agent therapy for bone metastases: A phase II trial in patients with breast cancer. EUR-J-CANCER-PART-A-GEN-TOP European-Journal-of-Cancer-Part-A:-General-Topics. 1995; 31(12):1976-80.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyrrell CT, Bruning PF, May Levin F et al</AU>
<TI>Pamidronate infusions as single-agent therapy for bone metastases: A phase II trial in patients with breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>12</NO>
<PG>1976-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012236"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012235"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Holten-1991" NAME="van Holten 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Van Holten Verzantvoort ATM, Zwinderman AH, Aaronson NK et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. EUR-J-CANCER European-Journal-of-Cancer. 1991; 27(5):544-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Holten Verzantvoort ATM, Zwinderman AH, Aaronson NK et al</AU>
<TI>The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>5</NO>
<PG>544-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012238"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012237"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Holten-1994" MODIFIED="2008-07-11 12:01:12 +0100" MODIFIED_BY="Jessica R Thomas" NAME="van Holten 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-07-11 12:01:12 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;RCT: same study as van Holten-Verzantvoort 1996 in included studies&lt;/p&gt;" NOTES_MODIFIED="2008-07-11 12:01:12 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Holten-Verzantvoort AT, Cleton FJ, Hermans J, Zwinderman AH, Bijvoet OL</AU>
<TI>Long-term bisphosphonate treatment of bone metastases in breast cancer patients? (Meeting abstract)</TI>
<SO>European Journal of Cancer</SO>
<YR>1996</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012240"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012239"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Holten-1996b" NAME="van Holten 1996b" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain assessment&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Holten-Verzantvoort AT, Hermans J, Beex LV, Blijham G, Cleton FJ, van Eck-Smit BC</AU>
<TI>Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?</TI>
<SO>European Journal of Cancer</SO>
<YR>1996</YR>
<VL>32A</VL>
<PG>450-454</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012242"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012241"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinholes-1996a" NAME="Vinholes 1996a" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Vinholes-J, Guo-CY, Purohit-OP, Eastell-R, Coleman-RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br-J-Cancer 1996; 73:1089-95.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE</AU>
<TI>Metabolic effects of pamidronate in patients with metastatic bone disease</TI>
<SO>Br J Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<PG>1089-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012244"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012243"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinholes-1996b" NAME="Vinholes 1996b" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Vinholes J POERCR. Evaluation of new bone resoption markers in a randomised trial of pamidronate for metastatic bone pain. Br-J-Cancer 1996; 73 NO:16.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vinholes J, Purohit OP, Eastell R, Coleman RE</AU>
<TI>Evaluation of new bone resorption markers in a randomised trial of pamidronate for metastatic bone pain (Abstract)</TI>
<SO>Br J Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<PG>16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012246"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012245"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinholes-1997b" NAME="Vinholes 1997b" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;RCT: no pain outcome.Same study as Purohit 1995 stated in the paper, although number of patients different! .&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>VinholesJ, Guo CY, Purohit OP et al</AU>
<TI>Evaluation of new bone resoption markers in a randomised comparison of pamidronate or clodronate for hypercalcaemia of malignancy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>1</NO>
<PG>131-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012248"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012247"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vorreuther-1993" NAME="Vorreuther 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Vorreuther R. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993; 72(5):792-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vorreuther R</AU>
<TI>Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate</TI>
<SO>Br J Urol</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>5</NO>
<PG>792-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012250"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012249"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-1997" NAME="Walker 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Walker P, Watanabe S, Lawlor P et al. Subcutaneous clodronate: a study evaluating efficacy in hypercalcaemia of malignancy and local toxicity. Annals of Oncology 1997; 8(9):915-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker P, Watanabe S, Lawlor P et al</AU>
<TI>Subcutaneous clodronate: a study evaluating efficacy in hypercalcaemia of malignancy and local toxicity</TI>
<SO>Annals of Oncology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>9</NO>
<PG>915-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012252"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012251"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenson-2000" NAME="Berenson 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenson J, Rosen L, Howell A, Porter L, Coleman R, Morley W et al</AU>
<TI>Zoledronic acide reduces skeletal related events in patients with oseolytic metastases: a double-blind, randomized dose response study</TI>
<SO>Breast Cancer Res Treat</SO>
<YR>2000</YR>
<VL>64</VL>
<PG>32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012254"/><IDENTIFIER TYPE="OTHER" VALUE="CGP-42, 446 (1423) 125E"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W et al</AU>
<TI>Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>91</VL>
<PG>1191-200</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012255"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012253"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraj-2000a" NAME="Kraj 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraj M, Poglod R, Pawlikowsky J, Maj S</AU>
<TI>The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma</TI>
<SO>Acta Haematologica Palonica</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>379-89</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012257"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012256"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraj-2000b" NAME="Kraj 2000b" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraj M, Poglod R, Pawlikowsky J, Maj S</AU>
<TI>Effect of pamidronate on skeletal morbidity in myelomatosis. Part I: The results of the 12 months of pamidronate therapy</TI>
<SO>Acta Poloniae Pharmaceutica</SO>
<YR>2000</YR>
<VL>57 (suppl)</VL>
<PG>113-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012259"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012258"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Major-2001" NAME="Major 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Major P, Lortholary A, Jon J, Abdi E, Mills G, Menssen HD et al</AU>
<TI>Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials</TI>
<SO>J Clin Oncol</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>558-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012261"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012260"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCloskey-2001" NAME="McCloskey 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCloskey EV, Dunn JA, Kanis JA, MacKennan ICM, Drayson MT on behalf of the Medical Research Council Working Party on Leukemia in Adults</AU>
<TI>Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma</TI>
<SO>British Journal of Haematology</SO>
<YR>2001</YR>
<VL>113</VL>
<PG>1035-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012263"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012262"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terpos-2000" NAME="Terpos 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, Meletis J, Yataganas X</AU>
<TI>Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma</TI>
<SO>Eur J Haematol</SO>
<YR>2000</YR>
<VL>65</VL>
<PG>331-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3012265"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3012264"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-11 11:59:02 +0100" MODIFIED_BY="Jessica R Thomas">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-11 11:59:02 +0100" MODIFIED_BY="Jessica R Thomas">
<REFERENCE ID="REF-Body-1996" MODIFIED="2008-07-11 11:58:38 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Body 1996" TYPE="JOURNAL_ARTICLE">
<AU>Body JJ, Coleman RE, Piccart M</AU>
<TI>Use of bisphosphonates in cancer patients</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>4</NO>
<PG>265-87</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1997178391"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CCOPGI-1999" MODIFIED="2008-07-11 11:58:45 +0100" MODIFIED_BY="Jessica R Thomas" NAME="CCOPGI 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bloomfield D, Warr D, Whelan T, Pritchard K, Levin M and the Breast Cancer Disease Site Group</AU>
<TI>Use of bisphosphonates in patients with bone metastases from breast cancer</TI>
<SO>Current Oncology</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>3</NO>
<PG>144-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cleeland-1989" NAME="Cleeland 1989" TYPE="BOOK_SECTION">
<AU>Cleeland CS</AU>
<TI>Measurement of pain by subjective report</TI>
<SO>Issues in pain management. Advances in pain research and therapy</SO>
<YR>1989</YR>
<VL>12</VL>
<PG>391-401</PG>
<ED>Chapman CR, Loeser JD</ED>
<PB>Raven</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Systematic reviews: identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized controlled trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2001" MODIFIED="2008-07-11 11:59:02 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Johnson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Johnson IS</AU>
<TI>Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK</TI>
<SO>Palliative Medicine</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipton-1997" MODIFIED="2008-07-11 11:58:54 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Lipton 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lipton A</AU>
<TI>Bisphosphonates and breast carcinoma</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>8 Suppl</NO>
<PG>1668-73</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1998026757"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mannix-2000" NAME="Mannix 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mannix K, Ahmedzai SH, Anderson H, Bennett M, Lloyd- Williams M, Wilcock A</AU>
<TI>Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care</TI>
<SO>Palliative Medicine</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>455-461</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1997" NAME="McQuay 1997" TYPE="JOURNAL_ARTICLE">
<AU>McQuay HJ, Carroll D, Moore RA</AU>
<TI>Radiotherapy for painful bone metastases: a systematic review</TI>
<SO>Clinical Oncology</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>3</NO>
<PG>150-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1996" NAME="Schulz 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Grimes DA, Altman DG, Hayes RJ</AU>
<TI>Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<PG>742-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutherland-1988" NAME="Sutherland 1988" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland JE, Wesley RM, Cole PM et al</AU>
<TI>Differences and similarities between patient and physician perceptions of patient pain</TI>
<SO>Family Medicine</SO>
<YR>1988</YR>
<VL>20</VL>
<PG>343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Does-1989" NAME="Van der Does 1989" TYPE="JOURNAL_ARTICLE">
<AU>Van der Does AJW</AU>
<TI>Patients' and nurses' ratings of pain and anxiety during burn wound care</TI>
<SO>Pain</SO>
<YR>1989</YR>
<VL>39</VL>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1979" NAME="WHO 1979" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>WHO Handbook for Reporting Results of Cancer Treatment</SO>
<YR>1979</YR>
<VL>48</VL>
<PG>15-22</PG>
<PB>WHO Offset Publications</PB>
<CY>Geneva, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-11 12:08:46 +0100" MODIFIED_BY="Jessica R Thomas">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-11 12:08:46 +0100" MODIFIED_BY="Jessica R Thomas" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-07-11 12:08:46 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Arican-1999">
<CHAR_METHODS MODIFIED="2008-07-11 11:42:53 +0100" MODIFIED_BY="Jessica R Thomas">
<P>2 active arms, 1 control</P>
<P>Pain measurement tool: 10 cm VAS</P>
<P>Definition of pain response: not specified</P>
<P>Analgesic scale: 0: no narcotics, 1: 30 mg morphine, 2: 60 mg morphine, 3: 90 mg morphine</P>
<P>Toxicity criteria: WHO classification<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 12:08:46 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary</P>
<P>Bone metastases required</P>
<P>Pain present</P>
<P>Cointervention: none described</P>
<P>Life expectancy &gt; 3 months</P>
<P>Other criteria: exclude bisphosphonates or radiotherapy within &lt;/ = 4 wks, hypercalcemia, renal dysfunction, Pagets disease, vitamin D deficiency<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:43:06 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Active arm 1:<BR/>Clodronate Oral 800 mg/day<BR/>x 3 months 16 pts</P>
<P>
<BR/>Active arm 2:<BR/>Clodronate<BR/>Oral<BR/>1600 mg/day<BR/>x 3 months 17 pts</P>
<P>
<BR/>Control:<BR/>No treatment 17 pts<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain: <BR/>a. Mean change<BR/>b. Proportion of pts with pain reduction </P>
<P>Analgesic:<BR/>a. Proportion of pts. with analgesia reduction</P>
<P>Others:<BR/>a. Changes in urinary calcium,<BR/>b. Urinary hydroxyproline, <BR/>c. Serum ICTP (type 1 collagen degradation product).</P>
<P>Withdrawals:<BR/>Active arm 1: 0/16<BR/>Active arm 2: 0/17<BR/>Control: 3/17</P>
<P>Adverse effects:<BR/>Active arm 1:<BR/>Nausea and vomiting: 2/16<BR/>Abdominal pain: 1/16<BR/>Hypocalcemia:1/16<BR/>Active arm 2:<BR/>Nausea and vomiting: 2/17<BR/>Diarrhea: 1/17<BR/>Abdominal pain: 1/17<BR/>Hypocalcemia: 2/17<BR/>Control arm:<BR/>none described</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 2<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:43:30 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Belch-1991">
<CHAR_METHODS>
<P>Active arm vs placebo control</P>
<P>Pain measurement tool: not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:43:17 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Multiple myeloma</P>
<P>80% of patients has at least 1 lytic lesion, bony involvement not required</P>
<P>Pain not required</P>
<P>Co-intervention: melphalan and prednisone</P>
<P>Performance status criteria: no specifications</P>
<P>Other criteria: exclude serious concurrent illness, chronic renal failure<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:43:21 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Etidronate<BR/>Oral<BR/>5 mg/kg/day/ x28 days every other 28 days<BR/>indefinitely<BR/>98 pts</P>
<P>2. Control arm:<BR/>Placebo 78 pts</P>
<P>All patients received melphalan and prednisone<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain: <BR/>a. P value shows no significant difference in pain</P>
<P>Others:<BR/>a. Episodes of hypercalcemia<BR/>b. Pathological fractures<BR/>c. Vertebral index</P>
<P>Withdrawals:<BR/>Active arm: 6/98<BR/>Control arm: 3/78</P>
<P>Adverse effects not reported</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-11 11:43:30 +0100" MODIFIED_BY="Jessica R Thomas">
<P>QS = 4</P>
<P>Study started with 3 arms with 2 active arms (an additional arm of etidronate 20 mg/kg/d). This arm was dropped because of reports of demineralization in another trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:43:53 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Berenson-1996">
<CHAR_METHODS>
<P>Active vs placebo control study, stratified by first or second line chemotherapy at study entry</P>
<P>Pain measurement tool: 0-9 point scale [pain severity (0-3) x pain intensity (0-3)]</P>
<P>Analgesic scale: 0-9 point scale</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:43:49 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Multiple myeloma SIII<BR/>with lytic lesions</P>
<P>Pain not required</P>
<P>Co-intervention: chemotherapy</P>
<P>Performance status criteria: life expectancy: &gt; 9 months</P>
<P>Other criteria: exclude skeletal event within 2 wks of enrolment, renal dysfunction, liver dysfunction, abnormal ECG, previous bisphosphonates, calcitonin, corticosteroid<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:43:53 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Pamidronate IV<BR/>90 mg/every 4 weeks<BR/>Total of 36 weeks<BR/>203 pts</P>
<P>2. Control arm:<BR/>Placebo 189 pts</P>
<P>All patients received chemotherapy as was clinically indicated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain:<BR/>a. Mean pain score in each group</P>
<P>Analgesic: States no change, no details</P>
<P>Others:<BR/>a. Any skeletal events<BR/>b. Performance status<BR/>c. Quality of life<BR/>d. Survival<BR/>e. Radiological changes<BR/>f. Serum paraproteins, beta 2 microglobulin, Urinary Bence Jones proteins</P>
<P>Withdrawals:<BR/>Active arm: 7/203<BR/>Control arm: 8/189</P>
<P>7. Adverse effects<BR/>a. Active arm:<BR/>Allergic reaction: 1/203<BR/>Hypocalcemia: 1/203<BR/>b. Control arm:<BR/>none described<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:44:08 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Brinker-1998">
<CHAR_METHODS>
<P>Active vs placebo control study, stratified by status on simultaneous study: on interferon, not on interferon trial, and not eligible for interferon trial</P>
<P>Pain measurement tool: 6-point scale<BR/>Pain score expressed by patient</P>
<P>Analgesic scale: amount consumed in the last 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:44:05 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Multiple myeloma</P>
<P>Lytic lesions not a requirement</P>
<P>Pain not required</P>
<P>Co-intervention: melphalan and prednisone+/- interferon</P>
<P>Performance status criteria: life expectancy &gt; 3 months</P>
<P>Other criteria: exclude peptic ulcer, renal dysfunction<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:44:08 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Pamidronate<BR/>Oral<BR/>75 mg twice daily<BR/>Indefinitely<BR/>152 pts</P>
<P>2. Control arm:<BR/>Placebo 148 pts</P>
<P>All pts receive melphalan and prednisone +/-interferon<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Pamidronate 126/152 episodes severe pain<BR/>Placebo 180/148 episodes severe pain</P>
<P>Others:<BR/>a. Skeletal related morbidity<BR/>b. Survival<BR/>c. Frequency of hypercalcemia</P>
<P>Withdrawals<BR/>a. Active arm: 16/152<BR/>b. Control arm: 14/148</P>
<P>Adverse effects<BR/>a. Active arm:<BR/>Nausea 18<BR/>Vomiting 7<BR/>Abdominal pain 3<BR/>Diarrhea 8<BR/>Dysphagia 10<BR/>GI hemorrhage 4<BR/>Esophageal ulcer 2<BR/>Gastric ulcer 4</P>
<P>b. Control arm:<BR/>Nausea 12<BR/>Vomiting 6<BR/>Abdominal pain 6<BR/>Diarrhea 9<BR/>Dysphagia 6<BR/>GI hemorrhage 2<BR/>Esophageal ulcer 0<BR/>Gastric ulcer 2<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:44:32 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Cascinu-1998">
<CHAR_METHODS>
<P>3 active arms</P>
<P>Pain and mobility measurement tool: use QoL questionnaire with focus on pain and mobility. Patient reported</P>
<P>Analgesic scale: total (mg) consumed in 24 hours </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:44:25 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary, failed hormones/ chemotherapy</P>
<P>Bone metastases present</P>
<P>Pain required</P>
<P>Co-intervention: none described</P>
<P>Performance status criteria: life expectancy &gt;/ = 3 months</P>
<P>Other criteria: exclude hypercalcemia, brain metastases, previous bisphosphonates, and ongoing chemotherapy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:44:32 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Active arm 1:<BR/>Pamidronate<BR/>Intravenous<BR/>45 mg every 3 weeks<BR/>for 12 weeks<BR/>23 pts</P>
<P>Active arm 2:<BR/>Pamidronate<BR/>Intravenous<BR/>60 mg every 3 weeks<BR/>for 12 weeks<BR/>24 pts</P>
<P>Active arm 3:<BR/>Pamidronate<BR/>Intravenous<BR/>90 mg every 3 weeks<BR/>for 12 weeks<BR/>23 pts<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain:<BR/>a. Proportion with pain and mobility reduction</P>
<P>Analgesic: reduction seen in all three groups</P>
<P>Withdrawal<BR/>None</P>
<P>7. Adverse effects<BR/>Active arm 1: <BR/>Fever and myalgia: 1/23</P>
<P>Active arm 2: <BR/>0/24</P>
<P>Active arm 3: <BR/>Fever and myalgia: 1/23<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:44:43 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Coleman-1998">
<CHAR_METHODS>
<P>2 active arms</P>
<P>Pain measurement tool: 6-point scale, and the Oswestry back pain questionnaire: <BR/>patient reported</P>
<P>Definition of pain response: any two of the following criteria: major response, any two of the lesser criteria in brackets: minor response<BR/>a: reduction in pain by at least 2 category at 2 consecutive 4 weekly visits<BR/>b: 20% (10%) improvement in the score of the pain and mobility questionnaire at two consecutive 4 weekly visits<BR/>c: 50% (25%) reduction for at least 2 months in the dose of the most powerful analgesic taken<BR/>Analgesic scale: 7-point analgesic scale based on total amount consumed in 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:44:43 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer, failed at least 1 systemic therapy</P>
<P>Bone metastases required (At least 2 lesions)</P>
<P>Pain required</P>
<P>Co-intervention: hormonal therapy that has been on going, no chemotherapy allowed</P>
<P>Performance status criteria: life expectancy &gt;/= 3 months, WHO performance status &lt;/=2</P>
<P>Other criteria: exclude peptic ulcer, bisphosphonates within last 6 months, hypercalcemia<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active arm 1:<BR/>Pamidronate Oral 150 mg twice a day indefinitely<BR/>24 pts</P>
<P>Active arm 2:<BR/>Pamidronate Oral<BR/>150 mg every morning and placebo every morning<BR/>23 pts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain:<BR/>a. Proportion of patients with pain reduction</P>
<P>Analgesic: Not an endpoint </P>
<P>Others:<BR/>Urinary calcium as a measure of bone resorption</P>
<P>Adverse effects<BR/>Active arm 1: 0/24</P>
<P>Active arm 2: (Grade 3)<BR/>Nausea and vomiting: 3<BR/>Diarrhea: 2<BR/>Abdominal pain: 1<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:44:54 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Conte-1994">
<CHAR_METHODS>
<P>Active vs control</P>
<P>Pain measurement tool: 6-point scale. Patient reported</P>
<P>Definition of pain response: <BR/>a. Some improvement: improvement by 1 point over 2 consecutive reports or by 2 points in 1 report<BR/>b. Marked improvement: improvement by 2 points over at least 2 consecutive reports</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:44:54 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer, no previous chemotherapy<BR/>Bone metastases required<BR/>Pain not required.<BR/>Co-intervention: chemotherapy<BR/>Performance status criteria: no specifications<BR/>Other criteria: none<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Active arm:<BR/>Pamidronate<BR/>Intravenous<BR/>45 mg every 3 weeks<BR/>Indefinitely until toxicity or progressive bone disease<BR/>143 pts</P>
<P>2. Control arm: <BR/>No additional intervention<BR/>152 pts</P>
<P>All patients received chemotherapy, standardized for each participating institution<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Proportion of patients with reduced pain<BR/>No pain: 80/131 pamidronate<BR/>70/134 control<BR/>Marked improvement:<BR/>54/131 pamidronate<BR/>38/134 control</P>
<P>2. Analgesic: stated is a secondary endpoint but no data /outcome reported</P>
<P>Withdrawals<BR/>Active arm: 6/143<BR/>Control arm: 6/152</P>
<P>Adverse reactions<BR/>Active arm: <BR/>Local reaction: 13<BR/>Fever: 8<BR/>Rigors: 2<BR/>Headache: 4<BR/>Musculoskeletal pain: 6<BR/>Hypocalcemia: 23</P>
<P>Control arm: <BR/>Local reaction: 7<BR/>Fever 4<BR/>Rigors 0<BR/>Headache: 5<BR/>Musculoskeletal pain: 22<BR/>Hypocalcemia: 9<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 1</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:45:08 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Daragon-1993">
<CHAR_METHODS>
<P>Active vs placebo control study, stratified by whether bone biopsy obtained</P>
<P>Pain measurement tools: <BR/>a. Visual analogue scale<BR/>b. 3-point categorical scale</P>
<P>Analgesic scale: analgesics consumed classified as:<BR/>a. Paracetamol <BR/>b. Codeine <BR/>c. Morphine</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:45:04 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Multiple myeloma (SII, III)</P>
<P>Bone lesion not specified</P>
<P>No pain requirement</P>
<P>Co-intervention: chemotherapy</P>
<P>Performance status criteria: poor physical activity</P>
<P>Other criteria: exclude renal dysfunction, severe bone marrow insufficient, age &gt;80, cardiac failure, diabetes, gastric or duodenal ulcer, prior chemotherapy, multiple myeloma diagnosed &gt;3 months.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:45:08 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Etidronate<BR/>Oral<BR/>10 mg/kg/day<BR/>4 months<BR/>49 pts</P>
<P>2. Control arm:<BR/>Placebo 45 pts</P>
<P>All patients receive cyclophosphamide and prednisone<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain: <BR/>a. Change in mean pain score of the group </P>
<P>2. Analgesic:<BR/>a. Proportion of patients taking codeine/morphine</P>
<P>Others:<BR/>a. Karnofsky performance status change<BR/>b. Incidence of new extraspinal mets<BR/>c. Incidence of fractures<BR/>d. Survival<BR/>e. Change in Vertebral index <BR/>f. Bone resorption as measured by urine hydroxyproline/ calcium/ creatinine levels</P>
<P>Withdrawals<BR/>Active arm: 10/49<BR/>Control arm: 6/45</P>
<P>Adverse effects<BR/>Active arm:<BR/>Skin allergy: 1</P>
<P>Control arm: <BR/>Pancreatitis: 1<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:45:23 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Delmas-1982a">
<CHAR_METHODS>
<P>Active vs placebo control</P>
<P>Pain measurement tool: 0-9 point scale based on severity and duration</P>
<P>Pain score expressed by: patient and physician</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:45:21 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Multiple myeloma<BR/>2. Bone involvement not specified<BR/>3. Pain not required<BR/>4. Co-intervention: chemotherapy<BR/>5. Performance status criteria: no specifications<BR/>6. Other criteria: exclude patients previously treated with &gt;10 cycles of chemotherapy, renal dysfunction<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:45:23 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Clodronate Oral<BR/>800 mg twice a day for<BR/>2 years 7 pts</P>
<P>2. Control arm:<BR/>Placebo 6 pts</P>
<P>All patients received melphalan and prednisone<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>No pain data within 12 weeks of enrollment</P>
<P>Others:<BR/>a. Mean pain score change at 6 months<BR/>b. Proportion with radiological progression at 1 year<BR/>c. Comments on serum calcium, urinary calcium, phosphorus, alkaline phosphatase, and bone histomorphology for subgroup of patients. </P>
<P>No withdrawals</P>
<P>Adverse effects not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:45:38 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Elomaa-1992">
<CHAR_METHODS>
<P>Active vs placebo control</P>
<P>Definition of pain response: proportion with no pain</P>
<P>Analgesic response definition: proportion with no analgesic</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:45:32 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Prostate cancer (failed 1 hormone)</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: chemotherapy/hormonal therapy</P>
<P>
<BR/>Performance status criteria: life expectancy &gt;/=3 months</P>
<P>Other criteria: exclude radiotherapy within 2 weeks<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:45:38 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Clodronate Oral<BR/>3.2 g per day for one month, then 1.6 g per day for 5 months<BR/>For 6 months<BR/>36 pts</P>
<P>2. Control arm:<BR/>Placebo 39 pts</P>
<P>All patients received Estramustine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Proportion of patients with no pain</P>
<P>2. Analgesic:<BR/>Analgesic consumption reduced in 15/17 Clodronate<BR/>3/17 placebo</P>
<P>Others:<BR/>a. Serum calcium<BR/>b. Survival</P>
<P>Evaluable data: 12 pts receiving Clodronate and 10 pts from the placebo group died within the first year of the study</P>
<P>No adverse effects reported.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:45:49 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Ernst-1992">
<CHAR_METHODS MODIFIED="2008-07-11 11:45:47 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Active vs placebo Crossover study<BR/>washout period: 2 weeks</P>
<P>Pain measurement: 10 cm VAS, patient reported</P>
<P>Analgesic scale: morphine equivalent for amount consumed in 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Any primary</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Other criteria: exclude radiotherapy, or change in chemotherapy or hormonal therapy within 4 weeks, heart failure, and abnormal renal function tests<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:45:49 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Clodronate<BR/>Intravenous<BR/>600 mg x1 dose</P>
<P>
<BR/>2. Control arm:<BR/>Placebo</P>
<P>Crossover after 4 weeks<BR/>24 pts<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Mean pain score change</P>
<P>2. Analgesic:<BR/>a. Mean morphine equivalent change</P>
<P>Others:<BR/>a. Patient and physician preference<BR/>b. Activity score</P>
<P>Withdrawals:<BR/>3 for both arms, number excluded for each arm not described</P>
<P>No adverse effects reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:45:58 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Ernst-1997">
<CHAR_METHODS>
<P>2 active arms, 1 placebo control<BR/>Crossover study: washout period: 2 weeks</P>
<P>Pain measurement tool: 15 cm VAS, <BR/>patient reported</P>
<P>Analgesic scale: morphine equivalent for amount consumed in 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:45:53 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: systemic therapy as part of standard practice</P>
<P>Performance status criteria: no specifications</P>
<P>Other criteria: exclude radiotherapy, chemotherapy within 4 weeks, cardiac failure, and renal failure.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:45:58 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm 1:<BR/>Clodronate<BR/>Intravenous<BR/>600mg<BR/>x1 dose</P>
<P>2. Active arm 2:<BR/>Clodronate<BR/>Intravenous<BR/>1500 mg<BR/>x1 dose</P>
<P>3. Control arm:<BR/>Placebo</P>
<P>Crossover after 2 weeks<BR/>Patients on chemotherapy or hormonal therapy as part of standard care</P>
<P>60 pts<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Mean change in pain score</P>
<P>2. Analgesic: <BR/>a. Mean change in morphine equivalent</P>
<P>Others:<BR/>a. Patient preference<BR/>26/60 preferred pamidronate<BR/>12/60 preferred placebo<BR/>8/60 no preference</P>
<P>No adverse effects reported</P>
<P>Withdrawals: <BR/>9 pts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:46:21 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Glover-1994">
<CHAR_METHODS>
<P>4 active arms</P>
<P>Pain measurement tool: <BR/>a. 0-9 point scale [pain severity (0-3) x pain frequency (0-3)]<BR/>severity: 0=none, 1 = mild, 2= moderate, 3= severe<BR/>frequency: 0=none, 1 = occasionally, 2= &gt;or =1/day, 3 = constant<BR/>No relief: pain score &gt;/= baseline</P>
<P>Definition of pain response (Pain relief score):<BR/>Complete relief: pain score of 0<BR/>Partial relief: pain score &lt;4<BR/>Minimal relief: pain score less than baseline but &gt;/=4</P>
<P>Analgesic scale: 0-9 point scale [ type of medication (0-3) x frequency (0-3)]<BR/>type: 0 = none, 1 = mild, 2 = mild narcotics, 3= strong narcotics<BR/>frequency: 0= none, 1 = &lt;daily, 2=once per day, 3= &gt;1per day</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:46:05 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer</P>
<P>Bone metastases required</P>
<P>Pain required: Pain score &gt;4 (i.e. at least moderate and intermittent)</P>
<P>Co-intervention: May be on chemotherapy or hormonal therapy as part of standard clinical care</P>
<P>Performance status criteria: life expectancy &gt;3m</P>
<P>Other criteria: exclude changes in chemotherapy/ hormones within 60 days, prior bisphosphonate, treatment for hypercalcemia within 90 days, radiotherapy within 2 weeks, history of hypercalcemia, pathological fractures, cord compression, renal, bone marrow dysfunction, ascites<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:46:15 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm 1:<BR/>Pamidronate<BR/>Intravenous<BR/>30 mg every 2 weeks for 3 months<BR/>14 pts</P>
<P>2. Active arm 2:<BR/>Pamidronate<BR/>Intravenous<BR/>60 mg every 4 weeks<BR/>17 pts</P>
<P>3. Active arm 3:<BR/>Pamidronate<BR/>Intravenous<BR/>60 mg every 2 weeks<BR/>14 pts</P>
<P>4. Active arm 4:<BR/>Pamidronate<BR/>Intravenous<BR/>90 mg every 4 weeks<BR/>16 pts</P>
<P>Chemo/hormonal therapy as part of standard clinical care unchanged at least 60 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-11 11:46:21 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Pain:<BR/>a. Change in mean pain score</P>
<P>2. Analgesic:<BR/>a. Change in mean pain score</P>
<P>Others:<BR/>a. Urinary calcium/creatinine and hydroxyproline/creatinine ratios, serum osteocalcin and bone alkaline phosphatase<BR/>b. Bone radiological response</P>
<P>Withdrawals:<BR/>Active arm 1: 5/14<BR/>Active arm 2: 2/17<BR/>Active arm 3: 1/14<BR/>Active arm 4: 2/16</P>
<P>Adverse effects (n = 51 evaluable)<BR/>Described for all patients in study<BR/>Fever: 6<BR/>Myalgia: 3<BR/>Increase pain: 5<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:46:39 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Heim-1995">
<CHAR_METHODS MODIFIED="2008-07-11 11:46:28 +0100" MODIFIED_BY="Jessica R Thomas">
<P>2 arm study, stratified by stage II vs III, bone involvement vs no bone involvement, high enrolment centers vs low enrolment centers</P>
<P>1 active arm, 1 open control</P>
<P>Pain measurement tool: WHO criteria (0-3), patient reported</P>
<P>Analgesic scale: analgesic consumed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:46:37 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Multiple myeloma (SII, SIII, and SI pretreated patients)</P>
<P>No bone involvement required</P>
<P>No pain requirement</P>
<P>Co-intervention: chemotherapy</P>
<P>Performance status criteria: life expectancy &gt; 1 year, ECOG 0-2</P>
<P>
<BR/>Other criteria: exclude no bisphosphonates, no renal dysfunction<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:46:39 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1.Active arm:<BR/>Clodronate Oral<BR/>1600 mg /day for 1 year<BR/>77 pts</P>
<P>2. Control arm:<BR/>No treatment<BR/>80 pts</P>
<P>All patients received melphalan and prednisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>at 3 months<BR/>85% no pain in Clodronate group<BR/>62% no pain in control group</P>
<P>2. Analgesic:<BR/>a. Proportion with no analgesics</P>
<P>Other:<BR/>a. Bone response<BR/>b. Incidence of hypercalcemia<BR/>c. Bone resorption index<BR/>d. Change in performance status<BR/>e. Change in serum calcium levels<BR/>f. Tumor response</P>
<P>13 pts withdrew from the study prior to treatment</P>
<P>Adverse effects (WHO criteria) Grade 3-4<BR/>Active:<BR/>Hemorrhage: 2<BR/>Fever: 1<BR/>Skin changes: 2<BR/>Anorexia: 14<BR/>Nausea: 7<BR/>Vomiting: 5<BR/>Dyspnea: 8<BR/>Infection: 6<BR/>Diarrhea: 3<BR/>Constipation: 2<BR/>Heart failure: 8<BR/>Cardiac arrhythmia: 2</P>
<P>Control: <BR/>Hemorrhage: 3<BR/>Hematuria: 1<BR/>Skin changes: 1<BR/>Anorexia: 16<BR/>Nausea: 10<BR/>Vomiting: 1<BR/>Dyspnea: 8<BR/>Infection: 7<BR/>Diarrhea: 1<BR/>Constipation: 1<BR/>Allergy: 1<BR/>Heart failure: 8<BR/>Cardiac arrhythmia: 1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:47:10 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Hortobagyi-1996a">
<CHAR_METHODS>
<P>Active vs placebo control stratified by ECOG PS 0,1 vs 2,3</P>
<P>Pain measurement tool: 0-9 point scale [pain severity (0-3) x pain intensity (0-3)]</P>
<P>Analgesic scale: 0-9 point scale</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:47:10 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: chemotherapy as indicated clinically</P>
<P>Performance status criteria: life expectancy &gt; 9 months, ECOG PS &lt;/ = 3</P>
<P>Other criteria: exclude previous skeletal complications, hypercalcemia, ascites, renal, liver, cardiac dysfunction, bisphosphonate/radiotherapy within 60 days, calcitonin within 2 weeks.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:47:01 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Pamidronate<BR/>Intravenous<BR/>90 mg monthly<BR/>for 1 year<BR/>185 pts</P>
<P>2. Control arm:<BR/>Placebo 197 pts</P>
<P>Chemotherapy as is indicated clinically</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Change in mean pain score</P>
<P>2. Analgesic: <BR/>Not an endpoint</P>
<P> Others:<BR/>a. Time to first skeletal complication<BR/>b. Proportion of patients with skeletal complication<BR/>c. Performance status<BR/>d. Change in Spitzer QoL score<BR/>e. Radiological response <BR/>f. Changes in urinary and serum markers for bone resorption<BR/>e. CEA level</P>
<P>Withdrawals:<BR/>Active: 0/185<BR/>Control: 2/197</P>
<P>Adverse effects:<BR/>Active: (withdrawn from study)<BR/>Weakness: 1<BR/>Fatigue: 1<BR/>Hypocalcemia: 1</P>
<P>Control: <BR/>None described<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
<P>Update of these results in Hortobagyi 1998<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:47:26 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Hultborn-1996">
<CHAR_METHODS>
<P>Active vs placebo, stratified by center</P>
<P>Pain measurement tool: VAS, patient reported</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:47:22 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer</P>
<P>Bone metastases required</P>
<P>Pain not required</P>
<P>Co-intervention: as clinically indicated</P>
<P>Performance status criteria: life expectancy &gt;3 months</P>
<P>Other criteria: exclude previous bisphosphonates, hypercalcemia<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:47:26 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Pamidronate<BR/>Intravenous<BR/>60 mg every 4 weeks, up to 2 yrs<BR/>201 pts</P>
<P>2. Control arm:<BR/>Placebo 203 pts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>No significant difference between groups</P>
<P>Others:<BR/>a. Skeletal event free survival<BR/>b. Cumulative incidence of skeletal events<BR/>c. Hypercalcemia event free time<BR/>d. Incidence of therapeutic activities for skeletal progression, change of antitumoral treatment <BR/>e. Pain progression free survival<BR/>f. Proportion of patients taking opioids</P>
<P>Adverse effects (withdrawal from therapy)<BR/>Active group: 9/201<BR/>Control group: 3/203<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:47:37 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Koeberle-1999">
<CHAR_METHODS>
<P>2 active arms, stratified by diagnosis (breast vs myeloma), baseline pain intensity (&lt;/=40mm Vs &gt;40 mm) </P>
<P>Pain measurement tool: <BR/>a. 10 cm VAS<BR/>b. PPA (0: no pain, 1: mild, 2: moderate, 3: severe, 4: intractable) (WHO definitions)<BR/>Pain patient reported</P>
<P>Definition of pain response: &gt;/=20% reduction in pain intensity or PPA on 2 consecutive visits</P>
<P>Analgesic scale: 0-5 point scale (WHO) <BR/>0: none, 1: mild analgesic, 2: non steroidal anti-inflammatory 3: opioids 4: opiates</P>
<P>Analgesic response criteria: 1 point change in score in 2 consecutive visits or &gt;/=2 point change</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:47:32 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary</P>
<P>Bone metastases required</P>
<P>Pain required (&gt;/ = 2), and analgesic score &gt;/ = 2</P>
<P>Co-intervention: none described</P>
<P>Performance status criteria: no specification</P>
<P>Other criteria: exclude prior bisphosphonates<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:47:37 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm 1 :<BR/>Pamidronate<BR/>Intravenous<BR/>60 mg every 3 weeks<BR/>x 6 doses over 18 weeks<BR/>35 pts</P>
<P>2. Active arm 2:<BR/>Pamidronate<BR/>Intravenous<BR/>90 mg every 3 weeks<BR/>x6 doses over 18 weeks<BR/>35 pts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Change in mean pain score<BR/>b. Duration of pain response</P>
<P>2. Analgesic:<BR/>a. Proportion with improvement</P>
<P>Others:<BR/>a. Performance status<BR/>b. Bone remineralization</P>
<P>Adverse effects: (discontinuation of therapy)<BR/>Active arm: 1/35<BR/>Control arm: 1/35<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:47:50 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Kylmala-1997">
<CHAR_METHODS MODIFIED="2008-07-11 11:47:42 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Active vs placebo</P>
<P>Pain measurement tool: 10 cm VAS, 0-4 ordinal scale</P>
<P>Pain scores expressed by: patient (VAS) physician (ordinal scale)</P>
<P>Definition of pain response: not applicable</P>
<P>Analgesic scale: 3 point scale (0: none, 1: non narcotics &lt;x3/d, 2: non narcotic &gt;x3/d, 3: narcotics)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:47:45 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Prostate cancer (hormonal therapy)</P>
<P>Bone metastases required</P>
<P>No pain required</P>
<P>Co-intervention: hormonal/chemotherapy</P>
<P>Performance status criteria: none</P>
<P>Other exclusion radiotherapy within 2 weeks<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:47:50 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Clodronate<BR/>300 mg/day IV x5 days, then 1.6 g/day oral x12 months<BR/>28 pts</P>
<P>2. Control arm:<BR/>Placebo 29 pts</P>
<P>All patients receive Estramustine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>No significant difference in any pain score</P>
<P>2. Analgesic:<BR/>a. Proportion of patients with reduced analgesic</P>
<P>Others:<BR/>a. Performance status change<BR/>b. Clinical response i.e. better, same, or worse as scored by doctor<BR/>c. Radiological response<BR/>d. Biochemical markers of bone resorption, serum calcium, alkaline phosphatase.<BR/>e. PSA levels</P>
<P>Withdrawals:<BR/>Active arm: 0/28<BR/>Control arm: 2/29</P>
<P>Adverse effects:<BR/>Active arm: <BR/>Nausea: 9</P>
<P>Control arm: <BR/>Nausea: 11<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:48:00 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Lahtinen-1992">
<CHAR_METHODS>
<P>Active vs placebo</P>
<P>Pain measurement tool: 0-4 pain scale, patient reported</P>
<P>Analgesic scale: Analgesic type used (narcotics Vs non-narcotics)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:47:58 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Multiple myeloma</P>
<P>Bone lesion not required</P>
<P>No pain requirement</P>
<P>Co-intervention: chemotherapy</P>
<P>Other: exclude patients who are asymptomatic, unable to tolerate chemotherapy, previous bisphosphonates<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:48:00 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Clodronate Oral<BR/>2.4 g/day at 4 weeks post CT, then for 24 months<BR/>175 pts</P>
<P>2. Control arm:<BR/>Placebo 175 pts</P>
<P>3. All patients received mephalan and prednisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. No pain data within 12 weeks<BR/>b. No significant difference in pain at 12 months</P>
<P>2. Analgesic:<BR/>b. No analgesic data within 12 weeks</P>
<P>Withdrawals:<BR/>Active arm: 7/175<BR/>Control arm: 7/175</P>
<P>Adverse effects<BR/>Active arm:<BR/>Nausea: 29<BR/>Diarrhea: 17<BR/>Abdominal pain: 18<BR/>Allergic reaction: 15</P>
<P>Control arm:<BR/>Nausea: 25<BR/>Diarrhea: 15<BR/>Constipation: 8<BR/>Abdominal pain: 33<BR/>Allergic reaction: 3<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:48:19 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Martoni-1991">
<CHAR_METHODS MODIFIED="2008-07-11 11:48:08 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Active vs placebo (stratified by type of bone lesion osteolytic vs blastic vs mix), type of anti-tumor therapy (chemotherapy and /or hormonal therapy)</P>
<P>Pain measurement tool: VAS, patient reported</P>
<P>Analgesic scale: analgesic consumed</P>
<P>Analgesic response definition:<BR/>Increase: no. of daily administration and or shift from the use of minor analgesics to morphine<BR/>Decrease: reduction in the no of daily administration and /or shift from the use of morphine to minor analgesics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:48:11 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer</P>
<P>Bone metastases required</P>
<P>No pain requirement</P>
<P>Co-intervention: systemic therapy</P>
<P>Performance status criteria: &gt;/ = 50</P>
<P>Other: exclude abnormal calcium, renal dysfunction, and stable disease<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:48:19 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>clodronate<BR/>300 mg/day IV x7 days, +100mg/day IM x3 weeks, +100 mg IM alt days x2 months<BR/>19 pts</P>
<P>2. Control arm:<BR/>Placebo<BR/>19 pts</P>
<P>Patients also received chemotherapy/hormonal therapy as was clinically indicated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain: <BR/>No significant difference in pain intensity</P>
<P>2. Analgesic:<BR/>a. Proportion of patients with pain reduction</P>
<P>Others:<BR/>a. Urinary calcium/ hydroxyproline levels<BR/>b. Incidence of hypercalcemia<BR/>c. Incidence of pathological fractures<BR/>d. Incidence of progressive bone disease</P>
<P>No withdrawals</P>
<P>Adverse effects:<BR/>Described for all patients, none significant<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:48:36 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Moiseyenko-1998">
<CHAR_METHODS MODIFIED="2008-07-11 11:48:29 +0100" MODIFIED_BY="Jessica R Thomas">
<P>2 active arms</P>
<P>Pain measurement tool: VAS 10 cm, patient reported</P>
<P>Definition of pain response: &gt;/=10 mm change</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:48:25 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: none described</P>
<P>Performance status criteria: no specifications</P>
<P>Other criteria: none<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:48:36 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm 1:<BR/>Clodronate<BR/>intravenous<BR/>300 mg x5 days<BR/>24 pts</P>
<P>2. Active arm 2:<BR/>Clodronate<BR/>Intravenous<BR/>1500 mg IV day 1 then placebo days 2-5<BR/>27 pts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Proportion with pain improvement</P>
<P>2. Analgesic:<BR/>Not an endpoint</P>
<P>Withdrawals: none</P>
<P>Adverse effects:<BR/>None reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 2</P>
<P>Russian article</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:48:48 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-O_x0027_Rourke-1995">
<CHAR_METHODS MODIFIED="2008-07-11 11:48:45 +0100" MODIFIED_BY="Jessica R Thomas">
<P>3 active arms, 1 placebo arm<BR/>(stratified by urinary calcium level: &lt;0.35 vs &gt;0.35 mmol/mmol creatinine)</P>
<P>Pain assessment: 10 cm VAS, patient reported</P>
<P>Toxicity criteria: WHO<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:48:40 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary</P>
<P>Bone metastases required</P>
<P>No pain requirement</P>
<P>Co-intervention: unrestricted concomitant tumor therapy as clinically indicated</P>
<P>Performance status criteria: life expectancy &gt;1m</P>
<P>Other criteria: exclude urinary calcium excretion &lt;0.175mmol/mmol creatinine, radiotherapy within 1 month, chemotherapy/bisphosphonate within 3 months<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:48:48 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm 1:<BR/>Clodronate oral<BR/>400 mg /day x4 weeks<BR/>20 pts</P>
<P>2. Active arm 2: 1600mg<BR/>19 pts</P>
<P>3. Active arm 3: 3200mg<BR/>20 pts</P>
<P>4. Placebo control:<BR/>May receive hormone/systemic chemotherapy if unchanged in previous 3 months<BR/>21 pts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>No change in bone pain</P>
<P>2. Analgesics:<BR/>No change in analgesic requirements</P>
<P>Withdrawals<BR/>4 for whole study</P>
<P>Adverse effects:<BR/>Active arm 1:<BR/>Nausea or vomiting: 3<BR/>Diarrhea: 1</P>
<P>Active arm 2:<BR/>Nausea or vomiting: 3<BR/>Diarrhea: 3</P>
<P>Active arm 3: <BR/>Nausea or vomiting: 4<BR/>Diarrhea: 1</P>
<P>Control arm:<BR/>Nausea or vomiting: 6<BR/>Diarrhea: 1<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:48:59 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Piga-1998">
<CHAR_METHODS>
<P>Active vs placebo control</P>
<P>Pain measurement tool: VAS</P>
<P>Analgesic assessment: O: none, 1: NSAIDS 2: opiates</P>
<P>Analgesic response definition: reduction in level </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:48:55 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary (poor prior response to chemotherapy)</P>
<P>Bone metastases required</P>
<P>No pain requirement</P>
<P>Co-intervention: none described</P>
<P>Performance status criteria: life expectancy &gt;/=3m, PS &gt;/=40</P>
<P>Other criteria: exclude hypercalcemia, renal dysfunction<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:48:59 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Clodronate Oral<BR/>1600 mg/day x1 year<BR/>27 pts</P>
<P>2. Control<BR/>Placebo 23 pts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>10/22 worse on placebo<BR/>5/27 worse on Clodronate</P>
<P>2. Analgesic:<BR/>a. Proportion of patients not requiring an increase</P>
<P>Adverse effects: <BR/>Active arm:<BR/>GI discomfort: 3/27</P>
<P>Control arm: <BR/>GI discomfort: 5/23<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:49:06 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Robertson-1995">
<CHAR_METHODS>
<P>Active vs placebo (stratified for primary site: breast, lung vs others)</P>
<P>Pain measurement tool: VAS. patient reported</P>
<P>Analgesic scale: morphine equivalent</P>
<P>Analgesic response definition: increase, static or reduced</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:49:04 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Any primary (Resistant to first line chemotherapy)<BR/>2. Bone metastases required<BR/>3. Pain required<BR/>4. Co-intervention: hormonal/chemotherapy as clinically indicated<BR/>5. Performance status criteria: life expectancy: &gt;2m<BR/>6. Other criteria: exclude renal dysfunction, use of bisphosphonates<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:49:06 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1.Active arm:<BR/>Clodronate Oral<BR/>1600 mg/day<BR/>Approx 170 days<BR/>27 pts</P>
<P>2. Control arm:<BR/>Placebo 28 pts</P>
<P>Patients can receive systemic therapy as was clinically indicated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Change of mean pain score</P>
<P>2. Analgesics:<BR/>a. Proportion of patients with reduction</P>
<P>Withdrawal:<BR/>None reported</P>
<P>Adverse effects<BR/>Active arm: <BR/>Hypocalcemia: 2/27</P>
<P>Control arm:<BR/>Hypocalcemia: 0/28<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:49:15 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Siris-1983">
<CHAR_METHODS>
<P>Active vs placebo Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:49:10 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer with hypercalcemia/ hypercalciuria</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: hormonal/ chemotherapy as clinically indicated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:49:15 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Clodronate Oral<BR/>3200 mg/day<BR/>Total: 24 weeks<BR/>5 pts</P>
<P>2. Control arm:<BR/>Placebo 5 pts</P>
<P>Patients receiving chemotherapy/hormonal therapy as was clinically indicated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Withdrawals:<BR/>3 for whole group</P>
<P>Adverse effects:<BR/>Active arm: <BR/>Diarrhea: 4/5</P>
<P>Control arm: <BR/>Diarrhea: 0/5<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:49:31 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Smith-1989">
<CHAR_METHODS>
<P>3 active arms, 1 placebo arm</P>
<P>Pain measurement tool: VAS, patient and physician reported</P>
<P>Definition of pain response: minor and major improvement, no criteria described</P>
<P>Analgesic scale: assessment/criteria described<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:49:22 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Prostate cancer (previous hormonal therapy)</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: hormonal therapy as clinically indicated</P>
<P>Other criteria: exclude radiotherapy within 1 month, renal dysfunction<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:49:31 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm 1:<BR/>Etidronate<BR/>Intravenous<BR/>7.5 mg/kg/day x3 days,<BR/>then 200mg orally twice a day x1 month<BR/>13 pts</P>
<P>2. Active arm 2:<BR/>Etidronate 7.5 mg/kg/day x3 days<BR/>12 pts</P>
<P>3. Active arm 3:<BR/>Etidronte placebo x3, then 200mg orally twice a day x 1 month<BR/>14 pts</P>
<P>4. Active arm 4:<BR/>Placebo only<BR/>12 pts</P>
<P>Systemic therapy as clinically indicated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>a. Proportion of patients with pain reduction</P>
<P>2. Analgesic:<BR/>a. State no difference, no comparative data</P>
<P>Toxicity: Yes</P>
<P>Withdrawals:<BR/>Active arm 1: 1/13<BR/>Active arm 2: 2/12<BR/>Active arm 3: 1/14<BR/>Placebo arm 4: 2/12</P>
<P>Adverse effects:<BR/>No serious ADRs reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:49:51 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Strang-1997">
<CHAR_METHODS>
<P>Active vs placebo </P>
<P>Pain measurement tool: VAS, patient reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:49:48 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Prostate cancer, hormone refractory</P>
<P>Bone metastases required</P>
<P>Pain required (&gt; 20 mm on VAS)</P>
<P>Co-intervention: none described</P>
<P>Performance status criteria: life expectancy &gt; 3 months</P>
<P>Other criteria: exclude renal dysfunction, bisphosphonate within 1 month<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:49:51 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm 1:<BR/>Clodronate Intravenous, 300 mg/day x3 days<BR/>then oral 600 mg twice a day x4 weeks<BR/>25 pts</P>
<P>2. Active arm 2:<BR/>Placebo 27 pts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>P value only</P>
<P>2. Analgesic:<BR/>Not a reported endpoint</P>
<P>Adverse effects: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 3</P>
<P>study closed early due to lack of accrual</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:50:14 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Theriault-1999">
<CHAR_METHODS>
<P>Active vs placebo (stratified by ECOG 0,1 vs 2, 3)</P>
<P>Pain measurement tool: 0-9 point scale [pain severity (0-3) x pain intensity (0-3)]</P>
<P>Analgesic scale: Type of medication x frequency </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:50:03 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer (on stable hormonal therapy within 3 months)</P>
<P>Bone metastases required</P>
<P>Pain not required</P>
<P>Co-intervention: Hormonal/ chemotherapy as clinically indicated</P>
<P>Performance status criteria: life expectancy &gt;/=9 months</P>
<P>Other criteria: exclude patients on chemotherapy, cord compression, calcitonin/ mitramycin within 14 days prior to enrolment, skeletal event within 2 weeks, renal cardiac, liver dysfunction<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:50:07 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Pamidronate<BR/>Intravenous<BR/>90 mg every 4 weeks<BR/>x24 cycles<BR/>182 pts</P>
<P>2. Control arm:<BR/>Placebo 192 pts</P>
<P>Hormonal therapy / chemotherapy as was necessary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-11 11:50:14 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1 Pain:<BR/>No data within 3 months of enrolment</P>
<P>2. Analgesic:<BR/>No data within 3 months of enrolment</P>
<P>Others:<BR/>a. Skeletal morbidity rate<BR/>b. Time to first skeletal event<BR/>c. Survival<BR/>d. Objective bone response rate<BR/>e. Mean bone pain score at 1 year and at 12 cycles<BR/>f. Mean analgesic requirement at 12 months and at 12 cycles<BR/>g. Urine hydroxyproline/creatinine, calcium/creatinine ratios</P>
<P>Adverse effects:<BR/>Active arm:<BR/>Allergic reaction: 1/182<BR/>Interstitial pneumonia: 1/182</P>
<P>Control arm:<BR/>None<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:50:30 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-van-Holten-1993">
<CHAR_METHODS>
<P>Active vs open control</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:50:17 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Breast cancer</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: unrestricted concomitant tumor therapy as clinically indicated</P>
<P>Performance status criteria: life expectancy: &lt;/=6 months</P>
<P>Other criteria: exclude hypercalcemia, upper gastrointestinal disease, and renal dysfunction<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:50:23 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Pamidronate<BR/>Oral<BR/>300 mg /day<BR/>Indefinitely<BR/>79 pts</P>
<P>2. Control arm:<BR/>No treatment 84 pts</P>
<P>Unrestricted concomitant tumor therapy as clinically indicated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Others:<BR/>a. Incidence of hypercalcemia<BR/>b. Incidence of severe bone pain <BR/>c. Incidence of symptomatic impending fractures<BR/>d. Need for systemic treatment<BR/>e. Need for radiotherapy<BR/>f. Event free period for radiologic course of disease<BR/>g. Survival</P>
<P>Withdrawals:<BR/>Active arm: 8/79<BR/>Control arm: 4/84</P>
<P>Toxicity: (Study discontinuation)<BR/>Active: 19/79<BR/>Control arm: None stated<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-11 11:50:30 +0100" MODIFIED_BY="Jessica R Thomas">
<P>QS= 2</P>
<P>Study started with pamidronate 600 mg, but due to severe GI side effects, dose reduced to 300 mg.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-11 11:50:38 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Vinholes-1997a">
<CHAR_METHODS>
<P>Active vs placebo </P>
<P>Pain measurement tool: <BR/>a. Overall pain score based on combination of pain (0-5), analgesic use (0-8), and Performance status (0-4)<BR/>b. Pain intensity score: 0: none, 1: mild, 2: moderate, 3: severe, 4: very severe, 5: intolerable<BR/>Patient reported pain</P>
<P>Definition of pain response: &gt;/=20% decrease in pain score on at least 2 consecutive measurements</P>
<P>Analgesic scale and analgesic response definition part of overall pain score </P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-11 11:50:35 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Any primary</P>
<P>Bone metastases required</P>
<P>Pain required</P>
<P>Co-intervention: stable hormonal therapy used prior to treatment</P>
<P>Other criteria: exclude renal dysfunction, bisphosphonate &lt;/ = 3m prior to study<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-11 11:50:38 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Active arm:<BR/>Pamidronate<BR/>Intravenous<BR/>120 mg x1 dose<BR/>25 pts</P>
<P>2. Control arm:<BR/>Placebo 27 pts</P>
<P>All patients received<BR/>pamidronate at 3 weeks after above (or earlier if symptoms) and continued as long as beneficial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Change in median % of baseline overall pain score</P>
<P>Others:<BR/>a. QoL <BR/>b. Bone resorption markers, including NTx and Crosslaps, urine calcium pre and post treatment</P>
<P>Withdrawals:<BR/>Active: 3/25<BR/>Control: 1/27</P>
<P>Adverse effects: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>QS = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>VAS: visual analogue scale<BR/>Pts: patients<BR/>N: number of evaluable patients<BR/>Withdrawal: number of patients withdrawal (N+ withdrawal= no. of patients randomized in the study)<BR/>ECOG PS : Eastern cooperative oncology Group performance status<BR/>vs: versus<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abildgaard-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subgroup analysis of RCT From Brinker 1998</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ahmedzai-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berenson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berenson-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate. Primary study : Berenson 1996 (included studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berenson-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate. Primary study :Berenson 1996 (included studies) no pain assessments</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berenson-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate.Update of Berenson 1996 , no further evaluable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blomqvist-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bloomfield-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Body-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Body-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Body-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chantraine-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chapuy-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clemens-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, Primary study (Heim 1995) Interim report on subset of patients treated at one of the participating institution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coleman-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; Primary study (Coleman 1998) included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coleman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study (Vinholes 1997b) included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coleman-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study (Vinholes 1997b) included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Colleoni-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Conte-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study (Conte 1994).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costa-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coukell-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cresswell-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crosby-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delmas-1982b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain endpoints</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delmas-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delmas-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Derrane-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diel-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain endpoint</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diel-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Diel 1997, excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diener-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Clinical review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dodwell-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dooley--1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dranitsaris-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cost utility study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dranitsaris-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cost utlity study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elomaa-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; updates in Elomaa 1987,1988. No pain outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elomaa-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Elomaa 1983 , included. No pain outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elomaa-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Elomaa 1983, included. No pain outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Engler-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No pain measures, randomisation not adequately described</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ernst-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; Primary study : Ernst 1997 included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ernst-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; Primary study: Ernst 1997 included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fitton-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fontana-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Francis-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fulfaro-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gucalp-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, No pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gurney-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harvey-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article describing RCT (duplicate of Berenson 1996)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hortobagyi-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Hortobagyi 1996a, included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hortobagyi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Hortobagyi 1996a, included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hortobagyi-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Hortobagyi 1996a, Duplicate of Hortobagyi 1996</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulin-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; Primary study Tubiana 1995, excluded. Abstract only, no pain outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iddon-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iveson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Kanis 1996, excluded. No pain endpoint</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jung-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, No pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kanis-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kanis-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, Inadequate pain outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koberle-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Koberle 1999, included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kristensen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, Physician reported pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kylmala-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Elomaa 1992 (included). Has more patients than Elomaa 1992, but no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Laakso-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Economic analysis of study reported by Lahtinen 1992.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-LaCivita-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipton-1994a">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, interim results with no pain data. Same design as Glover 1994, (included study) although unclear whether it is the same study.Current study describe breast and prostate cancer, Glover breast only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipton-1994b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipton-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Theriault 1999</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipton-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipton-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipton-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; describe two studies. Primary studies Hortobagyi 1996 (included) Theriault 1999 (included)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lortholary-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maolin-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maxon-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, evaluating Rhenium</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCloskey-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, Physician reported pain only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mercadante-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Merlini-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mundy-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Descriptive comment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Musto-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Namer-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paterson-1991b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Paterson 1994. Comparing clodronate vs placebo. No pain measurement/outcome . Same study as Paterson 1993.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paterson-1993a">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Paterson 1994. No pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paterson-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Paterson 1994.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paterson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paterson-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paterson-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary and opinion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peest-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT. No clinical outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pelger-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Plosker-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Powles-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Powles-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Purohit-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Radziwill-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ravn-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, No pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riccardi-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ripamonti-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rose-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rotstein-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ryzen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shucai-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, Radiotherapy for control arm, excluded because of significant use of radiotherapy (the control intervention) in bisphosphonate arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1983b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, no pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strang-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taube-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, No pain assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Theriault-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No pain outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Theriault-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Theriault 1999, included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thurlimann-1994a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thurlimann-1994b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tubiana_x002d_Hulin-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, abstract only, state pain reduction significant, p value only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tyrrell-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tyrrell-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open study duplicat publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Holten-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>earlier version of van Holten Verzantvoort 1993</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Holten-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study 1993, included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Holten-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study 1993, included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vinholes-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vinholes-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but duplicate; primary study Vinholes 1997b, Not full publication, abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vinholes-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, primary study ? No pain outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vorreuther-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walker-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Berenson-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kraj-2000a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kraj-2000b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Major-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-McCloskey-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Terpos-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-11 11:52:17 +0100" MODIFIED_BY="Jessica R Thomas">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-07-11 11:51:19 +0100" MODIFIED_BY="Jessica R Thomas" NO="1">
<TITLE>Items sought for inclusion in 'Characteristics of included studies' table</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TH>
<P>Methods</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Number of study arms</P>
</TD>
<TD>
<P>Primary site (prostate vs breast vs multiple myeloma vs lung vs combination)</P>
</TD>
<TD>
<P>For each of intervention arm/active control arm: name of bisphosphonate (etidronate, clodronate, pamidronate, others)</P>
</TD>
<TD>
<P>Which of the following pain measure outcome can be extracted from the study:</P>
</TD>
<TD>
<P>Oxford Quality Scale score (Jadad)</P>
</TD>
</TR>
<TR>
<TD>
<P>Study design (blind/ open/active controls)</P>
</TD>
<TD>
<P>Whether patients have to have bone metastases or not at the time of enrolment (bone mets vs bone mets not required)</P>
</TD>
<TD>
<P>Route of administration</P>
</TD>
<TD>
<P>Mean pain score pre and post treatment</P>
</TD>
<TD>
<P>Number and reason of dropouts</P>
</TD>
</TR>
<TR>
<TD>
<P>If crossover study, duration of washout period</P>
</TD>
<TD>
<P>Whether patients have to have pain prior to study enrolment (pain or pain not required)</P>
</TD>
<TD>
<P>Dose schedule</P>
</TD>
<TD>
<P>Proportion of patients with pain reduction</P>
</TD>
<TD>
<P>Other notes</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain measurement tool used</P>
</TD>
<TD>
<P>Other interventions in study arm (chemotherapy / hormonal therapy/ others)</P>
</TD>
<TD>
<P>Duration of therapy</P>
</TD>
<TD>
<P>P value only for a pain measure</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pain score expressed by : patient /physician/ unknown</P>
</TD>
<TD>
<P>Performance status measure (life expectancy / others)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Not reported as an endpoint</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Criteria of response for pain. This is only applicable if proportion of patients reponding is an outcome measure. Not specified infers that this is an outcome measure by definition not provided, not applicable infers that this is not an outcome measure used.</P>
</TD>
<TD>
<P>Other specifications for inclusion/exclusion</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Which of the following analgesics change can be extracted from the data:</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Analgesic measurement tool used</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>proportion with analgesic reduction</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Criteria of response for analgesic</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Others</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adverse effects for control, and study arm</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-07-11 11:51:42 +0100" MODIFIED_BY="Jessica R Thomas" NO="2">
<TITLE>Included studies by primary disease site</TITLE>
<TABLE COLS="6" ROWS="37">
<TR>
<TH>
<P>STUDY</P>
</TH>
<TH>
<P>BREAST</P>
</TH>
<TH>
<P>PROSTATE</P>
</TH>
<TH>
<P>MULTIPLE MYELOMA</P>
</TH>
<TH>
<P>LUNG</P>
</TH>
<TH>
<P>ANY PRIMARY</P>
</TH>
</TR>
<TR>
<TD>
<P>BLINDED STUDIES</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Theriault 1999</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Brinkler 1998</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Piga 1998</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Vinholes 1997a</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Strang 1997</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kylmala 1997</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Ernst 1997*</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Hultborn 1996</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hortobagyi 1996</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Berenson 1996</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Robertson 1995</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>O'Rourke 1995*</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Daragon 1993</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lahtinen 1992</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Elomaa 1992</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ernst 1992</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Martoni 1991</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Belch 1991</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Smith 1989*</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Siris 1983</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Demas 1982</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>OPEN CONTROL</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Arican 1999*</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Heim 1995</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Conte 1994</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Van Holten 1993</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>ACTIVE CONTROL</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Koeberle 1999</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Cascinu 1998</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Moiseyenko 1998</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Coleman 1998</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Glover 1994</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>* studies with &gt;1 active arms</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Studies by intervention (clodronate)</TITLE>
<TABLE COLS="9" ROWS="16">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>placebo control</P>
</TH>
<TH>
<P>open control</P>
</TH>
<TH>
<P>400mg/d PO</P>
</TH>
<TH>
<P>800mg/d PO</P>
</TH>
<TH>
<P>1600mg/d PO</P>
</TH>
<TH>
<P>2400mg/d PO</P>
</TH>
<TH>
<P>3200mg/d PO</P>
</TH>
<TH>
<P>Others</P>
</TH>
</TR>
<TR>
<TD>
<P>Arican 1999</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Delmas 1982a</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Elomaa 1992</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3.2g/dPO x1m then 1.6g/d PO x5m</P>
</TD>
</TR>
<TR>
<TD>
<P>Ernst 1992</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>600mg IV x1 dose</P>
</TD>
</TR>
<TR>
<TD>
<P>Ernst 1997</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>600mg IV x 1 dose vs 1500mg IV x1 dose</P>
</TD>
</TR>
<TR>
<TD>
<P>Heim 1995</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kylmala 1997</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>300mg/d IV x5d, then 1.6g/d PO</P>
</TD>
</TR>
<TR>
<TD>
<P>Lahtinen 1992</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Martoni 1991</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>300mg/d IV x7d, 100mg/d IM x3w, 100mg alt d IM x2m</P>
</TD>
</TR>
<TR>
<TD>
<P>Moisenyenko 1998</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>300mgIV x5d vs 1.5gIV x1 dose then placebo x4 d</P>
</TD>
</TR>
<TR>
<TD>
<P>O'Rourke 1995</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Piga 1998</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Robertson 1995</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Siris 1983</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Strang 1997</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>300mg/d IV x3d, 600mg bid x4w PO</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-07-11 11:52:01 +0100" MODIFIED_BY="Jessica R Thomas" NO="4">
<TITLE>Studies by intervention (Pamidronate IV)</TITLE>
<TABLE COLS="10" ROWS="10">
<TR>
<TH>
<P>study</P>
</TH>
<TH>
<P>Placebo control</P>
</TH>
<TH>
<P>Open control</P>
</TH>
<TH>
<P>40mg q3w IV</P>
</TH>
<TH>
<P>45mg q3w IV</P>
</TH>
<TH>
<P>60mg q3w IV</P>
</TH>
<TH>
<P>60mg q4w IV</P>
</TH>
<TH>
<P>90mg q3w IV</P>
</TH>
<TH>
<P>90mg q4w IV</P>
</TH>
<TH>
<P>others</P>
</TH>
</TR>
<TR>
<TD>
<P>Bereneson 1996</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cascinu 1998</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Conte 1994</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Glover 1994</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P>30 mg q2w vs 60 mg q2w</P>
</TD>
</TR>
<TR>
<TD>
<P>Hortobagyi 1996</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hultborn 1996</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Koeberle 1999</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Theriault 1999</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Vinholes 1997a</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>120 mg x 1dose</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2008-07-11 11:52:17 +0100" MODIFIED_BY="Jessica R Thomas" NO="5">
<TITLE>Studies by intervention (Pamidronate PO)</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Placebo control</P>
</TH>
<TH>
<P>Open control</P>
</TH>
<TH>
<P>150 mg/d</P>
</TH>
<TH>
<P>300 mg/d</P>
</TH>
</TR>
<TR>
<TD>
<P>Brinkler 1998</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Coleman 1998</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Holten 1993</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>+</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-11 11:59:51 +0100" MODIFIED_BY="Jessica R Thomas">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Proportion of patients with pain relief (Blinded and open control studies)</NAME>
<DICH_OUTCOME CHI2="1.8742849343909338" CI_END="4.116424004353917" CI_START="1.1904334358663524" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="2.213668622668208" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.6145201020639736" LOG_CI_START="0.07570511646148576" LOG_EFFECT_SIZE="0.3451126092627296" METHOD="MH" NO="1" P_CHI2="0.8662523175349638" P_Q="1.0" P_Z="0.012048331491113623" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="214" TOTAL_2="194" WEIGHT="100.00000000000001" Z="2.510725584253206">
<NAME>Proportion of patients with pain relief at 4 weeks (blinded and open studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="1" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="3.4933829148838753"/>
<DICH_DATA CI_END="7.728707557411744" CI_START="0.41106176451638543" EFFECT_SIZE="1.7824074074074074" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8881068745633782" LOG_CI_START="-0.3860929178482388" LOG_EFFECT_SIZE="0.2510069783575698" ORDER="1" O_E="0.0" SE="0.7484712654532806" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.5602092352092353" WEIGHT="17.88151337100196"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15132" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="29.864210222027232"/>
<DICH_DATA CI_END="6.967110119475996" CI_START="0.6509617734788353" EFFECT_SIZE="2.1296296296296298" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8430526748811786" LOG_CI_START="-0.18644451381989213" LOG_EFFECT_SIZE="0.3283040805306432" ORDER="15134" O_E="0.0" SE="0.6047317447362817" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="29" VAR="0.3657004830917874" WEIGHT="27.39233168428288"/>
<DICH_DATA CI_END="7.376858803044825" CI_START="0.2549616817600329" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.8678714709132598" LOG_CI_START="-0.5935250848626367" LOG_EFFECT_SIZE="0.13717319302531158" ORDER="15136" O_E="0.0" SE="0.8584315708923815" STUDY_ID="STD-Smith-1989" TOTAL_1="43" TOTAL_2="14" VAR="0.736904761904762" WEIGHT="13.59387189201985"/>
<DICH_DATA CI_END="60.13340568095146" CI_START="0.7026044761902381" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.7791158009943386" LOG_CI_START="-0.15328908770862754" LOG_EFFECT_SIZE="0.8129133566428556" ORDER="15137" O_E="0.0" SE="1.1351041971825928" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="25" TOTAL_2="27" VAR="1.2884615384615385" WEIGHT="7.774689915784202"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.311948268702936" CI_START="0.6388489940132724" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.566666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.01334072565322" LOG_CI_START="-0.19460178474758114" LOG_EFFECT_SIZE="0.40936947045281946" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1840274112765727" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="80" WEIGHT="100.0" Z="1.3284562991189648">
<NAME>Proportion of patients with pain response at 8w (Blinded and open studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.311948268702936" CI_START="0.6388489940132724" EFFECT_SIZE="2.566666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.01334072565322" LOG_CI_START="-0.19460178474758114" LOG_EFFECT_SIZE="0.40936947045281946" ORDER="1" O_E="0.0" SE="0.7095514100212919" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.5034632034632034" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.93761519519038" CI_END="4.481605242869674" CI_START="1.3798036990055955" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="2.486711782976557" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="55" I2="32.63288595663623" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.6514335995453705" LOG_CI_START="0.1398173048775459" LOG_EFFECT_SIZE="0.3956254522114583" METHOD="MH" NO="3" P_CHI2="0.20385600929199832" P_Q="1.0" P_Z="0.0024356497954659876" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14697062658394255" TOTALS="YES" TOTAL_1="317" TOTAL_2="317" WEIGHT="100.0" Z="3.031223382770791">
<NAME>Proportion of patients with pain relief at 12w (Blinded and open studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="1" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="17.7491342384427"/>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15139" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="14.766595764382284"/>
<DICH_DATA CI_END="2.9983068533348454" CI_START="1.1050296684415943" EFFECT_SIZE="1.8202247191011236" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.4768760774417277" LOG_CI_START="0.04337393835370861" LOG_EFFECT_SIZE="0.26012500789771814" ORDER="15140" O_E="0.0" SE="0.25464130237049903" STUDY_ID="STD-Conte-1994" TOTAL_1="143" TOTAL_2="152" VAR="0.0648421928729439" WEIGHT="42.63946028683844"/>
<DICH_DATA CI_END="8.158589133415132" CI_START="0.14515451581119143" EFFECT_SIZE="1.088235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9116150626081065" LOG_CI_START="-0.838169448558627" LOG_EFFECT_SIZE="0.03672280702473984" ORDER="15141" O_E="0.0" SE="1.0278320834323615" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="1.0564387917329092" WEIGHT="7.504997190488349"/>
<DICH_DATA CI_END="6.019274830211538" CI_START="0.5477555861370282" EFFECT_SIZE="1.8157894736842106" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.7795441729508843" LOG_CI_START="-0.2614131847099939" LOG_EFFECT_SIZE="0.25906549412044516" ORDER="15143" O_E="0.0" SE="0.6114635047120239" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="29" VAR="0.37388761759471134" WEIGHT="17.33981251984823"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.209993377698491" CI_END="3.4996391286022392" CI_START="1.6073132194012427" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.3717116676645635" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="62" I2="2.912532185508376" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5440232636254458" LOG_CI_START="0.20610051659072307" LOG_EFFECT_SIZE="0.37506189010808444" METHOD="MH" NO="4" P_CHI2="0.4073481169232507" P_Q="1.0" P_Z="1.3567596308450691E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.011104827464028473" TOTALS="YES" TOTAL_1="378" TOTAL_2="345" WEIGHT="100.00000000000001" Z="4.350744677805488">
<NAME>Proportion of patients with pain relief with best response within 12 weeks (blinded and open studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="1" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="1.3687467793463912"/>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="1" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="10.56388663982656"/>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15144" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="8.28180527873904"/>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15145" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="49.65951259701009"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15146" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="11.370030274810718"/>
<DICH_DATA CI_END="6.967110119475996" CI_START="0.6509617734788353" EFFECT_SIZE="2.1296296296296298" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8430526748811786" LOG_CI_START="-0.18644451381989213" LOG_EFFECT_SIZE="0.3283040805306432" ORDER="15148" O_E="0.0" SE="0.6047317447362817" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="29" VAR="0.3657004830917874" WEIGHT="10.456661347529533"/>
<DICH_DATA CI_END="7.376858803044825" CI_START="0.2549616817600329" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.8678714709132598" LOG_CI_START="-0.5935250848626367" LOG_EFFECT_SIZE="0.13717319302531158" ORDER="15150" O_E="0.0" SE="0.8584315708923815" STUDY_ID="STD-Smith-1989" TOTAL_1="43" TOTAL_2="14" VAR="0.736904761904762" WEIGHT="5.26747996607603"/>
<DICH_DATA CI_END="60.13340568095146" CI_START="0.7026044761902381" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.7791158009943386" LOG_CI_START="-0.15328908770862754" LOG_EFFECT_SIZE="0.8129133566428556" ORDER="15151" O_E="0.0" SE="1.1351041971825928" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="25" TOTAL_2="27" VAR="1.2884615384615385" WEIGHT="3.031877116661646"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Mean pain change (non standardized)</NAME>
<CONT_OUTCOME CHI2="0.3821428618304711" CI_END="1.0660126124582456" CI_START="-0.09045541938149088" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.48777859653837735" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.5364589673979641" P_Q="1.0" P_Z="0.0982577982370072" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="306" TOTAL_2="292" UNITS="" WEIGHT="99.99999999999999" Z="1.6533591164190524">
<NAME>mean pain score at 4 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1235271557115014" CI_START="-0.06352715571150092" EFFECT_SIZE="0.5300000000000002" ESTIMABLE="YES" MEAN_1="3.06" MEAN_2="2.53" ORDER="15152" SD_1="0.93" SD_2="0.8" SE="0.30282554189422234" STUDY_ID="STD-Arican-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="94.9130839202864"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="3.1" MEAN_2="3.69" ORDER="15153" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Berenson-1996" TOTAL_1="196" TOTAL_2="181" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.2637539938831432" CI_START="-2.8637539938831447" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="4.9" ORDER="15154" SD_1="5.2" SD_2="6.3" SE="1.3080617879235068" STUDY_ID="STD-Daragon-1993" TOTAL_1="39" TOTAL_2="39" WEIGHT="5.086916079713591"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.88" MEAN_2="1.27" ORDER="15155" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.3" MEAN_2="4.4" ORDER="15156" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Robertson-1995" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="196" TOTAL_2="181" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>mean pain score at 8 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="3.1" MEAN_2="3.54" ORDER="15157" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Berenson-1996" TOTAL_1="196" TOTAL_2="181" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="452" TOTAL_2="440" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>mean pain score at 12 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.66" MEAN_2="3.4" ORDER="15158" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Arican-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.4" MEAN_2="3.39" ORDER="15159" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Berenson-1996" TOTAL_1="196" TOTAL_2="181" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.6" MEAN_2="2.45" ORDER="15160" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Hortobagyi-1996a" TOTAL_1="185" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.15" MEAN_2="1.4" ORDER="15161" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="6.4" MEAN_2="6.4" ORDER="15162" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Piga-1998" TOTAL_1="27" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Proportion of patients with reduction in analgesics (Blinded and open studies)</NAME>
<DICH_OUTCOME CHI2="0.9279062699612765" CI_END="6.384196774085922" CI_START="1.2399486485077007" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.813552231936536" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.8051062643988587" LOG_CI_START="0.09340369957228369" LOG_EFFECT_SIZE="0.44925498198557123" METHOD="MH" NO="1" P_CHI2="0.628793057462807" P_Q="1.0" P_Z="0.013345474809664342" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="75" WEIGHT="100.0" Z="2.474414532372728">
<NAME>Proportion of patients with reduced analgesia at 4w (Blinded and open studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.433944878212783" CI_START="0.7877916901380032" EFFECT_SIZE="2.42" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.8712193365314621" LOG_CI_START="-0.10358860457059946" LOG_EFFECT_SIZE="0.38381536598043126" ORDER="15163" O_E="0.0" SE="0.5726070099804821" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.3278787878787879" WEIGHT="53.30389502924449"/>
<DICH_DATA CI_END="9.798363417893874" CI_START="0.7156999914632501" EFFECT_SIZE="2.6481481481481484" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.9911535432504365" LOG_CI_START="-0.1452689879662497" LOG_EFFECT_SIZE="0.42294227764209336" ORDER="15164" O_E="0.0" SE="0.667540220218936" STUDY_ID="STD-Ernst-1997" TOTAL_1="22" TOTAL_2="17" VAR="0.4456099456099456" WEIGHT="39.2208851341597"/>
<DICH_DATA CI_END="226.7161815378727" CI_START="0.5654683825237472" EFFECT_SIZE="11.32258064516129" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.355482518370056" LOG_CI_START="-0.2475916731069529" LOG_EFFECT_SIZE="1.0539454226315514" ORDER="15165" O_E="0.0" SE="1.5290586654986562" STUDY_ID="STD-Martoni-1991" TOTAL_1="19" TOTAL_2="19" VAR="2.3380204025365314" WEIGHT="7.475219836595822"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.476184270715853" CI_END="5.124277042812784" CI_START="1.0951147413393223" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.368896647870259" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.7096326017346897" LOG_CI_START="0.03945962503902082" LOG_EFFECT_SIZE="0.3745461133868553" METHOD="MH" NO="2" P_CHI2="0.788130080091815" P_Q="1.0" P_Z="0.02846855583401088" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="91" WEIGHT="100.0" Z="2.1907684085001575">
<NAME>Proportion of patients with reduced analgesia at 12w (Blinded and open studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.803767466303778" CI_START="0.5418174589677265" EFFECT_SIZE="1.92" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.8327494622264145" LOG_CI_START="-0.26614700481931536" LOG_EFFECT_SIZE="0.28330122870354957" ORDER="1" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="29" VAR="0.4166666666666667" WEIGHT="37.192919440764555"/>
<DICH_DATA CI_END="8.759393167168028" CI_START="0.42766636264455" EFFECT_SIZE="1.935483870967742" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.9424740201773214" LOG_CI_START="-0.3688949070785794" LOG_EFFECT_SIZE="0.28678955654937094" ORDER="15166" O_E="0.0" SE="0.7703045992509977" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.5933691756272401" WEIGHT="26.117045514882992"/>
<DICH_DATA CI_END="12.097905623278574" CI_START="0.9469094617280238" EFFECT_SIZE="3.3846153846153846" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="1.0827101922188433" LOG_CI_START="-0.023691543860142016" LOG_EFFECT_SIZE="0.5295093241793507" ORDER="15168" O_E="0.0" SE="0.6499058565497179" STUDY_ID="STD-Piga-1998" TOTAL_1="27" TOTAL_2="23" VAR="0.42237762237762244" WEIGHT="36.69003504435245"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Dose comparison studies</NAME>
<DICH_OUTCOME CHI2="0.6341110702762076" CI_END="2.9615904117856626" CI_START="0.6248210942499124" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3603176694478265" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.4715249953731324" LOG_CI_START="-0.20424431690013295" LOG_EFFECT_SIZE="0.1336403392364997" METHOD="MH" NO="1" P_CHI2="0.7282903567507617" P_Q="1.0" P_Z="0.43821788167601505" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="62" WEIGHT="100.0" Z="0.7752061155429798">
<NAME>Proportion of patients with pain relief</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lower</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Higher</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.035484971579679" CI_START="0.13938845119272272" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.6058957343058171" LOG_CI_START="-0.8557732075224169" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="15169" O_E="0.0" SE="0.8585915718078574" STUDY_ID="STD-Arican-1999" TOTAL_1="17" TOTAL_2="16" VAR="0.7371794871794872" WEIGHT="21.374644180246843"/>
<DICH_DATA CI_END="5.471511625848551" CI_START="0.5263090621664949" EFFECT_SIZE="1.696969696969697" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.7381073263464736" LOG_CI_START="-0.2787591520898478" LOG_EFFECT_SIZE="0.22967408712831294" ORDER="15170" O_E="0.0" SE="0.5973124030037438" STUDY_ID="STD-Cascinu-1998" TOTAL_1="23" TOTAL_2="23" VAR="0.35678210678210676" WEIGHT="44.16406802895368"/>
<DICH_DATA CI_END="5.578631507385121" CI_START="0.3938905517070994" EFFECT_SIZE="1.4823529411764707" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7465276753385597" LOG_CI_START="-0.40462443653201935" LOG_EFFECT_SIZE="0.1709516194032702" ORDER="15171" O_E="0.0" SE="0.6761924488076329" STUDY_ID="STD-Coleman-1998" TOTAL_1="24" TOTAL_2="23" VAR="0.45723622782446316" WEIGHT="34.461287790799474"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Toxicity</NAME>
<DICH_OUTCOME CHI2="3.616739344006475" CI_END="1.5780561069377104" CI_START="0.7858844069523385" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.113629062003259" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.19812244025506331" LOG_CI_START="-0.10464132815212199" LOG_EFFECT_SIZE="0.04674055605147062" METHOD="MH" NO="1" P_CHI2="0.6058019013097891" P_Q="1.0" P_Z="0.5450746889489828" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="524" TOTAL_2="470" WEIGHT="100.0" Z="0.6051569972207024">
<NAME>Nausea and vomiting</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6368392012183928" CI_START="0.1590310182703693" EFFECT_SIZE="0.5102040816326531" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.21400601755880036" LOG_CI_START="-0.7985181602717525" LOG_EFFECT_SIZE="-0.292256071356476" ORDER="1" O_E="0.0" SE="0.5947617141331807" STUDY_ID="STD-O_x0027_Rourke-1995" TOTAL_1="59" TOTAL_2="21" VAR="0.3537414965986394" WEIGHT="8.941224498683225"/>
<DICH_DATA CI_END="105.21711480293634" CI_START="0.27091353028092097" EFFECT_SIZE="5.338983050847458" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.022086388676274" LOG_CI_START="-0.5671693043813614" LOG_EFFECT_SIZE="0.7274585421474563" ORDER="15172" O_E="0.0" SE="1.5209416111244458" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="2.313263384449825" WEIGHT="1.367281459106684"/>
<DICH_DATA CI_END="2.6149400005031653" CI_START="0.7012655589643583" EFFECT_SIZE="1.3541666666666667" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.41746172848079494" LOG_CI_START="-0.15411748994625812" LOG_EFFECT_SIZE="0.13167211926726838" ORDER="15173" O_E="0.0" SE="0.33574846226681354" STUDY_ID="STD-Brinker-1998" TOTAL_1="152" TOTAL_2="148" VAR="0.1127270299145299" WEIGHT="28.05788583258809"/>
<DICH_DATA CI_END="2.8073328352871254" CI_START="0.47769938773522463" EFFECT_SIZE="1.158041958041958" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.44829390531682595" LOG_CI_START="-0.3208453153492269" LOG_EFFECT_SIZE="0.06372429498379954" ORDER="15174" O_E="0.0" SE="0.45179618551978507" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.20411979325022805" WEIGHT="15.495225059880806"/>
<DICH_DATA CI_END="2.309171305029712" CI_START="0.2601844305349683" EFFECT_SIZE="0.7751196172248804" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.36345615208976495" LOG_CI_START="-0.584718695226611" LOG_EFFECT_SIZE="-0.11063127156842303" ORDER="15175" O_E="0.0" SE="0.5569625988548298" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="29" VAR="0.31020733652312604" WEIGHT="10.196026216010623"/>
<DICH_DATA CI_END="2.1315806499968972" CI_START="0.6663325300373477" EFFECT_SIZE="1.1917808219178083" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.3287017691604884" LOG_CI_START="-0.17630898416416307" LOG_EFFECT_SIZE="0.07619639249816267" ORDER="15176" O_E="0.0" SE="0.29664581634644616" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="175" TOTAL_2="175" VAR="0.08799874035584947" WEIGHT="35.94235693373057"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1940301849390185" CI_END="58.353800596291244" CI_START="1.2474395261572655" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="8.531871855889136" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="3" I2="52.313171059614575" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.7660691470008372" LOG_CI_START="0.09601950091443061" LOG_EFFECT_SIZE="0.9310443239576339" METHOD="MH" NO="2" P_CHI2="0.12282254743442933" P_Q="1.0" P_Z="0.02886390938725774" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.5372724720066784" TOTALS="YES" TOTAL_1="457" TOTAL_2="478" WEIGHT="100.00000000000001" Z="2.1853402349369335">
<NAME>Discontinuation of therapy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="146.1694822819681" CI_START="0.38468668735413514" EFFECT_SIZE="7.498630136986302" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1648567087366355" LOG_CI_START="-0.41489284282933736" LOG_EFFECT_SIZE="0.8749819329536489" ORDER="15178" O_E="0.0" SE="1.515357656556084" STUDY_ID="STD-Hortobagyi-1996a" TOTAL_1="185" TOTAL_2="195" VAR="2.2963088272831467" WEIGHT="25.10321176384083"/>
<DICH_DATA CI_END="11.716495518968262" CI_START="0.8334936828328976" EFFECT_SIZE="3.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.068797730763303" LOG_CI_START="-0.07909768740311508" LOG_EFFECT_SIZE="0.494850021680094" ORDER="15179" O_E="0.0" SE="0.6742794508049149" STUDY_ID="STD-Hultborn-1996" TOTAL_1="201" TOTAL_2="203" VAR="0.45465277777777774" WEIGHT="48.31265790741196"/>
<DICH_DATA CI_END="1011.8901456935275" CI_START="3.534019987465204" EFFECT_SIZE="59.8" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="3.005133366546513" LOG_CI_START="0.548269001430309" LOG_EFFECT_SIZE="1.7767011839884108" ORDER="15180" O_E="0.0" SE="1.4431742897440065" STUDY_ID="STD-van-Holten-1993" TOTAL_1="71" TOTAL_2="80" VAR="2.0827520305781175" WEIGHT="26.584130328747225"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-07-11 11:59:51 +0100" MODIFIED_BY="Jessica R Thomas" NO="6">
<NAME>Sensitivity analysis</NAME>
<DICH_OUTCOME CHI2="8.655140538374736" CI_END="4.177674659805298" CI_START="1.5692152174895995" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5604043918660895" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="61" I2="19.12320812165043" I2_Q="8.747157395665214" ID="CMP-006.01" LOG_CI_END="0.6209346158853536" LOG_CI_START="0.1956825110555843" LOG_EFFECT_SIZE="0.40830856347046895" METHOD="MH" MODIFIED="2008-07-11 11:59:51 +0100" MODIFIED_BY="Jessica R Thomas" NO="1" P_CHI2="0.2783727191826417" P_Q="0.33425352758080806" P_Z="1.673880869426708E-4" Q="2.1917125460648323" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09406349305602638" TOTALS="YES" TOTAL_1="345" TOTAL_2="340" WEIGHT="100.0" Z="3.7637442349721386">
<NAME>Route/type of bisphosphonate.Best response within 12 weeks (blinded studies only)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4892760459442098" CI_END="7.151911562118342" CI_START="0.7706321847655522" DF="1" EFFECT_SIZE="2.347656966501978" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="39" I2="32.85328111444954" ID="CMP-006.01.01" LOG_CI_END="0.8544221354968288" LOG_CI_START="-0.11315285702273989" LOG_EFFECT_SIZE="0.3706346392370444" NO="1" P_CHI2="0.22232917149348186" P_Z="0.1332136693865313" STUDIES="2" TAU2="0.33443522681422894" TOTAL_1="153" TOTAL_2="160" WEIGHT="42.92524778192601" Z="1.5015488203885374">
<NAME>Pamidronate IV</NAME>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15181" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="38.44551348585611"/>
<DICH_DATA CI_END="68.6342551216994" CI_START="0.7877370250288221" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.836540924704283" LOG_CI_START="-0.10361874144471793" LOG_EFFECT_SIZE="0.8664610916297825" ORDER="15182" O_E="0.0" SE="1.1396593918411608" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="22" TOTAL_2="26" VAR="1.2988235294117647" WEIGHT="4.4797342960699"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.742301792154055" CI_END="5.88789857808348" CI_START="1.8008636650861263" DF="4" EFFECT_SIZE="3.2562712744768065" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="21" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.769960320460208" LOG_CI_START="0.25548083567241175" LOG_EFFECT_SIZE="0.5127205780663099" MODIFIED="2008-07-11 11:59:51 +0100" MODIFIED_BY="Jessica R Thomas" NO="2" P_CHI2="0.4420033952327338" P_Z="9.363238398853316E-5" STUDIES="5" TAU2="0.0" TOTAL_1="179" TOTAL_2="168" WEIGHT="54.939134593230094" Z="3.906526486890005">
<NAME>Clodronate PO</NAME>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15183" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="11.168051860053724"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15184" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="14.528149826371411"/>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="15185" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="13.685513105429562"/>
<DICH_DATA CI_END="6.4039827255961885" CI_START="0.5903926290149196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="15186" O_E="0.0" SE="0.60814576364657" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" VAR="0.3698412698412698" WEIGHT="13.45052748786084"/>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="15187" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="2.1068923135145536"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.666599142775863" CI_START="0.010516782155215626" DF="0" EFFECT_SIZE="0.28395061728395055" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.546757182861057" MODIFIED="2008-07-11 11:59:51 +0100" MODIFIED_BY="Jessica R Thomas" NO="3" P_CHI2="1.0" P_Z="0.45405270676786935" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="2.1356176248438854" Z="0.7486756876563363">
<NAME>Etidonrate IV</NAME>
<DICH_DATA CI_END="7.666599142775863" CI_START="0.010516782155215626" EFFECT_SIZE="0.2839506172839506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.5467571828610569" ORDER="15188" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Smith-1989" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="2.1356176248438854"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.655140538374738" CI_END="4.177674659805299" CI_START="1.5692152174895992" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5604043918660895" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="61" I2="19.123208121650446" I2_Q="54.36545828646903" ID="CMP-006.02" LOG_CI_END="0.6209346158853537" LOG_CI_START="0.19568251105558424" LOG_EFFECT_SIZE="0.40830856347046895" METHOD="MH" NO="2" P_CHI2="0.2783727191826417" P_Q="0.08679078596623424" P_Z="1.6738808694267146E-4" Q="6.573967629240983" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09406349305602647" TOTALS="YES" TOTAL_1="345" TOTAL_2="340" WEIGHT="100.0" Z="3.7637442349721377">
<NAME>Primary disease site</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.756963048821697" CI_END="3.042154795197125" CI_START="1.10578690728534" DF="1" EFFECT_SIZE="1.834114211946545" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="38" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.48318130866160347" LOG_CI_START="0.04367144350885593" LOG_EFFECT_SIZE="0.26342637608522973" NO="1" P_CHI2="0.3842806378829957" P_Z="0.018800483451662877" STUDIES="2" TAU2="0.0" TOTAL_1="136" TOTAL_2="139" WEIGHT="40.55240579937066" Z="2.3494635758654305">
<NAME>Breast</NAME>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15189" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="38.445513485856104"/>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="15190" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="2.1068923135145545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3048527788121036" CI_END="4.020816015922251" CI_START="0.8157257871513792" DF="2" EFFECT_SIZE="1.811044811587789" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.6043142011561816" LOG_CI_START="-0.08845580833090491" LOG_EFFECT_SIZE="0.25792919641263834" NO="2" P_CHI2="0.520780658782985" P_Z="0.14444102255501806" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="30.114294939076146" Z="1.4594509825978608">
<NAME>Prostate</NAME>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15191" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="14.528149826371413"/>
<DICH_DATA CI_END="6.4039827255961885" CI_START="0.5903926290149196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="15192" O_E="0.0" SE="0.60814576364657" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" VAR="0.3698412698412698" WEIGHT="13.450527487860844"/>
<DICH_DATA CI_END="7.666599142775863" CI_START="0.010516782155215626" EFFECT_SIZE="0.2839506172839506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.5467571828610569" ORDER="15193" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Smith-1989" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="2.1356176248438863"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.40436971563334" CI_START="1.0788763984543002" DF="0" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683959" LOG_EFFECT_SIZE="0.5450214903575982" NO="3" P_CHI2="1.0" P_Z="0.03696330357880083" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="80" WEIGHT="13.685513105429568" Z="2.0861691509092015">
<NAME>Multiple myeloma</NAME>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="15194" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="13.685513105429568"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.02131223074145705" CI_END="26.66879771566699" CI_START="2.692162695732044" DF="1" EFFECT_SIZE="8.473295837520523" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" I2="0.0" ID="CMP-006.02.04" LOG_CI_END="1.426003437241394" LOG_CI_START="0.4301013021060166" LOG_EFFECT_SIZE="0.9280523696737052" NO="4" P_CHI2="0.8839315897777793" P_Z="2.5932816657196E-4" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="43" WEIGHT="15.647786156123628" Z="3.6528673976188584">
<NAME>Any primary</NAME>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15195" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="11.168051860053726"/>
<DICH_DATA CI_END="68.6342551216994" CI_START="0.7877370250288221" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.836540924704283" LOG_CI_START="-0.10361874144471793" LOG_EFFECT_SIZE="0.8664610916297825" ORDER="15196" O_E="0.0" SE="1.1396593918411608" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="22" TOTAL_2="26" VAR="1.2988235294117647" WEIGHT="4.479734296069902"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.655140538374738" CI_END="4.177674659805299" CI_START="1.5692152174895992" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.56040439186609" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="61" I2="19.123208121650446" I2_Q="74.60593882219938" ID="CMP-006.03" LOG_CI_END="0.6209346158853537" LOG_CI_START="0.19568251105558424" LOG_EFFECT_SIZE="0.40830856347046907" METHOD="MH" NO="3" P_CHI2="0.2783727191826417" P_Q="0.04720893898253553" P_Z="1.6738808694267146E-4" Q="3.9379286085763847" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09406349305602651" TOTALS="YES" TOTAL_1="345" TOTAL_2="340" WEIGHT="100.00000000000001" Z="3.7637442349721377">
<NAME>Study design (Blinded /open control) Pain relief using best response within 12 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4989235434931802" CI_END="2.9204366094378167" CI_START="1.2616340295384092" DF="5" EFFECT_SIZE="1.919510929267276" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="52" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.46544778394666253" LOG_CI_START="0.1009333945261724" LOG_EFFECT_SIZE="0.28319058923641743" NO="1" P_CHI2="0.6235506423794226" P_Z="0.002323825066877488" STUDIES="6" TAU2="0.0" TOTAL_1="235" TOTAL_2="243" WEIGHT="75.14643503451671" Z="3.0453851577517694">
<NAME>Blinded studies</NAME>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15197" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="38.445513485856104"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15198" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="14.528149826371415"/>
<DICH_DATA CI_END="6.4039827255961885" CI_START="0.5903926290149196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="15199" O_E="0.0" SE="0.60814576364657" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" VAR="0.3698412698412698" WEIGHT="13.450527487860848"/>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="15200" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="2.106892313514555"/>
<DICH_DATA CI_END="7.666599142775863" CI_START="0.010516782155215626" EFFECT_SIZE="0.2839506172839506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.5467571828610569" ORDER="15201" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Smith-1989" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="2.1356176248438867"/>
<DICH_DATA CI_END="68.6342551216994" CI_START="0.7877370250288221" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.836540924704283" LOG_CI_START="-0.10361874144471793" LOG_EFFECT_SIZE="0.8664610916297825" ORDER="15202" O_E="0.0" SE="1.1396593918411608" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="22" TOTAL_2="26" VAR="1.2988235294117647" WEIGHT="4.4797342960699025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0573281406947639" CI_END="13.14738885407851" CI_START="2.131232968583094" DF="1" EFFECT_SIZE="5.2934061412850255" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="9" I2="5.4219819267360005" ID="CMP-006.03.02" LOG_CI_END="1.118839508044961" LOG_CI_START="0.32863092575361186" LOG_EFFECT_SIZE="0.7237352168992863" NO="2" P_CHI2="0.3038257416892628" P_Z="3.304514986094733E-4" STUDIES="2" TAU2="0.023691652668844383" TOTAL_1="110" TOTAL_2="97" WEIGHT="24.8535649654833" Z="3.5901785712139693">
<NAME>Open studies</NAME>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15203" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="11.16805186005373"/>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="15204" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="13.68551310542957"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.655140538374738" CI_END="4.1776746598053" CI_START="1.5692152174895995" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.56040439186609" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="61" I2="19.123208121650446" I2_Q="30.277041677678433" ID="CMP-006.04" LOG_CI_END="0.6209346158853538" LOG_CI_START="0.1956825110555843" LOG_EFFECT_SIZE="0.40830856347046907" METHOD="MH" NO="4" P_CHI2="0.2783727191826417" P_Q="0.23107270541902092" P_Z="1.673880869426711E-4" Q="1.4342478059767774" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09406349305602651" TOTALS="YES" TOTAL_1="345" TOTAL_2="340" WEIGHT="99.99999999999997" Z="3.763744234972138">
<NAME>Pain as study entry criteria (Y/N) Pain relief using best response within 12 wks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.495169593753888" CI_END="10.167035158510348" CI_START="1.422447453536726" DF="4" EFFECT_SIZE="3.8029032687200193" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" I2="27.208797986023573" ID="CMP-006.04.01" LOG_CI_END="1.0071943253885185" LOG_CI_START="0.15303623214229647" LOG_EFFECT_SIZE="0.5801152787654075" NO="1" P_CHI2="0.24015462916006836" P_Z="0.007761272017787273" STUDIES="5" TAU2="0.33736083694522184" TOTAL_1="109" TOTAL_2="99" WEIGHT="34.41844592085348" Z="2.662282456261539">
<NAME>Pain required</NAME>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15205" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="11.168051860053726"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15206" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="14.528149826371411"/>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="15207" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="2.1068923135145545"/>
<DICH_DATA CI_END="7.666599142775863" CI_START="0.010516782155215626" EFFECT_SIZE="0.2839506172839506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.5467571828610569" ORDER="15208" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Smith-1989" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="2.1356176248438863"/>
<DICH_DATA CI_END="68.6342551216994" CI_START="0.7877370250288221" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.836540924704283" LOG_CI_START="-0.10361874144471793" LOG_EFFECT_SIZE="0.8664610916297825" ORDER="15209" O_E="0.0" SE="1.1396593918411608" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="22" TOTAL_2="26" VAR="1.2988235294117647" WEIGHT="4.479734296069902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0873355550694555" CI_END="3.0501023418505033" CI_START="1.272915899703654" DF="2" EFFECT_SIZE="1.970412080419945" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="48" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="0.4843144117255607" LOG_CI_START="0.10479971119398145" LOG_EFFECT_SIZE="0.2945570614597711" NO="2" P_CHI2="0.5806148933037281" P_Z="0.002346855283418573" STUDIES="3" TAU2="0.0" TOTAL_1="236" TOTAL_2="241" WEIGHT="65.5815540791465" Z="3.0424182833732614">
<NAME>No pain required</NAME>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15210" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="38.44551348585609"/>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="15211" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="13.685513105429566"/>
<DICH_DATA CI_END="6.4039827255961885" CI_START="0.5903926290149196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="15212" O_E="0.0" SE="0.60814576364657" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" VAR="0.3698412698412698" WEIGHT="13.450527487860844"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.655140538374736" CI_END="4.177674659805299" CI_START="1.5692152174895995" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.56040439186609" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="61" I2="19.12320812165043" I2_Q="42.14629389970135" ID="CMP-006.05" LOG_CI_END="0.6209346158853537" LOG_CI_START="0.1956825110555843" LOG_EFFECT_SIZE="0.40830856347046907" METHOD="MH" NO="5" P_CHI2="0.2783727191826417" P_Q="0.1886029655746696" P_Z="1.673880869426708E-4" Q="1.728497735765346" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0940634930560264" TOTALS="YES" TOTAL_1="345" TOTAL_2="340" WEIGHT="100.0" Z="3.7637442349721386">
<NAME>Pain reporting (patient vs not specified) Pain relief using best response within 12 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7467730371830603" CI_END="3.061610473616158" CI_START="1.3079975814127887" DF="4" EFFECT_SIZE="2.0011444462402" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="50" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.4859499349186648" LOG_CI_START="0.11660694094539602" LOG_EFFECT_SIZE="0.3012784379320304" NO="1" P_CHI2="0.4413597452225595" P_Z="0.0013860417392822994" STUDIES="5" TAU2="0.0" TOTAL_1="271" TOTAL_2="279" WEIGHT="72.19690600006031" Z="3.197542107475323">
<NAME>Patient reporting</NAME>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15213" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="38.44551348585611"/>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="15214" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="13.685513105429566"/>
<DICH_DATA CI_END="6.4039827255961885" CI_START="0.5903926290149196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="15215" O_E="0.0" SE="0.60814576364657" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" VAR="0.3698412698412698" WEIGHT="13.450527487860846"/>
<DICH_DATA CI_END="7.666599142775863" CI_START="0.010516782155215626" EFFECT_SIZE="0.2839506172839506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.5467571828610569" ORDER="15216" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Smith-1989" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="2.135617624843886"/>
<DICH_DATA CI_END="68.6342551216994" CI_START="0.7877370250288221" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.836540924704283" LOG_CI_START="-0.10361874144471793" LOG_EFFECT_SIZE="0.8664610916297825" ORDER="15217" O_E="0.0" SE="1.1396593918411608" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="22" TOTAL_2="26" VAR="1.2988235294117647" WEIGHT="4.479734296069901"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7503442515702385" CI_END="12.407297404624615" CI_START="1.4921152383363692" DF="2" EFFECT_SIZE="4.302687244503331" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="11" I2="27.281830306946077" ID="CMP-006.05.02" LOG_CI_END="1.093677192451111" LOG_CI_START="0.17380236565737492" LOG_EFFECT_SIZE="0.633739779054243" NO="2" P_CHI2="0.2527963169451417" P_Z="0.006921445193578388" STUDIES="3" TAU2="0.25063095784241907" TOTAL_1="74" TOTAL_2="61" WEIGHT="27.803093999939694" Z="2.7006003563465395">
<NAME>Not specified</NAME>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15218" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="11.168051860053728"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15219" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="14.528149826371411"/>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="15220" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="2.106892313514554"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.269684853428696" CI_END="3.5475738931766347" CI_START="1.446282361635022" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.2651255038735165" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="66" I2="15.353485361685483" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="0.5499314502365281" LOG_CI_START="0.16025308972801655" LOG_EFFECT_SIZE="0.35509226998227233" METHOD="MH" NO="6" P_CHI2="0.3094154046439809" P_Q="0.9095782187477587" P_Z="3.5424799171266834E-4" Q="0.012898274714166625" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06522063098998228" TOTALS="YES" TOTAL_1="345" TOTAL_2="357" WEIGHT="100.0" Z="3.572012874646784">
<NAME>Blinded control, pain required, patient pain reporting, Pain relief using best response within 12 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5673728590151317" CI_END="42.91478301985349" CI_START="0.07781074156658865" DF="1" EFFECT_SIZE="1.8273563119829825" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="61.0496778257752" ID="CMP-006.06.01" LOG_CI_END="1.6326069210431986" LOG_CI_START="-1.1089604456698743" LOG_EFFECT_SIZE="0.26182323768666216" NO="1" P_CHI2="0.10908912395182968" P_Z="0.7081378359505863" STUDIES="2" TAU2="3.23389834568629" TOTAL_1="35" TOTAL_2="38" WEIGHT="5.652271614889076" Z="0.37435820283838006">
<NAME>Blinded control, pain required, patient pain reporting</NAME>
<DICH_DATA CI_END="7.666599142775863" CI_START="0.010516782155215626" EFFECT_SIZE="0.2839506172839506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.5467571828610569" ORDER="15221" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Smith-1989" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="1.8111385517946992"/>
<DICH_DATA CI_END="68.6342551216994" CI_START="0.7877370250288221" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.836540924704283" LOG_CI_START="-0.10361874144471793" LOG_EFFECT_SIZE="0.8664610916297825" ORDER="15222" O_E="0.0" SE="1.1396593918411608" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="22" TOTAL_2="26" VAR="1.2988235294117647" WEIGHT="3.8411330630943774"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.6496285682034495" CI_END="3.3718480037891196" CI_START="1.432495454049453" DF="5" EFFECT_SIZE="2.197761801736857" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="64" I2="11.498606684687376" ID="CMP-006.06.02" LOG_CI_END="0.5278679892612878" LOG_CI_START="0.15609325243044314" LOG_EFFECT_SIZE="0.34198062084586545" NO="2" P_CHI2="0.341817460933728" P_Z="3.112119150414527E-4" STUDIES="6" TAU2="0.036090674190581214" TOTAL_1="310" TOTAL_2="319" WEIGHT="94.34772838511093" Z="3.605784007714935">
<NAME>Others</NAME>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15223" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="9.888178163437331"/>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15224" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="39.25917394915958"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15225" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="13.077376054281347"/>
<DICH_DATA CI_END="4.5377204354464435" CI_START="0.7180891558447868" EFFECT_SIZE="1.8051282051282052" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.6568377359114232" LOG_CI_START="-0.14382163168019724" LOG_EFFECT_SIZE="0.256508052115613" ORDER="15226" O_E="0.0" SE="0.4703112758511071" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="97" VAR="0.22119269619269616" WEIGHT="18.29340546258223"/>
<DICH_DATA CI_END="6.4039827255961885" CI_START="0.5903926290149196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="15227" O_E="0.0" SE="0.60814576364657" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" VAR="0.3698412698412698" WEIGHT="12.043056663957806"/>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="15228" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="1.7865380916926357"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.65514053837474" CI_END="4.177674659805301" CI_START="1.5692152174895995" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5604043918660904" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="61" I2="19.12320812165046" I2_Q="29.74673191474709" ID="CMP-006.07" LOG_CI_END="0.6209346158853539" LOG_CI_START="0.1956825110555843" LOG_EFFECT_SIZE="0.4083085634704691" METHOD="MH" NO="7" P_CHI2="0.2783727191826417" P_Q="0.22322173971003367" P_Z="1.673880869426711E-4" Q="5.69368530321745" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09406349305602657" TOTALS="YES" TOTAL_1="345" TOTAL_2="340" WEIGHT="100.0" Z="3.763744234972138">
<NAME>Quality of studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8063181622593E-31" CI_END="2.9562758691267446" CI_START="1.0617845061796922" DF="0" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" I2="100.0" ID="CMP-006.07.01" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" NO="1" P_CHI2="0.0" P_Z="0.028563112123790056" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="134" WEIGHT="38.44551348585609" Z="2.189464278802311">
<NAME>QS = 1</NAME>
<DICH_DATA CI_END="2.9562758691267446" CI_START="1.0617845061796922" EFFECT_SIZE="1.771701982228298" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.47074495842686476" LOG_CI_START="0.026036383719625106" LOG_EFFECT_SIZE="0.2483906710732449" ORDER="15229" O_E="0.0" SE="0.2612240181259801" STUDY_ID="STD-Conte-1994" TOTAL_1="131" TOTAL_2="134" VAR="0.06823798764588239" WEIGHT="38.44551348585609"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6035294933504165" CI_END="8.443649134696388" CI_START="1.7119437452128283" DF="2" EFFECT_SIZE="3.8019800529349435" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="15" I2="23.18120439548966" ID="CMP-006.07.02" LOG_CI_END="0.9265301784452868" LOG_CI_START="0.23348948957883836" LOG_EFFECT_SIZE="0.5800098340120626" NO="2" P_CHI2="0.2720514064994476" P_Z="0.001035825696497927" STUDIES="3" TAU2="0.11566920096171396" TOTAL_1="146" TOTAL_2="136" WEIGHT="39.38171479185471" Z="3.2806108028146754">
<NAME>QS = 2</NAME>
<DICH_DATA CI_END="33.90871919418492" CI_START="2.343482493126603" EFFECT_SIZE="8.914285714285715" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.530311385844053" LOG_CI_START="0.3698617134922814" LOG_EFFECT_SIZE="0.9500865496681672" ORDER="15230" O_E="0.0" SE="0.6816538818579518" STUDY_ID="STD-Arican-1999" TOTAL_1="33" TOTAL_2="17" VAR="0.4646520146520146" WEIGHT="11.16805186005373"/>
<DICH_DATA CI_END="6.582257226875625" CI_START="0.6798354905874712" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8183748500078628" LOG_CI_START="-0.16759616696101093" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="15231" O_E="0.0" SE="0.5791642560027642" STUDY_ID="STD-Elomaa-1992" TOTAL_1="36" TOTAL_2="39" VAR="0.33543123543123543" WEIGHT="14.528149826371415"/>
<DICH_DATA CI_END="11.404369715633335" CI_START="1.0788763984543004" EFFECT_SIZE="3.5076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0570712881583568" LOG_CI_START="0.03297169255683968" LOG_EFFECT_SIZE="0.5450214903575982" ORDER="15232" O_E="0.0" SE="0.6015611718310871" STUDY_ID="STD-Heim-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3618758434547908" WEIGHT="13.68551310542957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.666599142775863" CI_START="0.010516782155215626" DF="0" EFFECT_SIZE="0.28395061728395055" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.07.03" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.546757182861057" NO="3" P_CHI2="1.0" P_Z="0.45405270676786935" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="2.135617624843887" Z="0.7486756876563363">
<NAME>QS = 3</NAME>
<DICH_DATA CI_END="7.666599142775863" CI_START="0.010516782155215626" EFFECT_SIZE="0.2839506172839506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8846027562480634" LOG_CI_START="-1.978117121970177" LOG_EFFECT_SIZE="-0.5467571828610569" ORDER="15233" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Smith-1989" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="2.135617624843887"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.4039827255961885" CI_START="0.5903926290149196" DF="0" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-006.07.04" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" NO="4" P_CHI2="1.0" P_Z="0.2741967796309276" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="13.450527487860848" Z="1.0934488791073889">
<NAME>QS = 4</NAME>
<DICH_DATA CI_END="6.4039827255961885" CI_START="0.5903926290149196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.806450151762507" LOG_CI_START="-0.22885907326856786" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="15234" O_E="0.0" SE="0.60814576364657" STUDY_ID="STD-Kylmala-1997" TOTAL_1="28" TOTAL_2="27" VAR="0.3698412698412698" WEIGHT="13.450527487860848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0010566173049863321" CI_END="47.88858287392594" CI_START="1.1766537718024808" DF="1" EFFECT_SIZE="7.506549251479047" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-006.07.05" LOG_CI_END="1.6802319855257926" LOG_CI_START="0.0706486912921998" LOG_EFFECT_SIZE="0.8754403384089962" NO="5" P_CHI2="0.9740688120104594" P_Z="0.033005238551917844" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="6.586626609584458" Z="2.132019560643101">
<NAME>QS = 5</NAME>
<DICH_DATA CI_END="217.1058246036601" CI_START="0.284353006144591" EFFECT_SIZE="7.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.336671475040307" LOG_CI_START="-0.5461421760803328" LOG_EFFECT_SIZE="0.895264649479987" ORDER="15235" O_E="0.0" SE="1.6933790088259828" STUDY_ID="STD-Siris-1983" TOTAL_1="5" TOTAL_2="5" VAR="2.8675324675324676" WEIGHT="2.1068923135145554"/>
<DICH_DATA CI_END="68.6342551216994" CI_START="0.7877370250288221" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.836540924704283" LOG_CI_START="-0.10361874144471793" LOG_EFFECT_SIZE="0.8664610916297825" ORDER="15236" O_E="0.0" SE="1.1396593918411608" STUDY_ID="STD-Vinholes-1997a" TOTAL_1="22" TOTAL_2="26" VAR="1.2988235294117647" WEIGHT="4.479734296069903"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>